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SYNOPSIS 
 Low-grade chronic inflammation in patients with type 2 diabetes mellitus 
(T2DM) may be influenced by circulating endotoxin levels, acting as an inflammatory 
stimulus. Health- promoting live microorganisms, such as probiotics, may influence 
circulating endotoxin levels and reduce inflammation. Limited information is 
available whether or not probiotics do so in patients with T2DM. The aim of this study 
was to characterise the beneficial effects of a multi-strain probiotics on circulating 
endotoxin levels and other biomarkers related to systemic low-grade inflammation and 
cardiometabolic status in patients with T2DM. 
 A total of 150 adult Saudi T2DM patients (naïve and without co-morbidities, 
aged 40-60 years) were initially recruited, 96 of whom were randomized, 78 
completed 3 months, and 61 completed the entire clinical trial. They were randomized 
to receive twice daily placebo or probiotics [(2.5×109cfu/gram) containing the 
following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium 
lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus 
casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus 
lactis W58 (Ecologic®Barrier)]  in a double-blind manner over a 6 month period. 
Anthropometrics, glycaemic and lipid profiles, as well as inflammatory and other 
markers, including adipocytokines, were measured. Measurements/samples were 
obtained at baseline and after 3 and 6 months of treatment. 
 After 12/13 weeks of intervention and using intention-to-treat analysis, no 
difference was noted in endotoxin levels between groups [Placebo -9.5% vs 
Probiotics -52.2%; (CI: -0.05-0.36; p=0.15)]. Compared with the placebo group 
however, participants in the probiotics groups had a significant but modest 
XXIII 
 
improvement in WHR [Placebo 0.0% vs Probiotics 1.11%; (CI: -0.12- -0.01; 
p=0.02)] as well as a clinically significant improvement in HOMA-IR [Placebo -
12.2% vs Probiotics -60.4%; (CI: -0.34- -0.01; p=0.04)].  
 After 6 months of intervention, significant improvements were observed in 
endotoxin levels, glycaemic, lipid, inflammatory and adipocytokine profiles in the 
probiotics group, which were not seen in the placebo group. Between group analyses, 
however, revealed that only HOMA-IR demonstrated a clinically significant reduction 
in favour of the probiotics group after adjusting for baseline covariates [Placebo % 
change: 0.80 vs. Probiotics % change: -3.40 (CI: -0.59 - -0.17); p=0.001].  
 The current thesis expanded our knowledge on the beneficial effects of a multi-
strain probiotics intake in improving insulin resistance among Saudi patients with 
T2DM and is therefore recommended as a promising adjuvant anti-diabetes therapy. 
Larger trials may causally confirm whether the beneficial effects of probiotics in 
reducing endotoxin levels may extend in preventing complications of T2DM.  
 
 
 
 
 
 
 
XXIV 
 
ABBREVIATIONS 
µg Microgram 
ADA American Diabetes Association 
AHA American Heart Association 
AMPK AMP-activated Protein Kinase 
ANCOVA Analysis of Covariance 
BMI Body Mass Index 
BP Blood Pressure 
BRP Biomarkers Research Program 
CHOD/POD Cholesterol Oxidase/Peroxidase 
CI Confidence Interval 
cm Centimetre 
CRF Case Report Form 
CRP C-Reactive Protein 
CVD Cardiovascular Disease 
DBP Diastolic Blood Pressure 
DM Diabetes Mellitus 
ECL Electrochemiluminiscence 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme Linked Immunosorbent Assay 
FAO Food and Agriculture Organization 
FFA Free Fatty Acids 
FPG Fasting Plasma Glucose 
GDM Gestational Diabetes Mellitus 
HBA Hydroxybenzoic Acid 
HbA1c Glycated Haemoglobin 
HDL High Density Lipoprotein 
HMW High Molecular Weight 
HOMA-IR 
Homeostasis Model Assessment for Insulin 
Resistance 
IBS Irritable Bowel Syndrome 
IDF International Diabetes Federation 
XXV 
 
IFG Impaired Fasting Glucose 
IL-6 Interleukin 6 
iNOS Inducible Nitric Oxide Synthase 
ITT Intention-to-Treat 
IU International Units 
JNK c-Jun NH2-terminal kinase  
kg Kilogram 
Kinetic-QCL Kinetic Quantitative Chromogenic LAL 
KSU King Saud University 
l Litre 
LAL Limulus Amoebocyte Lysate  
LDL Low Density Lipoprotein 
LOCF Last Observation Carried Forward 
LPS Lipopolysaccharides 
m Metre 
M/F Males/Females 
MAP Mean Arterial Pressure 
MD Maryland  
MDC Minimum Detectable Concentration 
MENA Middle East and North Africa 
MetS Metabolic Syndrome 
mmHg Millimetres Mercury 
mmol millimole 
MN Minnesota 
MS Microsoft 
NAFLD non-Alcoholic Fatty Liver Disease 
NEC Necrotizing Enterocolitis 
NFκB Nuclear Factor-kappaB  
ng Nanogram 
NIH National Institute of Health 
NOD Non Obese Diabetic 
Ob Obese 
PEG Polyethylene Glycol-Modified  
XXVI 
 
pg Picogram 
pNA p-Nitroaniline 
PPA Per Protocol Analysis 
PPARα Peroxisome Proliferator Activator Receptor Alpha 
R Coefficient 
RCT Randomised Control Trial 
RETN Resistin Gene 
RT-PCR Reverse Transcription-Polymerase Chain Reaction 
SBP Systolic Blood Pressure 
SD Standard Deviation 
SFDA Saudi Food and Drug Administration 
SPSS Statistical Package for the Social Sciences 
SST Serum Separator Tube 
STZ Streptozotocin 
T2DM Type 2 Diabetes Mellitus 
TC Total Cholesterol 
TEER Transepithelial Electrical Resistance 
TER Transepithelial Resistance 
TG Triglycerides 
TJ Tight Junction 
TLR Toll-like Receptor 
TNF-α Tumour Necrosis Factor Alpha 
TPA Tripropylamine 
TX Texas 
USA United States of America 
USNLM US National Library of Medicine 
VA Virginia 
VLDL Very Low Density Lipoprotein 
WHO World Health Organization 
WHR Waist-Hip Ratio 
 
  
- 1 - 
 
Chapter 1  
Introduction 
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1.1 Obesity  
The definition of overweight obesity according to the Centre for Disease Control 
(CDC) and Prevention was based on weight that is higher than what is average or 
normal for a given height in both sexes as measured by the body mass index (BMI) 
(CDC, https://www.cdc.gov/obesity/adult/defining.html). BMI was also previously 
called the Quetelet's index or formula as a reliable indicator of fatness based on the 
study of Garrow and Webster (1985). As of 2016, an estimated 1.9 billion people 
above 18 years old were considered overweight, 650 million of whom were considered 
under the category of obese (≥30kg/m2) (WHO Fact Sheet, 
http://www.who.int/mediacentre/factsheets/fs311/en/). Currently, obesity is 
considered by the most respectable international medical associations as a disease that 
needs treatment (Kilov and Kilov, 2017). 
 
Figure 1.1.1 Age-standardized prevalence of obesity in men aged 18 and over 
(BMI≥18kg/m2) in 2014. 
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Figure 1.1.2 Age-standardized prevalence of obesity in women aged 18 and over 
(BMI≥18kg/m2) in 2014. 
 Whilst the prevalence of obesity is highest among highly industrialized 
nations, it was observed that it has started to plateau. This is in opposition to emerging 
economies such as the Middle East, including Saudi Arabia, with obesity trends 
continuing to grow especially amongst children and adolescents (NCD Risk Factor 
Collaboration 2017). 
 In Saudi Arabia, it was previously observed that as of 2010, the prevalence of 
obesity plateaued, with a reported over-all prevalence of 40% in Saudi adults similar 
to the year 2000. This was despite the increasing incidence of T2DM (from 28.6% in 
2000 to 31.6 in 2010), hypertension (from 30% in 2000 to 32.6% in 2010) and 
coronary artery disease (from 6.2% to 6.9%) (Al-Daghri et al., 2011) (Figure 1.2.1). 
More recent epidemiologic studies now suggest that the incidence of T2DM continues 
to rise as the prevalence of being overweight or obesity among Saudi adults increases 
from 52.6-55.1% (Azzeh et al., 2017; Ahmed et al., 2017) and there is a significant 
increase in the prevalence of childhood obesity from 12.6% in 2008 to 15.3% in 2013 
as well, affecting population data (Al-Daghri et al., 2016). 
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Figure 1.1.3 Trends in the prevalence of non-communicable diseases in Saudi Arabia 
(Adopted from Al-Daghri et al., 2011). 
 
 Obesity has been consistently considered as the single biggest risk factor for 
type 2 diabetes mellitus (T2DM), as obesity was hypothesized to induce insulin 
resistance and β-cell failure (Eckel et al., 2011). On the other hand, diabetes is defined 
as "a group of metabolic diseases characterised by hyperglycaemia resulting from 
defects in insulin secretion, insulin action, or both. The chronic hyperglycaemia of 
diabetes is associated with long-term damage, dysfunction, and failure of different 
organs, especially the eyes, kidneys, nerves, heart, and blood vessels" (ADA, 2010). 
The two most common types of diabetes mellitus include type 1 (T1DM), caused by 
cellular-mediated auto-immune destruction of the β cells of the pancreas and accounts 
for 5-10% of all people with diabetes (ADA, 2010). The most common type is type 2 
(T2DM), and most patients with this type are obese, having chronic insulin resistance 
with comparative insulin deficiency to mostly an insulin secretory defect with insulin 
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resistance (ADA, 2010). T2DM accounts for 90-95% of patients considered to have 
diabetes. 
 
1.2 Diabetes Mellitus in the Middle East and Saudi Arabia 
 Diabetes mellitus (DM) is a chronic, non-communicable disease that 
debilitates not only the overall well-being of the individual affected but also impacts 
the general health of the society involved in terms of productivity and economy. 
According to the International Diabetes Federation (IDF) and as of 2015, one out of 
every 11 human adults has diabetes. By the year 2040 this incidence will increase to 
one out of 10, or 640 million (IDF, 2015) (Figure 1.1.1).  
 
Figure 1.2.1. The Growing Diabetes Pandemic 
Whilst globally the trend for diabetes incidence is clearly rising, the rate of 
escalation is fastest in developing nations, particularly in the Middle East and North 
Africa (MENA) region (NCD-RisC, 2016). Furthermore in the MENA region, the 
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highest prevalence of DM is observed in the Gulf nations, with Saudi Arabia topping 
the list at 23.87% followed by Kuwait at 23.09%, Qatar at 22.87% and Bahrain at 
21.84% (Majeed et al., 2014; Meo et al., 2017) (Table 1.1.1).  
Table 1.2.1.1 Top 10 countries with the highest prevalence of T2DM in the MENA 
region 
Rank MENA Country Prevalence (%)2013 
1 Saudi Arabia 23.9 
2 Kuwait 23.1 
3 Qatar 22.9 
4 Bahrain 21.8 
5 United Arab Emirates 19.0 
6 Egypt 16.8 
7 Lebanon 15.0 
8 Oman 14.2 
9 Jordan 11.4 
10 Iran 9.9 
Note: Table adopted from Majeed et al., 2014 
With regards to Saudi Arabia, there is no lack of updated epidemiologic data 
pointing to increased prevalence of DM, particularly T2DM in all populations 
including children and adolescents at 10.84% (Al-Rubeaan, 2015) and higher than 
20% in adults (Al-Rubeaan et al., 2015; Al-Daghri et al., 2011). Even more alarming 
in the case of Saudi adults is the higher prevalence of those unaware they already have 
T2DM (>40%) as well as those with impaired fasting glucose (IFG) at >25% (Al-
Rubeaan et al., 2015). The most recent observations from Meo (2016) indicates that 
the based on the current trends of DM in Saudi Arabia (Figure 1.1.2), the prevalence 
will continue to ascend by as much >45% by the year 2030, with higher rates among 
females, adolescents and those living in urban areas (Alotaibi et al., 2017). It was 
reported that in 2014 alone, direct expenses related to DM in Saudi Arabia was ~14% 
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of the entire health expenditure budget, or 25 billion Saudi riyals out of 180 billion 
(Robert et al., 2017). Among the major conventional risk factors for T2DM identified 
particularly in the Saudi population include obesity, sedentary lifestyle, unhealthy 
nutrition, smoking and aging (Alneami and Coleman, 2016). 
 
Figure 1.2.2. Ascending Prevalence of T2DM in Saudi Arabia (1982-2014) 
[Adopted from Meo, 2016]. 
 
Given the increasing incidences of DM, it is unfortunate that Saudi Arabia up 
to the present time still has limited interventional studies or clinical trials that would 
address the expanding T2DM epidemic in the populations. Amongst the limited 
prospective studies undertaken in Saudi Arabia a primary care study gave a 12 month 
dietary lifestyle program to improve management of DM patients in a primary care 
facility (Alfadda et al., 2011). This study showed no differences in glycaemic and 
HbA1c control and whilst management remained substandard, the intervention given 
was more efficacious in improving adherence (Alfadda et al., 2011). In another more 
recent study which was a non-randomised, single-blind trial, Badar and colleagues 
observed the lipid-lowering effects of one year Nigella sativa supplementation among 
Saudi T2DM subjects (Badar et al., 2017). Other local studies have reported modest 
improvements in cardiometabolic profiles with the use of moderate exercise (Abd El-
- 8 - 
 
Kader et al., 2013), self-monitoring lifestyle modification (Al-Daghri et al., 2014), and 
better insulin sensitivity including glycaemic profile among those receiving vitamin 
D supplements (Al-Daghri et al., 2013; Al-Shahwan et al., 2015; Al-Sofiani et al., 
2015; Al-Jabri et al., 2010). From these limited interventional studies, it is clear that 
more prospective studies are required to provide further insights for prevention and 
control of DM. Furthermore and given the current evidence in the literature, it also 
appears that the Saudi T2DM population is more inclined to participate in trials 
involving nutritional supplements as adjuvant management for T2DM (Alfadda et al., 
2011; Badar et al., 2017; Abd El-Kader et al., 2013; Al-Daghri et al., 2014; Al-Daghri 
et al., 2013; Al-Shahwan et al., 2015; Al-Sofiani et al., 2015; Al-Jabri et al., 2010). 
 
1.3 Syndrome X 
The concept of “Syndrome X” was first developed in 1988 by Professor Gerald 
Reaven which later evolved into what is commonly known now as the “Metabolic 
Syndrome” (MetS), a condition from a cluster of several independent cardiovascular 
risk factors that include obesity, hypertension, dyslipidaemia and hyperglycaemia, 
which, as a single entity linked centrally to insulin resistance. This cluster of factors 
is considered to compound the risk of the individual in progressing to full blown 
cardiovascular/atherosclerotic disease and or DM (Reaven, 1988). In 2006, the global 
prevalence of MetS according to IDF was estimated to be a quarter of the world’s 
human adult population (Kaur 2014). Currently, several MetS definitions still exist 
and diagnosis is highly dependent on the definition used, creating considerable 
confusion among epidemiologists and clinicians, not to mention the lack of standard 
definition to other populations at risk such as children and adolescents (Kassi et al., 
2011). As such, MetS management and prevention are focused more on reducing the 
- 9 - 
 
individual risk factors through lifestyle interventions targeting weight reduction (Case 
et al., 2002), increased physical activity (Zhang et al., 2017) and dietary modification 
(Steckhan et al., 2016). 
In the Middle East and the Gulf countries in particular, the prevalence of MetS as 
of 2010 was relatively higher by 10-15% compared to other developed nations and 
higher amongst Arab women (Mabry et al., 2010). In Saudi Arabia, the single largest 
country-wide survey was undertaken on 17,293 subjects aged 30-70 years old from 
1995-2000 and determined that the prevalence of MetS was 39.3% (Al-Nozha et al., 
2005). More recent evidence indicates a steady and modestly decreasing prevalence 
in Saudi adults, with the highest prevalence reported among the age group 50-55 years 
(Figure 1.2.1), but an increasing incidence among Saudi children (Al-Daghri et al., 
2011).  
 
Figure 1.3.1. Increasing prevalence of MetS in Saudi adults according to age 
(Adopted from Al-Daghri et al., 2011). 
The succeeding sub-section highlights the different MetS risk factors and their 
relevance in the Saudi Arabian context. 
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1.3.1 The Other Cardiometabolic Risk Factors of MetS 
 There is a worldwide consensus that despite varying definitions of MetS, they 
all agree that obesity (as discussed previously), dyslipidaemia, hypertension and 
elevated glucose are its core factors (Kassi et al., 2011).  
  
1.3.1.1 Hypertension 
 Hypertension is defined as elevated systolic and/or diastolic blood pressure 
and is considered the leading preventable cause of premature death worldwide (Mills 
et al., 2016). The American Heart Association (AHA) defines hypertension as 
≥140/90mmHg (Bertoia et al., 2012). As of 2010, the global prevalence of 
hypertension among adults was 31.1% (95% Confidence Interval 30.2-32.9%) (Mills 
et al., 2016). Uncontrolled hypertension greatly increases risk of target organ damage 
and as such, treatment has been focused on reducing cardiovascular and renal 
complications (Cushman, 2003). In Saudi Arabia, the most recent countrywide survey 
examining hypertension prevalence revealed that among 10,735 Saudis aged 15 and 
above, 15.2% and 40.6% of Saudis were hypertensive or borderline hypertensive, 
respectively with more than half of the hypertensive population unaware of their 
condition (El Bchearoui et al., 2014). It was also noted that being male, older, and 
diagnosed with diabetes were associated as increased risk factors elicited (El 
Bchearoui et al., 2014). The prevalence of hypertension is high even among Saudi 
women, with a recent meta-analysis of studies revealing a prevalence of 21.8% 
(Alshaikh et al., 2016). The prevalence is almost doubled in the presence of T2DM 
with almost half (45%) of Saudi patients co-currently presenting with hypertension as 
well (Al Slail et al., 2106).  
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1.3.1.2 Dyslipidaemia  
 Dyslipidaemia or abnormal lipid profile, is defined as elevated triglycerides 
and/or low levels of HDL-cholesterol (Musunuru, 2010). It has been associated with 
more than half of the global cases of ischemic heart disease (Smith 2007).  In Saudi 
Arabia, low levels of HDL-cholesterol (<1.29mmol/l in females and <1.03mmol/l in 
males) is the most common cardiometabolic disorder amongst Saudis overtime, with 
a reported alarming prevalence of >85% in both children and adults (Al-Daghri et al., 
2010; Al-Daghri et al., 2011) (Figure 1.2.1), affirming previous national survey on the 
prevalence of MetS in Saudi Arabia (Al-Nozha et al, 2005). Hypertriglyceridemia is 
the second most common MetS risk factor amongst Saudis with a prevalence of 33% 
in Saudi children and 34% in Saudi adults (Al-Daghri et al., 2010; Al-Daghri et al., 
2011). 
 
Figure 1.3.1.2 Prevalence of low-HDL cholesterol among Saudi adults according to 
age (Adopted from Al-Daghri et al., 2011) 
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1.4 Biomarkers of Metabolic Dysfunction 
The adipose tissue was once known as a storage depot where accumulation of 
fat cells takes place. Physiologically, adipose tissue has been classified as white 
adipose tissue (WAT) and brown adipose tissue (BAT) (Saely et al., 2012; Reddy et 
al., 2014). The latter is highly vascularised with an abundance of mitochondria as 
opposed to the latter, hence its thermogenic function rather than storage. Metabolically 
active BAT has recently been shown in adults using magnetic resonance imaging-
based method and was identified to be fairly static over long periods of time (Jones et 
al., 2017; Reddy et al., 2014). On the other hand, our understanding of the WAT has 
observed that fat cells (adipocytes) are not just for storage, but like BAT,  also have 
both metabolic and endocrine functions, which, during weight gain, can alter their 
functionality and contribute to metabolic disorders (Jung and Choi, 2014; Baker et al., 
2006).  The adipose tissue as it is now known, produces a vast array of adipocyte-
derived factors, known as adipocytokines (or adipokines) (Tilg and Moschen, 2006). 
Under normal physiological processes, adipocytokines play a significant role in 
energy homeostasis, triglyceride storage and the mobilization of fat (Leal and Mafra, 
2013). However, when the volume of adipose tissue is enhanced, central abdominal 
fat in particular, it can initiate a cascade of other altered metabolic functions within fat 
leading to systemic metabolic consequences (McTernan et al., 2002; Harte et al., 2003; 
Valsamakis et al., 2004a; Lois et al., 2008; Freemantle et al., 2008; Genske et al., 
2017). These major adipocytokines with adipose tissue include leptin, adiponectin, 
resistin complement components, plasminogen activator inhibitor-1, biomarkers of 
inflammation such as tumour necrosis factor (TNF-α), interleukin-6 (IL-6) and 
proteins of the rennin-angiotensin system (Kershaw and Flier, 2004; Harte et al., 
2006). The endocrine functions of various adipocytokines to key metabolisms of the 
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human body has been hypothesised to connect obesity to most of the chronic non-
communicable diseases since it mediates crosstalk between different cell groups not 
only within the adipose tissue but to other organs as well in maintaining energy 
homeostasis (Cao, 2014) (Figure 1.4.1.1). Hence, many studies have focused on the 
role of adipocytokines as major biomarkers of interest not only to monitor efficacy of 
nutritional interventions and obesity prevention/reduction programs but as therapeutic 
targets themselves in reversing obesity-induced, insulin resistance-related disorders 
(Valsamakis et al., 2004b; Borges et al., 2007; Quarta et al., 2016). Similar to insulin 
resistance and body fat distribution however, these biomarkers are affected by 
ethnicity and should be taken into consideration when conducting intervention studies 
(Mente et al., 2010; Sulistyoningrum et al, 2013). 
Variations in adipocytokine expression have been demonstrated across ethnic 
groups (Parvaresh Rizi et al., 2015). In the Arab population, adipocytokines were 
demonstrated to be highly heritable, with parental adipocytokine patterns transmitted 
to offspring and manifesting as early as pre-teens (Al-Daghri et al., 2011b). 
Furthermore, adipocytokines exhibit differential expression according to sex (Al-
Daghri et al., 2011c) and lifestyle modifications (Al-Daghri et al., 2015). This unusual 
combination of differing adipocytokine levels can be due to high degree of 
consanguineous marriages as well as the shared specific social and environmental 
exposures that led to aberrant heritability patterns that are yet to be demonstrated in 
other ethnic groups. 
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For the purpose of this thesis, the adipocytokines discussed in detail in the 
succeeding subsections were the parameters of interest measured in the trial studies.
 
Figure 1.4.1.1. The metabolic adipose tissue and known adipocytokines (Adopted 
from Cao, 2014) 
 
1.4.1 Leptin   
 Leptin was one of the first adipocytokines to be discovered in adipose tissue, 
it is a 167-amino acid protein with the first 21 amino acid residues cleaved as a peptide 
(John, 1998). It was first identified as the product of the ob gene in leptin-deficient 
obese (ob/ob) mice and was initially described as the adipocytokine associated with 
the regulation of appetite and energy homeostasis (John, 1998). The human leptin has 
146 amino acid residues composed of four anti-parallel α-helices that are 5-6 turns 
long and is connected by cross-over links. Both crystal structure and nuclear magnetic 
resonance studies have revealed that leptin adopts a cytokine fold similar to that 
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exhibited by the short-helix subfamily of cytokine folds (Figure 1.3.1.2) (Zhang et al., 
1997).  
Figure 1.4.1.2 Crystal Structure of Leptin 
(Adopted from Zhang et al., 1997) 
 Elevated levels of circulating leptin is an 
integral feature of human obesity with total 
body fat mass being the best predictor of 
leptin levels, followed by % body fat and 
BMI as the least, among anthropometric measures (Sinha and Caro, 1998). Amongst 
humans, leptin has a highly conserved structure secretion within a 24-hour period. 
This circadian pattern is characterized by basal levels between 08:00 and 12:00 hours, 
ascending gradually to peak between 24:00 and 04:00 hours and constantly descending 
to its lowest point by 12:00 hours (Anubhuti and Arora, 2008). 
Although the rate of leptin production is related to adiposity, a large portion of 
the inter-individual variability in plasma leptin concentration is independent of body 
fatness. It is leptin resistance and not leptin deficiency per se which is regarded as a 
pathogenic mechanism in human obesity (Al-Daghri et al., 2007). Among its essential 
functions, leptin acts via hypothalamic receptors that inhibit feeding and increase 
thermogenesis, resulting in weight loss (Jequier, 2002). Evidence also suggests that 
leptin has inhibitory role on insulin secretion, and levels above 20ng/ml help predict 
development of gestational diabetes mellitus (Maghbooli et al., 2007).  
Evidence amongst the Saudi Arabian population have demonstrated the 
associations of leptin to MetS and coronary artery disease among Saudi patients (Al-
Daghri et al., 2003), postmenopausal breast cancer among Saudi women (Assiri et al., 
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2015) and obesity among non-diabetic Saudi men (Al-Sheikh, 2017) with higher leptin 
levels as compared to 
their T2DM counterparts 
(Anandaraj et al., 2017). 
1.4.2 Adiponectin  
Figure 1.4.2.1. Structure 
of Adiponectin 
(Adopted from Okamoto 
et al., 2006). 
 Adiponectin is a 
30-kDa collagen-like protein, clinically noted to be anti-atherogenic and insulin 
sensitizing at higher levels (Al-Daghri et al., 2008). The protein forms the basic unit 
of a trimer, which self-associates to form hexamers then multimers of high molecular 
weight (HMW) (Figure 1.3.2.1) (Okamoto et al., 2006). HMW adiponectin seems to 
be the most active ones in relation to insulin sensitivity (Ferrarezi et al., 2007). 
AdipoR1 and AdipoR2 are the known receptors of adiponectin, with AdipoR1 being 
present in muscle tissues as high-affinity receptor for globular adiponectin and low 
affinity for full-length adiponectin, whereas AdipoR2 is abundantly noted in the liver 
and serves as intermediate-affinity receptors for both forms of adiponectin. The 
physiology of adiponectin in various glycaemic and lipid functions can be explained 
by the activation of AMP-activated protein kinase (AMPK) and stimulation of 
PPARα, which lead to elevated glucose uptake and oxidation of fatty acids in skeletal 
muscles and depressed hepatic glucose output (Adya et al., 2015). In skeletal muscle, 
adiponectin increases expression of molecules involved in fatty-acid transport such as 
CD36, in combustion of fatty acid such as acyl-coenzyme A oxidase, and in energy 
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dissipation such as uncoupling protein 2, leading to decreased triglyceride contents 
(Lai et al., 2015).  
 Adiponectin as an insulin-sensitizing hormone is reduced in the presence of 
insulin resistance and has thus been associated with diabetes and pre-diabetes risk 
(Mather et al., 2008; Jiang et al., 2016). As a biomarker, low-circulating levels of 
adiponectin has been a classic feature of endothelial dysfunction and insulin resistance 
(Al-Jiffri et al., 2016; Anandaraj et al., 2017). Owing to its inverse associations to 
various metabolic abnormalities including abdominal obesity, insulin resistance and 
dyslipidaemia, improvement in its levels owing to the simplest lifestyle and dietary 
modifications can therefore translate to reduction of risk.  
In the Saudi population, adiponectin and other well-known biomarkers of 
obesity have been studied (Al-Daghri et al., 2013; Al-Daghri et al., 2015; Al-Attas et 
al., 2013; Alokail et al, 2013; Alokail et al., 2011; Al-Attas et al., 2010). Adiponectin, 
in particular, has been shown to be inversely associated with abdominal adiposity, 
insulin resistance and other anthropometric measures in adults (Al-Daghri et al., 
2013); including vitamin D deficiency (Al-Daghri et al., 2015), cigarette smoking (Al-
Attas et al., 2013), obesity-related malignancies such as breast cancer (Alokail et al, 
2013), prostate cancer (Alokail et al., 2011) and premature biological aging (Al-Attas 
et al., 2010).  
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1.4.3 Resistin 
 Resistin is a cysteine-rich signalling molecule unique among the class of 
adipocytokines since it initially showed what appeared compelling evidence that 
directly linked obesity to diabetes, at least in animal models, hence the name resistin 
(resistance to insulin) (Steppan et al., 2001). 
Crystal structures of resistin and RELMbeta 
show an uncommon multimeric 
arrangement (Figure 1.3.3.1). with each 
protomer containing a carboxy-terminal 
disulfide-rich β-sandwich "head" domain 
and an amino-terminal α-helical "tail" sector 
(Patel et al, 2004).  
Figure 1.4.3.1. Crystal structure of resistin 
(Adopted from Patel et al., 2004) 
Overtime, human studies highlighted that the function of resisitn appeared to have a 
more pro-inflammatory role via the integration of nuclear factor-kappaB (NFκB) and 
c-Jun NH2-terminal kinase (JNK) signaling pathways from human adipocytes 
(Kusminski et al., 2007). Resistin, together with the other pro-inflammatory 
adipocytokines, were shown to be modulated by nutrition as well as gut derived 
circulating gram negative bacterial fragments also known as endotoxin (Piya et al, 
2013), with a modest effect in glycaemic metabolism but as dramatic as previously 
seen in animal studies (McTernan et al, 2003; McTernan et al., 2006; Kusminski et 
al., 2005). 
 Studies examining the adipocytokine resistin in the Saudi population has 
demonstrated higher levels of resistin among patients with T2DM (Habib 2005), 
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gestational diabetes mellitus (GDM) (Noureldeen et al., 2014), tuberculosis and khat 
addiction (a local shrub commonly chewed and acts as a stimulant) (Alvi et al., 2015) 
as well as obesity-related malignancies such as breast cancer (Assiri and Kamel 2016; 
Assiri et al., 2015). Furthermore, resistin gene (RETN) polymorphisms have shown 
differential expression among Saudi patients with colon cancer (Alharithy, 2014). 
 
1.4.4. The Inflammatory Biomarkers: C - reactive protein, TNF-α and IL-6 
Chronic, low-grade inflammation has been implicated in the pathogenesis of 
atherosclerosis and other chronic, non-communicable diseases (Geng et al., 2016). 
Tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) are classified as 
adipocytokines, and, together with the hepatocyte-derived acute phase reactant, C-
reactive protein (CRP), are major players involved in local and systemic inflammation, 
respectively. The circulating biomarkers are consistently shown to be elevated in the 
presence of injury and infection, but systemic levels that are 2-3 times normal are 
classified as low-grade (Ross, 1999). Figure 1.3.3.4 shows a graphic representation of 
chronic, low-grade inflammation. 
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Figure 1.4.4.1. Chronic low-grade systemic inflammation. TNF-α is produced in the 
adipose tissue and stimulates the production of IL-6 in both adipose tissue and blood 
mononuclear cells. IL-6 enhances systemic levels of other inflammatory markers 
including CRP (Adopted from Petersen and Pedersen, 2005).     
 
TNF-α has been shown to stimulate tumorigenesis by disruption of cell-
epithelial adhesion and promotion of cell migration (Montesano et al, 2005; Alokail 
et al., 2014). IL-6, has also been shown to be elevated in most cancer types studied 
and are strongly associated with several phenotypic features of cancer (Culig, 2011; 
Alokail et al., 2014). CRP, as a first line of defence against pathogens, has been studied 
comprehensively since it is one of the biomarkers visible in atherosclerotic lesions and 
has consistently shown to be elevated in all other non-communicable diseases that 
involve chronic, low-grade inflammation (Danesh et al., 2004). 
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1.5 Gut Microbiota and Endotoxin  
The study of the human gut microbiome has rapidly evolved through 
technological advancements and with it laid the foundations of the microbiome's 
influence in human health and disease not limited to the gastrointestinal system but to 
the an array of metabolic processes (Shreiner et al., 2015). As of 2016, it has been 
identified that the more realistic commensal bacteria to human host cell ratio is 1.3:1 
(Sender et al., 2016), and while it did debunk the long standing accepted ratio of 10:1, 
it did not in any way minimize the significant importance of the gut microbiome in 
human physiology and metabolism. Among the multitude of bacteria residing in our 
bodies, majority belong only to two phyla: Bacteroidetes and Firmicutes, with low 
levels of the latter being more associated with a variety of metabolic disorders 
(Johnson et al., 2017). Furthermore, the largest and earliest source of microbial 
exposure in humans is the intestinal tract, which contains a large and diverse 
population of microbes. As a result, the intestinal tract is considered the most 
important postnatal source of microbial stimulation of the immune system (Rodriguez 
et al., 2015). The initial gut composition from exposure to maternal microbiome can 
significantly influence immune system development (Belkaid and Hand, 2014), 
including the transition from milk-based diet (whether from breast-feeding or infant 
formula) to solid foods (Tognini, 2017), as microbial colonization during infancy can 
set the stage for the microbiome in adulthood (Houghteling and Walker, 2015). Hence, 
disruption of this process in early life during a time of dynamic changes (Rodriguez 
et al., 2015; Belkaid and Hand, 2014) in the infant’s gut might have long-term health 
effects. Some chronic metabolic disorders such as asthma and obesity often begin in 
early childhood, after the gut microbiota is established (Ly et al., 2011). Previous 
studies in both animal models and in humans have demonstrated relationships between 
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gut microbiota, atopic diseases (e.g., eczema, allergic rhinitis and asthma) and obesity 
(Sepp et al, 1997; Bjorksten et al, 1999; Bottcher et al, 2000; Murray et al, 2005; 
Penders et al, 2007; Adlerberth et al, 2007; Verhulst et al, 2008; Kalliomaki et al, 
2001, 2008; Ley et al, 2005, 2006; Turnbaugh et al, 2009). Early-life factors (e.g., diet, 
medications, hygiene, antioxidants and nutrients) associated with asthma, obesity, or 
both, might alter the gut milieu (Turnbaugh et al, 2009; Litonjua et al, 2008). 
The metabolic state of obesity and weight gain has been observed to distort the 
microbial balance in the gut aside from modifying adipocyte functions (Figure 1.5.1) 
(John and Mullin, 2015). This alteration in the microbial balance undesirably impacts 
health by promoting low-grade chronic inflammatory states, the same feature found in 
T2DM and CVD (Chassaing and Gewirtz, 2014). The results of several recent studies 
suggest that low-grade systemic inflammation can result from the absorption of 
endotoxin across the intestinal tract (Creely et al, 2007; Brun et al, 2007; Al-Attas et 
al, 2009; Harte et al, 2010). The absorption of endotoxin is positively correlated with 
obesity (Ley et al, 2005; Triantafyllou et al, 2007; Cani et al, 2007b) and has been 
associated with a number of measurable clinical effects, which include T2DM (Creely 
et al, 2007; Cani et al, 2008), non-alcoholic steatohepatitis (Brun et al, 2007), 
cardiovascular disease (Miller et al, 2009) and multi-organ injury. Previous studies 
have shown that there is a 2-3 fold increase in circulating endotoxin in patients with 
insulin resistance and or T2DM compared with non-diabetic insulin sensitivity lean 
controls (Al-Attas, et al, 2009; Harte et al, 2010; Creely et al, 2007).  
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Figure 1.5.1: An overview of the potential impact of systemic endotoxin derived from 
the gut (Adopted from Castanon et al., 2014). 
 
The intestinal mucosa provides a selectively permeable barrier between the 
circulation and intestinal lumen contents. Paracellular transport through the intact 
epithelial cell layer occurs through apical junctional complexes, which are composed 
of tight junctions (TJs) and adherens junctions. They regulate barrier permeability in 
response to a number of physiological and pathological stimuli, (Liu, et al., 2009) 
metabolic abnormalities and inflammation (Triantafyllou et al, 2007). TJs are also 
under cytokine control as well (Watson et al, 2005). The intestinal mucosa permits 
limited paracellular transport of bacterial lipopolysaccharide (LPS), another term for 
endotoxin (Watson et al, 2005), and TJ dysfunction increases intestinal permeability 
to these toxic luminal contents (Cani et al, 2008; Liu et al, 2009). Evidence from 
murine models suggests that obesity is associated with increased endotoxin absorption 
(Brun et al, 2007) and a number of mechanisms could explain the presence of 
endotoxemia in obese mice. First, diet may impair the intestine’s barrier function 
through its effects on intestinal flora or motility; the intestines of mice fed a high-fat 
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diet are colonized by a greater proportion of LPS-containing bacteria [Cani et al, 
2007]. The introduction of dietary fiber reduces the proportion of gram-negative 
bacteria in the gut lumen and hence reduces plasma endotoxemia (Cani et al, 2007). 
Second, the ecology of murine gut microbiota is altered by obesity (Ley et al, 2005), 
an effect potentially mediated by insulin resistance, because reduced intestinal motility 
and bacterial overgrowth are apparent in hyperglycemic and hyperinsulinemic states 
(Zietz et al, 2000; Cuoco et al, 2002; Triantafyllou et al, 2007). Hyperglycemia 
increases gut mucosal permeability in LPS-treated rats, independently of the plasma 
insulin concentration (Yajima et al, 2009). However, insulin can also act directly on 
the intestine to increase absorption (Westergaard, 1989). Finally, obesity is a disorder 
of chronic low-grade inflammation (Weisberg et al, 2003), and inflammation is 
implicated in impaired intestinal permeability. A previous study in patients with 
Crohn’s disease showed increased absorption of polyethylene glycol 400 and lactulose 
(Katz et al, 1989) compared with healthy controls. Pro-inflammatory cytokines in 
obese patients may disrupt tight junctions, compromising the intestinal barrier to gut 
microbiota. TNF-α modifies permeability by targeting TJs and reduces the expression 
of p-glycoprotein MDR-1 (Belliard et al, 2004). TNF-α also alters the lipid 
composition and fatty acyl structure of phospholipids in microdomains at TJs (Li et 
al, 2008) and increases translocation of Escherichia coli through a monolayer of 
glutamine-starved epithelial cells in vitro (Clark et al, 2003). Treating Crohn’s disease 
with the anti-TNF drug infliximab restores the intestinal barrier, although this may 
simply represent restoration of the normal mucosa (Suenaert et al, 2002). 
Previous and recent evidence suggests a complex relationship between 
metabolic factors, inflammation, and intestinal permeability. However, the transport 
of luminal contents across the intestinal mucosa may initiate the innate pathway 
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through binding of toll-like receptors (TLRs) to bacterial antigens, such as LPS, a 
component of the gram-negative cell membrane (Nesto et al, 2004; Kaisho & Akira, 
2002). Activation of TLRs results in transduction of nuclear factor κΒ (NFκB) to the 
nucleus and subsequent transcription of inflammatory mediators, such as interleukin 
(IL)-1, IL-6, and TNF-α (Muzio et al, 2004). LPS has been shown to upregulate TLR-
2 expression and induce both IL-6 and TNF-α in human adipocytes (Lin et al, 2000; 
Creely et al, 2007; Song et al, 2006). Many studies have shown that impairments in 
gut barrier function result in plasma endotoxemia (Cani et al, 2007; Cani et al, 2008; 
Liu et al, 2009; Yajima et al, 2009). Circulating endotoxin may, in turn, aggravate 
intestinal barrier damage by promoting mucosal immunodeficiency (Liu et al, 2009). 
Murine studies have shown that continuous infusion of endotoxin increases gut 
permeability, as does high-fat dietary feeding (Cani et al, 2007; Brun et al, 2007). 
Although the underlying mechanism is poorly understood, LPS/endotoxin shows 
particular affinity to chylomicrons, the lipoproteins responsible for transporting fatty 
acids across the intestinal wall. This affinity has been implicated in the post-prandial 
inflammatory response (Ghoshal et al, 2009) and may account for translocation of 
LPS/endotoxin across the intestinal wall. Therefore, endotoxemia could at least partly 
explain the chronic low-grade inflammation associated with obesity. As such, there is 
intense interest in manipulation of the gut microbiota. 
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1.6 Probiotics  
 The definition of probiotics has been widely debated, but in 2001, the Food 
and Agriculture Organization (FAO) and the WHO defined them as “Live 
microorganisms which, when administered in adequate amounts, confer a health 
benefit on the host: (FAO/WHO, 2001). This universally accepted definition implies 
that a probiotic strain, unless protected by a capsule, should be intrinsically resistant 
to low pH, bile and pancreatic enzymes to ensure gastrointestinal transit in numbers 
adequate to elicit a defined benefit to the host. It was also recognized that the concept 
of probiotics can improve the host’s health by modifying the composition of the 
intestinal microbiota. The recent advent of powerful molecular techniques has made 
it possible to monitor changes in the gut microbiota following probiotic 
administration, to better understand their functions. This has also helped researchers 
to identify that probiotics offer remarkable potential for the prevention and 
management of various infective and non-infectious disorders. Scientific evidence 
indicates that the ability of probiotic bacteria to confer their health effects largely 
depend on the strain being used (Tuohy et al, 2007). However, the host’s own 
intestinal microbiota, which has a less diverse population of intestinal anaerobes in 
early life, appears to be associated with both atopic diseases and obesity (Forno et al, 
2008; Turnbaugh et al, 2009). 
Many different probiotics strains have been identified and the effects of these 
bacteria, either given in monoculture or as a cocktail of various strains, have been 
subject to increasing scientific evaluation in recent years. Probiotic bacteria, the most 
common of which are the lactose-fermenting Lactobacilli, inhibit the growth of 
pathogenic bacteria by acidifying the gut lumen, competing for nutrients, and 
producing antimicrobial substances (Gorbach et al, 2000; Liu et al, 2004). 
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Furthermore, they adhere to the gastrointestinal mucosa and are thought to prevent 
bacterial translocation from the gut (Chiva et al, 2000). The strongest evidence for the 
use of probiotics has been in the management of diarrheal diseases (Allen et al, 2010). 
Data extrapolated from a large number of studies, including systemic reviews (Allen 
et al, 2004; Checkley et al, 2008; Johnston et al, 2007) meta-analyses (Cremonini et 
al, 2002; Huang et al, 2002; Sazawal et al, 2006; Van Niel et al, 2002), open-label 
studies (Fang et al, 2009; Guandalini et al, 2000) and multicenter trials testing the 
efficacy of probiotics in preventing diarrhoea concluded that, in addition to having a 
good safety profile, probiotics significantly reduced the duration and frequency of 
acute diarrhea (Henker et al, 2007). In addition, trials have documented favourable 
effects of probiotics in other gastrointestinal diseases [e.g., irritable bowel syndrome 
(IBS) and pouchitis]. A recent systematic review and meta-analysis identified 19 
randomized clinical trials reporting the effect of probiotics on IBS symptoms 
(Moayyedi et al, 2010). From these 19 studies, 10 randomized clinical trials reported 
that the significant effects of probiotics were superior to placebo, and 15 out of 19 
reported improved IBS scores in the probiotics group as an outcome. In the largest 
randomized clinical trial to date of probiotics in IBS using encapsulated doses of 
Bifidobacterium infantis, the authors reported a statistically significant benefit of B. 
infantis at a dose of 108 colony forming units (CFU) on abdominal pain, bloating, 
tenesmus and straining (Whorwell et al. 2006). 
Studies of obesity have also shown altered gut microbial compositions in 
human subjects and in mice (Turnbaugh et al, 2009; Ley et al, 2005, 2006). The guts 
of obese human subjects had reduced numbers of Bacteroidetes and increased 
numbers of Firmicutes compared with lean people (Turnbaugh et al, 2009). In some 
obese humans, an increased proportion of fecal Bacteroidetes was found to parallel 
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weight loss on a hypocaloric diet during a 1-year intervention trial (Turnbaugh et al, 
2009). Diet-induced obesity in animal models may also lead to increased Mollicutes 
(a class of Firmicutes), which appears to be reversible with dietary manipulation 
aimed at limiting weight gain (Ley et al, 2005). The finding that the microbial 
composition is reversible by dietary modification suggests that differences in the gut 
composition between obese and lean individuals are related to dietary factors 
independent of obesity (Hildebrandt et al, 2009; Cani et al, 2009). It should also be 
noted that not all of the studies have shown beneficial effects of probiotics, which 
means that caution should be taken in terms of the dosage and strains to be used, as 
these may have important ramifications on the effects observed. 
Taken together, the current evidence supports a role for the gut microbiota in 
the pathogenesis of diet-induced obesity and related metabolic disorders, which might 
be reversible with dietary and/or gut microbiota manipulation (Ly et al, 2011). As the 
gut flora is the main source of endotoxin, treatment with probiotics may influence the 
circulating levels of endotoxin by altering the microbiota composition. To date, 
relatively few studies have examined the effects of endotoxin in metabolic diseases by 
using probiotics. To our knowledge, very few interventional studies have been 
performed other than in a small study of patients with cirrhosis in which a 25% 
reduction in endotoxin was reported (Backhed, et, al 2005). However, animal studies 
have revealed that treatment with probiotics may be beneficial in insulin-resistant 
states (Ley et al, 2005, 2006; Husebye et al, 2001). Studies by, Li and co-workers have 
reported that treatment with probiotics decreased liver inflammation in a mouse model 
of non-alcoholic fatty liver disease (Li, et al, 2003). More recently, it has been shown 
that probiotics can delay the onset of glucose intolerance in high-fructose-fed rats 
(O’Hara et al, 2006).  
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The limited interventional studies performed on probiotics supplementation 
thus far have several limitations, including the study design, small sample size and 
short duration of intervention (Table 1.5.1). Furthermore and to the best of our 
knowledge, no randomised clinical trial has been conducted using a multi-strain 
probiotic (8 bacterial strains) in the T2DM population. For the purpose of this thesis, 
a summary of preliminary findings performed involving one or several of the 
probiotics strains used in the present interventional studies are presented in Table 
1.5.1. 
Table 1.6.1 Probiotic Strains Used in the Thesis 
Probiotic Strain Effects References 
Bifidobacterium 
bifidum  
Decrease in FPG, CRP & increase in total 
antioxidant capacity (12 weeks) 
 
Decreased insulin and HOMA-IR (12 
weeks) 
 
Increase in quantitative insulin sensitivity 
index; decreased triglycerides and VLDL 
concentrations  
(6 weeks) 
 
Increased adiponectin mRNA and 
decreased monocyte chemoattractant 
protein 1 and IL-6  
(obese mice 5 weeks) 
 
Decrease in total cholesterol and 
triglycerides, increase in HDL cholesterol  
(elderly T2DM for 30 days) 
 
Reduces abdominal adoposity and 
increases antioxidant enzyme in 
combination with other probiotic strains in 
overweight women (RCT, N=43, 8 weeks) 
 
Badehnoosh et 
al., 2017  
Soleimani et al., 
2017  
Ahmadi et al., 
2016  
 
Le et al., 2014  
 
Moroti et al., 
2012   
 
Gomes et al., 
2017  
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Bifidobacterium 
lactis  
Increases intestinal barrier integrity by 
increasing TEER in Caco-2 cells 
 
Reduces visceral fat accumulation and 
improves glucose tolerance by increasing 
gut acetate levels 
 
Reduces glycemia in combination with 
metformin in animal models 
 
Reduces abdominal adoposity and 
increases antioxidant enzyme in 
combination with other probiotic strains in 
overweight women (RCT, N=43, 8 weeks) 
 
Mokkaka et al., 
2016. 
 
Aoki et al., 2017  
 
 
Stenman et al., 
2015  
 
Gomes et al., 
2017  
 
Lactobacillus 
acidophilus  
Decrease in FPG, CRP & increase in total 
antioxidant capacity 
 
Decreased insulin and HOMA-IR 
 
Increase in quantitative insulin sensitivity 
index; decreased triglycerides and VLDL 
concentrations  
(6 weeks) 
 
Decrease in total cholesterol and 
triglycerides, increase in HDL cholesterol  
(elderly T2DM for 30 days) 
 
Reduces abdominal adoposity and 
increases antioxidant enzyme in 
combination with other probiotic strains in 
overweight women (RCT, N=43, 8 weeks) 
Badehnoosh et 
al., 2017  
 
Soleimani et al., 
2017  
Ahmadi et al., 
2016  
 
 
Moroti et al., 
2012  
 
 
Gomes et al., 
2017  
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Modulates LPS-induced inflammatory 
activity by regulating TLR4 and NFκB 
expression in weaned pigs 
 
Lee et al., 2016  
 
Lactobacillus 
brevis  
Attenuates hyperglycemia in diabetes-
induced mice in STZ rat model 
 
Inhibits lipopolysaccharide production by 
E.coli, NFκB activation and p16 
expression in aged mice 
Marques et al., 
2016  
 
Jeong et al., 
2016 
 
Lactobacillus 
casei  
Decrease in FPG, CRP & increase in total 
antioxidant capacity 
 
Decreased insulin and HOMA-IR 
 
Increase in quantitative insulin sensitivity 
index; decreased triglycerides and VLDL 
concentrations  
(6 weeks) 
 
Reduces abdominal adiposity and 
increases antioxidant enzyme in 
combination with other probiotic strains in 
overweight women (RCT, N=43, 8 weeks) 
 
Improves glucose intolerance, 
dyslipidemia, immunoregulation and 
oxidative stress in high-fat diet and STC-
induced T2DM in mice  
 
Anti-obesity effects observed in obese rats 
Badehnoosh et 
al., 2017  
 
Soleimani et al., 
2017  
Ahmadi et al., 
2016  
 
 
 
Gomes et al., 
2017b  
 
 
Chen et al., 2014  
 
 
 
Karmimi et al., 
2015  
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Lactobacillus 
salivarius  
Corrects diabetes-induced enteric 
dysbiosis by inhibition of gut iNOS 
protein expression (Lin et al, 2017) and 
through induction of non-defensin proteins 
(Chung et al, 2015). 
No effect on glycemic control among 
pregnant women with abnormal glucose 
tolerance (RCT, N =149). 
 
Lin et al., 2017  
 
Chung et al., 
2016  
Lindsay et al., 
2015  
 
Lactococcus 
lactis W19 
Lactococcus 
lactis W58 
Reverses diabetes in NOD mice in 
combination with low-dose Anti-CD3 
 
Prevents hyperglycemia and improves 
glucose tolerance by inhibition of antigen-
specific proliferation of T cells in NOD 
mice  
 
Reduces abdominal adiposity and 
increases antioxidant enzyme in 
combination with other probiotic strains in 
overweight women (RCT, N=43, 8 weeks) 
 
Inhibits increases in blood glucose levels 
after ingesting sucrose in silkworms 
Takiishi et al., 
2017  
 
Liu et al., 2016  
 
 
Gomes et al., 
2017  
 
 
 
Matsumoto et 
al., 2016   
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1.7 Study Hypothesis and Aims of the Study 
 The current research hypothesis is that, gut-derived components also known 
as endotoxin or lipopolysaccharides, act as a potent initiator of systemic low grade 
inflammation, that may be modulated by consumption of multi-strain probiotics, to 
reverse the damaging effects of endotoxaemia amongst people with T2DM. 
 In order to test this hypothesis, a randomised, double-blind, placebo-controlled 
trial has been conducted over a 3 and 6 month duration to determine the beneficial 
effects of a multi-strain probiotics supplementation among adult, medication naïve 
and newly diagnosed T2DM Saudi patients. Specifically, the main objectives of this 
thesis were: 
1. To investigate the effects of probiotics supplementation on circulating 
endotoxin levels of Saudi patients with T2DM (primary outcome). 
2. To define the effects of probiotics supplementation on different 
cardiometabolic indices including anthropometry, glycaemic, lipid, 
inflammatory and adipocytokine profiles of Saudi patients with T2DM. 
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Chapter 2  
Materials and Methods 
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2.1 Study Design 
The main study design is a randomised, double-blind, placebo-controlled trial, 
considered the gold standard of interventional studies due to its ability to demonstrate 
causality, elimination of unknown biases secondary to randomisation and reduction of 
confounding effects from interventions due to blinding (Misra, 2012). Parts of the 
study protocol has been previously published (Alokail et al., 2013) and has been 
registered at the US National Library of Medicine (USNLM) at the National Institute 
of Health (NIH): ClinicalTrials.gov Identifier: NCT01765517 (Appendix I). Records 
of the protocol have also been deposited and submitted to the Saudi Food and Drug 
Administration (SFDA) in Riyadh, Saudi Arabia, as a requirement to obtain approval 
for the conduct of clinical trial (Approval number 8/25/126307; date: April 7, 2013) 
(Appendix II) and the use of imported probiotic and placebo sachets (Code: 2-1434-
1-8188-90-2; Approved date: June 26, 2013) (Appendix III).  
 
2.2 Ethical approval 
The study protocol has been approved by the Ethics Committee of the College 
of Science (Approval number 8/25/16519) (Appendix IV), King Saud University, 
Riyadh, Saudi Arabia and the Ministry of Health in Riyadh, Saudi Arabia, for the 
recruitment of participants from different primary care centres (Approval number 
8/25/136164) (Appendix V). The study conforms to the revised ethical standards for 
the conduct of human research studies under the declaration of Helsinki (Carlson et 
al, 2004). 
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2.3 Sample Size Calculation 
Prior to the conduct of the trial, the hypothesis was that treatment with 
probiotics should reduce mean endotoxin levels by 25–30%, while no change seen in 
the placebo group. To obtain 80% power and demonstrate a statistically significant 
difference (two-sided p-value = 0.05) between the two treatments, 100 participants 
must be treated (50 patients per arm). Since dropouts were anticipated, recruitment 
was made sure to exceed N=100. The sample size was calculated based on the 
estimated mean change during treatment (Δ-values) and corresponding standard 
deviation (SD) of the change. On the assumption that the correlation between 1 
(placebo) and 2 (probiotics) had a measurement of 0.70, the SD for the Δ-value was 
78% of the SD of separate measurements, as demonstrated in the following table. 
 
Table 2.3.1 SD for single measurement, corresponding correlations and Δ-value 
SD for each measurement Correlation between measures SD of the Δ-value 
1 0.60 0.89 
1 0.65 0.84 
1 0.70 0.78 
1 0.75 0.71 
1 0.80 0.63 
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The table below shows the estimated sample sizes according to various 
assumptions of treatment effect and correlation between 1 and 2 measurements. 
 
Table 2.3.2 Estimated Sample Sizes 
Endotoxin 
baseline 
(U/L) 
Difference in Δ-
value  
(probiotics –
placebo) 
SD for change  
(common for 
both 
treatments) 
Correlati
on for 
1. and 2. 
measure
ment 
Sample 
size (total) 
2-tailed α: 
0.05 
Power: 
80% 
Sample 
size (total) 
2-tailed α: 
0.05 
Power: 
90% 
10 (± 6) –2 5.34 0.60 224 298 
 –2 5.04 0.65 200 266 
 –2 4.68 0.70 176 236 
 –2 4.26 0.75 148 198 
 –2 3.78 0.80 116 154 
 –2.5 5.34 0.60 144 192 
 –2.5 5.04 0.65 128 172 
 –2.5 4.68 0.70 114 152 
 –2.5 4.26 0.75 96 128 
 –2.5 3.78 0.80 76 100 
 
 
2.4 Participant Recruitment 
A total of 150 adult Saudi male and female T2DM participants (medication 
naïve and without co-morbidities, aged 30-60 years) were initially recruited, 96 of 
whom were randomized, 78 completed 3 months and 61 completed the entire clinical 
trial (Figure 2.1.1). Interventions were performed at weeks 0, 12 and 26 in all 
participants who completed the trial. Participant enrolment was initially undertaken 
with collaborating primary care centres and the Out-Patient Department of King 
Salman Hospital in Riyadh, Saudi Arabia in Riyadh. Due to the low turnout of 
participants from primary care centres and their reluctance to participate compared 
with subjects attending King Salman Hospital, the study recruitment was performed 
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only on King Salman Hospital, a tertiary hospital, and as such the present trial was 
considered as a single-centre study.  
 
Figure 2.4.1. CONSORT Flowchart detailing number of participants at enrolment, 
allocation and treatment for the entire duration of the clinical trial. 
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2.4.1 Inclusion and Exclusion Criteria 
Participants were initially recruited and screened at various primary care 
centres but since most of those attending these centres were determined to be long-
term DM patients, the recruitment refocused to King Salman University Hospital in 
Riyadh, Saudi Arabia. Saudi adult males and females aged 30-60 years with stable and 
well controlled (HbA1c <7.5%), newly diagnosed T2DM (less than 6 months post-
diagnosis), naïve to treatment (uninitiated in any oral hypoglycemic agents, including 
insulin), were invited to participate. They were oriented about the protocol and those 
who showed interest were asked for written informed consent prior to enrolment. 
Participants who were non-Saudis, with long standing gastrointestinal disease, intake 
of systemic antibiotics within six weeks before inclusion or use of probiotics 
supplements within three months before inclusion, regular intake of insulin or insulin 
analogues, antacids, H2-receptor blockers, proton pump inhibitors, loperamide, 
cholestryramine, ω3-unsaturated fatty acid supplements, fibrates, corticosteroids or 
sex steroids were excluded. In addition, those who were mentally incapable to give 
consent were excluded. Other criteria for exclusion included those who were actively 
participating in another clinical trial or participated in another intervention study 
within the last 6 months, lactating or pregnant and/or with known cardiovascular 
disease. 
 
2.5 Allocation to Treatment 
After confirmation of eligibility and obtaining written informed consent, 
participants were given a unique subject number by the research nurse. The 
randomization scheme was computer generated by Winclove using permuted blocks 
with block size equal to 4, whilst both the patients and clinicians at the primary care 
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centre and King Salman Hospital were blinded to the treatment received. Eligible 
participants were allocated (1:1) to treatment for 26 weeks with either the probiotics 
supplement or placebo. Participants allocated to the probiotics group received two 
sachets with two grams of freeze-dried powder of the probiotic mixture 
EcologicBarrier daily (Winclove, Amsterdam, Netherlands). EcologicBarrier 
(2.5x109 cfu/gram) contains the following bacterial strains: Bifidobacterium bifidum 
W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus 
brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus 
lactis W19 and Lactococcus lactis W58. Participants in the placebo group received 
sachets consisting of the carrier of the probiotic product (maize starch and 
maltodextrins). Placebo content contains no probiotic bacteria, but is indistinguishable 
in colour, smell and taste from the probiotic sachets. A sample sachet used in the study 
and the actual sachets used commercially are shown in figure 2.5.1. 
 
Figure 2.5.1 Actual sachets used in the intervention study (A) versus commercial 
sachets (B) 
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Participants were instructed to dissolve all sachet contents in lukewarm water 
and consume it completely. This was performed twice: one sachet before breakfast 
and one sachet before bedtime. Store unused sachets at room temperature. Return 
unused sachets at designated appointment times to monitor compliance and to be given 
fresh refill. Unblinding was performed after the last participant submitted unused 
sachets and blood samples. The company responsible for the blinding and 
randomization (Winclove) was informed and the excel sheet containing allocation was 
then provided electronically. 
Figure 2.5.2 shows the actual box with code and label provided for each participant 
containing sachets for the intervention study. 
 
Figure 2.5.2 Refill box with code and instructions. 
 
2.6 Data Handling and Record Keeping 
Case report forms (CRF) were used to record data for all participants and 
completed by the research field nurse and data given to the research team to enter the 
data into an electronic database. 
2.7 Study Schedule and Location 
Following participants’ induction into the study all further treatments were 
managed at the out-patient clinic in King Salman Hospital, Riyadh, Saudi Arabia 
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where all participants were initially screened and recruited (see Table 2.7.1 for 
scheduled visits). The assigned research nurse and research assistant were responsible 
for all contacts with patients and reported accordingly to the research team. The 
research team and the collaborating physician were available throughout the entire 
intervention period to ensure that participant concerns were addressed and medical 
queries were noted and attended to. 
 
2.8 Acquisition of Clinical Data and Assessment of Compliance 
Medical history including the presence of chronic diseases, medications 
regularly taken and other habits (i.e., smoking) were recorded before inclusion. 
Changes in existing medications during the intervention stage of the study were also 
noted. All anthropometric and clinical measurements were performed at baseline and 
at weeks 12 and 26, with participants notified a week before the intended appointment. 
Compliance was monitored accordingly from unused sachets submitted by the 
participants during visits. Participants were free to refuse further participation during 
the intervention period. 
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Table 2.7.1 Participant Schedule of Visits 
 Pre-
Screening 
Screening Inclusion Weeks 
0 12 26 
Participant visits out-
patient clinic 
 ●  ● ● ● 
Phone review ●      
Eligibility check ● ●     
Obtain informed consent   ●    
Blood sampling    ● ● ● 
Provision of test product    ● ●  
Return of unused product     ● ● 
Monitor compliance & 
adverse events  
    ● ● 
 
 
2.9 Acquisition of Anthropometric Measurements  
Anthropometric measurements were performed using standardized methods. 
Height (cm) was measured using a stadiometre. Weight (kg) was taken with the 
participant in light clothing without shoes or items in pockets. Waist (cm) was 
measured as a horizontal plane at the level of the umbilicus and hip circumference 
(cm) was measured as a horizontal plane at the level of the trochanter major using a 
regular tape measure. Systolic and diastolic blood pressure (mmHg) were measured 
twice using an aneroid mercurial sphygmomanometer and the mean blood pressure 
calculated and noted accordingly. Body mass index (BMI) was calculated as the 
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quotient between weight (kg) and height in squared metres. Waist-to-hip (WHR) ratio 
was calculated as waist divided by hip circumference. Finally, mean arterial pressure 
(MAP) was calculated using the formula: 
[(Diastolic Blood Pressure x 2 + Systolic Blood Pressure)]/3. All anthropometric and 
clinical measurements were repeated at weeks 0, 12, and 26. 
 
2.10 Acquisition of Routine Biochemical Data and Biological Samples 
2.10.1 Blood and Sample Collection 
             All eligible participants were requested to fast for 8-10 hours the night before 
scheduled appointment for collection of fasting blood samples and anthropometric 
measurements. Fasting blood samples were collected at baseline (week 0), week 12 
and 26. Peripheral venous blood drawn were collected into pyrogen-free tubes without 
any anticoagulant. The tubes were allowed to coagulate, immediately positioned in ice 
and centrifuged (2500 ×g for 10 min at 4°C) within two hours of extraction for instant 
delivery to the Biomarkers Research Program, Biochemistry Department, College of 
Science, King Saud University, Riyadh, Saudi Arabia. Delivered serum samples were 
divided into 2 (1ml) aliquots and immediately stored at –20°C until use. At least 2ml 
serum samples were collected at each time-point.  
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2.10.2 Clinical and Biochemical Measurements 
The materials used in the study is listed in Table 2.10.2.1 for the analysis of 
circulating endotoxin, glycaemic (glucose, insulin and C-peptide), lipid (triglycerides, 
HDL- and total cholesterol), adipocytokine (leptin, adiponectin and resistin) and 
inflammatory (TNF-α, C-reactive protein and IL-6) profiles of participants. Fasting 
serum glucose, triglycerides, total cholesterol and HDL-cholesterol were measured 
using a chemical analyser (Konelab, Espoo, Finland). Circulating insulin and c-
peptide were measured using electrochemiluminiscence (ECL) assay by Roche 
ELECSYS® and Cobas e411 (Roche Diagnostics, Basel, Switzerland). Serum leptin, 
TNF-α and IL6 (human bone magnetic bead panel) as well as adiponectin and resistin 
(human adipokine magnetic bead panel) were measured using Milliplex Map® 
(Millipore, Billerica, MA, USA) multiple assays by Luminex® xMAP® (Luminex 
Corp, Austin, TX, USA). Finally, CRP was measured using enzyme-linked 
immunosorbent assay (ELISA) (R&D Systems Inc., Minneapolis, MN, USA). 
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Table 2.10.2.1 Materials Used in the Study 
MATERIALS SUPPLIER 
Chemicals and solutions  
70% ethanol Fisher Chemical, VA, USA 
Sheath fluid Luminex Corp, TX, USA   
SysWash Roche, Basel, Switzerland 
ISE cleaning solution Roche, Basel, Switzerland 
Kits   
Insulin  Roche, Basel, Switzerland 
C-peptide  Roche, Basel, Switzerland 
Human Adipokine  Magnetic bead panel EMD Millipore Corp, 
Germany 
Human Bone Magnetic bead panel EMD Millipore Corp, 
Germany 
ELISA Human C-reactive protiein R&D System, USA 
Total Cholesterol   Thermo Scientific, VA, USA 
Glucose  Thermo Scientific, VA, USA 
Triglycerides  Thermo Scientific, VA, USA 
HDL-Cholesterol  Thermo Scientific, VA, USA 
Endotoxin  Lonza, MD, USA 
Equipment   
Cobas e 411 analyzer Roche, Basel, Switzerland  
Microplate reader Molecular devices, CA, USA  
FlexMap 3D multiplex platform Luminex Corp, TX, USA   
Power Sonic405  Hwashin Tech, Korea 
DCA Vantage Siemens, USA 
Vortex mixer Velp Scientifica, Velate, Italy 
Multichannel pipette  Eppendorf, Hamburg, 
Germany 
Timer Thermo Scientific, VA, USA 
 
2.10.3 Sample Analysis Principles and Detailed Procedures 
2.10.3.1 Insulin and C-peptide 
The sandwich principle was applied to higher molecular weight analytes such 
as insulin and c-peptide. The total time period of the assay was 18 minutes. In the first 
incubation, insulin from 20μL sample, a biotinylated monoclonal insulin-specific 
antibody, and a monoclonal insulin-specific antibody labelled with a ruthenium 
complex formed a sandwich complex. In the second incubation, streptavidin-coated 
micro particles were added and the complex was bound to the solid phase via 
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interaction of biotin and streptavidin. The reaction mixture was aspirated into the 
measuring cell where the micro particles were magnetically captured onto the surface 
of the electrode. Unbound substances were then removed with ProCell and provided 
tripropylamine (TPA), an essential compound for the ECL-reaction. Application of 
voltage to the electrode then induced chemiluminescent emission which was measured 
by a photomultiplier. Results were determined via a calibration curve which was 
provided via the reagent barcode. The lower detection limit for insulin was 0.2IU/ml 
with an intermediate precision of 2.5%-2.8% and a repeatability of 1.9%-2.0% specific 
for e cobas 411 analyzer. The lower detection limit for c-peptide was 0.01 ng/ml with 
an intermediate precision of 0.6%-1.5% and a repeatability of 1.6%-2.3%. 
 
2.10.3.1.1 Reagents and Sample Preparation for Insulin and C-Peptide 
Waste water was first replaced by a new one (1 litre deionized water with 
10mL SysWash) followed by Cobas-e machine cleaning with the use of ISE cleaning 
solution placed in ProCell and finally replacement of all instrument's reagents 
(calibrators, and controls, ProCell and ControlCell). For the calibration step, calibrator 
powder bottles were left at room temperature for 15 minutes, dissolved (calibrators 1 
and 2) in 1000 µl of deionized water and allowed to stand for 30 minutes to 
reconstitute. Mixing was performed carefully to avoid foam formation. Around 100 
µl of the reconstituted calibrator was then transferred in the empty labelled cap. The 
system automatically regulated the temperature of the reagents and the 
opening/closing of the bottles. For the quality control step, control powder bottles 
were left at room temperature for 15 minutes, carefully dissolved (controls 1 and 2) in 
3000 µl deionized water and allowed to stand for 30 minutes to reconstitute. Mixing 
was also performed carefully to avoid foam formation. Around 100 µl of the 
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reconstituted control was then transferred in the empty labelled cap and processed in 
the machine. Controls were run in parallel with participant samples, one per reagent 
kit, whenever a calibration was performed. The control interval and limits was adapted 
to the laboratory requirements. For the sample tests, serum samples were thawed to 
approximately 20°C and placed on the reagent disk (20°C) of the analyser. Samples 
were vortexed and 100 µl of each samples in the test cups was added, avoiding foam 
formation as much as possible. Cup positions and samples’ serial number were entered 
manually in the system.  
 
2.10.3.2 Glucose 
Glucose oxidase catalysed the oxidation of glucose to gluconate. The formed 
hydrogen peroxide (H2O2) was detected by a chromogenic oxygen acceptor, phenol, 
4-aminophenazone (4-AP) in the presence of peroxidase. The resulting colour is then 
automatically quantified spectrophotometrically at 505nm (Konelab, Espoo, Finland). 
The required reagents (Thermo Fisher Scientific Inc., Middletown, VA, USA) were 
ready for use. Presence of bubbles were avoided in the bottleneck or on the surface of 
the reagent whenever the reagent vials or vessels in the analyser were inserted. 
Reagents in unopened vials were stable at 2-8 °C until the expiration date printed on 
the label and were kept away from sunlight. The samples were processed using 
collection tubes, in accordance with the manufacturer’s instructions to avoid erroneous 
results. Special attention was given to the pre-analytical variables such as mixing, 
standing time before centrifugation and centrifuge settings. Sample types such as 
unhemolysed serum, heparin or EDTA plasma can still be used in the Konelab 
analyser (Konelab, Espoo, Finland).  All samples were taken from participants on a 
fasted state. All samples were separated from the cells as soon as possible after 
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collection in order to avoid glycolysis. If the sample was not separated or analysed 
without delay, a glycolytic inhibitor was used. 
 
2.10.3.2.1 HOMA-IR 
Homeostasis model assessment (HOMA-IR) was calculated as the product of 
insulin (IU/ml) and glucose (mmol/l) divided by 22.5 (Matthews et al., 1985).  
 
2.10.3.3 Total Cholesterol 
The approach used was the CHOD/POD method. Cholesterol esters were 
enzymatically hydrolysed by cholesterol esterase to cholesterol and free fatty acids. 
Free cholesterol was then oxidized to cholesterol oxidase to cholest-4-en-3-one and 
hydrogen peroxide. The hydrogen peroxide combines with HBA and 4-
aminoantipyrine to form a chromophore (quinonemine dye) which was quantified 
spectrophotometrically at 500-550nm. Results were automatically calculated by the 
instrument (Konelab, Espoo, Finland). The required reagents for total cholesterol were 
ready for use (Thermo Fisher Scientific Inc., Middletown, VA, USA) and the sample 
preparation was similar to glucose assessment (refer to section 2.8.2). 
 
2.10.3.4 Triglycerides 
Triglycerides were hydrolysed by lipase to glycerol and fatty acids. The 
glycerol was phosphorylated to glycerol-3-phosphate, which was then oxidised to 
dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide reacted 
with 4-aminoantipyrine and 4-chlorophenol forming a quinoneimine dye. The 
absorbance of the formed colour was then automatically measured 
spectrophotometrically at 510nm (Konelab, Espoo, Finland). The required reagents 
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for triglycerides were ready for use (Thermo Fisher Scientific Inc., Middletown, VA, 
USA) and the sample preparation was similar to glucose assessment (refer to section 
2.8.2). 
 
2.10.3.5 High Density Lipoproteins (HDL) 
Measurement of HDL-cholesterol was performed as a homogenous enzymatic 
colorimetric test which was in the presence of magnesium sulfate and dextran sulfate 
which selectively forms water-soluble complexes with low density lipoprotein (LDL), 
very low density lipoprotein (VLD) and chylomicrons, compounds resistant to 
polyethylene glycol-modified (PEG) enzymes. The cholesterol concentration of HDL 
was determined enzymatically by cholesterol oxidase coupled with PEG to the amino 
acid groups. The results were automatically calculated by the instrument (Konelab, 
Espoo, Finland). Reagents A and B were ready for use. The pink intrinsic colour of 
the reagent did not interfere with the test. Both serum and heparin plasma can be used. 
EDTA plasma can cause lower than actual values. Samples that contained precipitates 
were centrifuged before the assay was performed.  
 
2.10.3.6 Low Density Lipoproteins (LDL) 
LDL-cholesterol levels were not measured similar to the other lipids. In this 
study, the widely used Friedewald formula was chosen to calculate LDL-cholesterol 
levels (Whelton et al., 2017):   
LDL = Total cholesterol – HDL-cholesterol – [Triglycerides/2.17mmol/l]  
- 51 - 
 
2.10.3.7 Human C-reactive protein (CRP) 
This assay employed the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for CRP has been pre-coated onto a 
microplate. Standards and samples were pipetted into the wells and any CRP present 
was bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked monoclonal antibody specific for CRP was added to the 
wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate 
solution was added to the wells and colour develops in proportion to the amount of 
CRP bound in the initial step. The colour development was halted and the intensity of 
the colour was measured. The intra-assay precision as mentioned in the procedure was 
4.4%-8.3% whilst the inter-assay precision was 6.0%-7.0%. Materials were provided 
and storage conditions were kept at 2-8°C. 
 
2.10.3.7.1 Preparation of CRP Reagents 
A serum separator tube (SST), a polypropylene tube, was used to contain 
samples. The samples were allowed to clot for 30 minutes before centrifugation for 15 
minutes at 1000 x g.  Serum was removed and assayed immediately or stored at ≤ -20 
°C. Serum samples required a 100-fold dilution and as such 10 μL of sample + 990 μL 
of calibrator diluent RD5P (1X) was performed. The wash buffer bottle was warmed 
to room temperature and mixed gently until the crystals have been completely 
dissolved. Wash buffer concentrate (20 ml) was diluted into deionized or distilled 
water and 500 mL of wash buffer was prepared. The calibrator diluent RD5P (1X) (20 
mL) was diluted into 80 mL of deionized or distilled water 100 mL of calibrator 
diluent RD5P (1X) was prepared. Colour reagents A and B for the substrate solution 
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were mixed together in equal volumes within 15 minutes of use and was protected 
from light. Around 200 μL of the resultant mixture was required per well. For the CRP 
standard, polypropylene tubes were used. Around 200 μL of the calibrator diluent 
RD5P (1X) was pipetted into each of the six tubes. Around 200 μL of the standard 
was added to the 25 ng/mL tube for the 2-fold dilution series. Each tube was mixed 
thoroughly before the next transfer. The 50 ng/mL standard served as the high 
standard. The calibrator diluent RD5P (1X) served as the zero standard (0 ng/mL). 
Stop solution (6ml of 2N H2SO4) was prepared with caution by wearing protective 
gloves, clothing and facial protection. The solution (0.337 ml of H2SO4) was slowly 
added to 105 ml deionized water and the final volume was adjusted to 6 ml with 
deionized water. 
All reagents and samples were brought to room temperature before use. All 
standards, samples, and controls were assayed in duplicate. Detailed steps as provided 
by the manufacturer was followed. 
2.10.3.8 Leptin, IL-6 and TNF-α 
Leptin, interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α) were 
measured simultaneously using the human bone magnetic bead panel assay [bone 
metabolism multiplex assay analytes included: ACTH, DKK-1, FGF-23, IL-1β, IL-6, 
insulin, leptin, osteocalcin, OPN - osteopontin, osteoprotegerin, PTH, SOST, TNF-
α] (Milliplex Map ®) based on the Luminex ® xMAP ® technology. Serum samples 
were diluted 1:2 in the assay buffer provided in the kit. 
 
2.10.3.8.1 Preparation of Leptin, IL-6 and TNF-α Reagents  
For individual vials of beads [Anti-leptin beads (bead region 39); anti-IL6 
beads (bead region 34 and anti-TNFα beads (bead region 55)], each antibody-bead 
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vial was sonicated for 30 seconds; then vortexed for 1 minute. 150μL from each 
antibody-bead vial added to the mixing bottle and final volume brought to 3.0mL with 
bead diluent. The mixed beads were vortexed well. Quality controls 1 and 2 were 
reconstituted with 250μL deionized water, vortexed and allowed to sit for 5-10 
minutes. Wash buffer was prepared using 60 mL of 10X wash buffer (two bottles) 
diluted with 540mL deionized water. For serum matrix, 1.0 mL of deionized water 
and 1.0mL of assay buffer was added to the bottle containing lyophilized serum 
matrix, mixed well and allowed to rest for at least 10 minutes for complete 
reconstitution. For the standards, the human bone standard vial was reconstituted with 
250 μL deionized water, vortexed for 10 seconds, allowed to sit for 5-10 minutes and 
labelled as standard 7. Six polypropylene microfuge tubes were then labelled as 
standards 1-6. Assay buffer (150 μL) was added to each of the six tubes and serial 
dilutions (1:4) were prepared by adding 50 μL of the reconstituted standard 7 to 
standard 6 tube onwards until standard 1. 
 
2.10.3.8.2 Immunoassay Procedure for Leptin, IL-6 and TNF-α 
All reagents were allowed to warm to room temperature (20-25ºC) before use 
in the assay. The placement of 8 standards [0 (Background), 1-7] controls 1 and 2, and 
samples were diagrammed on Well Map Worksheet in a vertical configuration. The 
assay was run in duplicate and the 96-well plate was prepared and arranged according 
to manufacturer’s instructions. The plate was run on Luminex 200TM, HTS, 
FlexMAP 3DTM or MAGPIX® with xPONENT software. The intra-assay variation 
was 1.4%-7.9% and inter-assay variation of <21%. Minimum detectable 
concentrations (MDC) were as follows: leptin, 85.4 pg/ml, IL-6, 0.4 pg/ml and TNFα, 
0.14 pg/ml.  
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2.10.3.9 Adiponectin and Resistin 
Serum adiponectin and resistin were measured simultaneously using the 
human adipokine magnetic bead panel assay [endocrine multiplex assay analytes 
included: adiponectin, adipsin, lipocalin-2/NGAL, PAI-1 (total), resistin] (Milliplex 
Map®) based on the Luminex® xMAP® technology. Serum samples were diluted 
1:400 in the assay buffer provided in the kit. The rest of the immunoassay procedure 
was similar to the human bone magnetic bead panel assay (refer to section 2.10.3.8.2). 
The intra-assay variation was 1.4%-7.9% and inter-assay variation of <21%. 
Minimum detectable concentrations (MDC) for adiponectin was adiponectin was 
145.4 pg/ml and 6.7 pg/ml for resistin.  
 
2.10.3.9.1 Preparation of Adiponectin and Resistin Reagents  
For individual vials of beads, each antibody-bead vial [anti-human adiponectin 
(bead region 51) and anti-human resistin (bead region 64) was sonicated for 30 
seconds then vortexed for 1 minute. The rest of the preparation reagents and 
immunoassay procedure were similar to the human bone magnetic bead panel (see 
sections 2.10.8.1 and 2.10.8.2). 
 
2.10.3.10 Endotoxin 
In this study, three different endotoxin quantifying kits were used to measure 
circulating endotoxin level in participants’ sera. At the beginning, Limulus 
Amoebocyte Lysate (LAL) QCL-1000® kit was used, followed by 
PyroGene™ Recombinant Factor C Endotoxin Detection Assay, and finally the last 
kit, the Limulus Amoebocyte Lysate (LAL) Kinetic-QCL™. The last kit gave good 
results in terms of spike recovery. 
- 55 - 
 
 
2.10.3.10.1 Principle behind Endotoxin Quantification 
Gram-negative bacterial endotoxin catalyses the activation of a proenzyme in 
the LAL. The initial rate of activation was determined by the concentration of 
endotoxin present. The activated enzyme catalyzes the release of pNA from the 
colourless substrate Ac-lle-Glu-Ala-Arg-pNA. The free pNA was measured 
photometrically at 405–410 nm after the reaction was stopped using the stop reagent. 
The correlation between the absorbance and the endotoxin concentration was linear in 
the 0.1–1.0 EU/ml range. The concentration of endotoxin in a sample was calculated 
from the absorbance values of solutions containing known amounts of endotoxin 
standard.  
 
2.10.3.10.2 Reagents Supplied for Endotoxin 
The kinetic-QCL reagent vial contained a lyophilized mixture of lysate 
prepared from the circulating amebocytes of the horseshoe crab, Limulus polyphemus 
and chromogenic substrate. This reagent was reconstituted immediately with 2.6 ml 
of LAL reagent water per vial and swirled gently to avoid foaming. It was used 
immediately. The LAL reagent water bottles contained 30 ml and were used in the 
reconstitution of all reagents and as a negative control (blank). Lastly, the E. coli 
endotoxin vial contained approximately 50 EU/ml. It was reconstituted with a specific 
volume of LAL reagent water and mixed vigorously for 15 minutes at high speed on 
a vortex mixer. The reconstituted stock endotoxin was stable for four weeks at 2-8°C.  
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2.10.3.10.3 Specimen Collection and Preparation for Endotoxin Assessment 
Careful technique was used to avoid microbial or endotoxin contamination. 
All materials that came into contact with the specimen or test reagents were endotoxin 
free. Clean glassware and materials were rendered endotoxin free by heating at 250°C 
for 30 minutes. Appropriate precautions were taken to protect materials from 
subsequent environmental contamination. From experience, most sterile, individually 
wrapped, plastic pipettes and pipette tips were endotoxin free. However, these 
materials tested before regular use. Samples to be tested stored in such a way that all 
bacteriological activity is stopped or the endotoxin level may increase with time. For 
example, stored samples at 2-8°C for less than 24 hours; samples stored longer than 
24 hours should be frozen. If the container of diluent used to rehydrate the reagents 
has been opened previously or was not supplied by Lonza, the diluent alone must be 
tested for endotoxin contamination. 
 
2.10.3.10.4 Product Inhibition in Measuring Endotoxin 
Product inhibition occurs when substances in the test sample interfere with the 
LAL reaction. In the Kinetic-QCL™ Assay, this inhibition results in a longer reaction 
time, indicating lower levels of endotoxin than may actually be present in the test 
sample. The lack of product inhibition should be determined for each specific sample, 
either undiluted or at an appropriate dilution. To verify the lack of product inhibition, 
an aliquot of test sample (or a dilution of test sample) was spiked with a known amount 
of endotoxin. 
In an inhibition/enhancement assay, the spiked solution (PPC) was assayed along with 
the unspiked sample, their respective endotoxin concentrations, as well as the 
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endotoxin recovered in the spiked sample were automatically calculated. The 
endotoxin recovered should equal the known concentration of the spike within 50 – 
200%. A spiked aliquot of the test sample (or dilution) was prepared: tube method (50 
μl) of the 50.0 EU/ml solution was transferred into 4.95 ml of test sample (or dilution). 
This solution contained an endotoxin concentration of 0.5 EU/ml in test sample (or 
dilution). This sample was vigorously vortexed for one minute prior to use. Around 
100 μl of this solution was transferred into the 96-well plate as directed by the assay 
template. 
 
2.10.3.10.5 Reagents Preparation in Endotoxin Assessment 
Reagents were allowed to equilibrate to room temperature prior to use. In order 
to calculate endotoxin concentrations in unknown samples, each Kinetic-QCL test was 
referenced to a valid standard curve. Due to the large concentration range over which 
endotoxin values can be determined, it was possible to adjust the quantitative range of 
any given test by adjusting the concentration of endotoxin standards used to generate 
the standard curve. A minimum of three standards were required. The Kinetic-QCL 
assay was optimized to be linear from 0.005 EU/ml to 50.0 EU/ml. Plastic tubes were 
never used for making endotoxin solutions. 
A solution containing 5.0 EU/ml endotoxin was prepared by adding 0.1 ml of 
the 50.0 EU/ml endotoxin stock into 0.9 ml of LAL reagent water in a suitable 
container and labelled 5.0 EU/ml. This solution was vortexed vigorously for at least 1 
minute before proceeding. Serial dilutions were done. 
Due to the variability of this assay, all the samples were undertaken together 
on the same day. All lab areas, heat block, pipettes which used were cleaned with 70% 
ethanol. Cleaned and autoclaved (free endotoxin) reservoirs were used. Filtered tips 
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and unopened boxes of autoclaved multichannel tips were also used. The addition of 
all reagents in the LAL assay was made consistent. All tubes or microplate wells were 
treated in exactly the same manner in order to determine the proper endotoxin 
concentration. It was suggested that, in a series of tests, reagents should be pipetted in 
the same order from tube to tube or well to well, and at the same rate. A specific 
template for the test was created to be run. This template had the name of the analyst, 
type of assay, lot numbers of reagents, the number and concentration of endotoxin 
standards, number of replicates and how standards and samples were supposed to be 
organized on the microplate. The template was printed for use as a guide in placing 
standards and samples into the microplate. The template was used following the 
WinKQCL™ Software prompts. Around 100 μl LAL reagent water was dispensed at 
wells blank, endotoxin standards, product samples, positive product controls, etc. into 
the appropriate wells of the microplate. The filled plate was then placed in the 
microplate reader and the lid closed. The plate was pre-incubated for ≥10 minutes at 
37°C ± 1°C. Near the end of the pre-incubation period, each of the appropriate number 
of Kinetic-QCL™ reagent vials were reconstituted with 2.6 ml LAL reagent water. It 
was then mixed gently but thoroughly. The lysate was not vortexed. The reagents were 
pooled into a reagent reservoir and mixed gently by shaking the reservoir from side to 
side. Using an eight channel pipette, a 100 μl of the Kinetic-QCL™ reagent was 
dispensed into all wells of the microplate beginning with the first column (A1-H1) and 
proceeding sequentially up to the last column used. Reagents were added as quickly 
as possible. Bubble formation was also avoided as much as possible. OK button was 
clicked immediately in the WinKQCL™ software to initiate the test and quantification 
of endotoxin. 
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2.11 Data Analysis 
The actual sample size after the intervention period (N=39 per group) has an 
actual power of 83% based on within group analysis. All analyses were performed 
using SPSS (version 16.5 Chicago, IL, USA). Mean and standard deviations were used 
to represent the data for the continuous normal variables, while median and 
interquartile range were used to report continuous non-normal variables. Furthermore, 
frequencies and percentages (%) were reported for categorical data. Changes, which 
were differences between follow-up and baseline values, were also calculated as mean 
and as percentage (%). Bivariate correlations between endotoxin anthropometrics, 
glycaemic and lipid profile were measured using Spearman correlation coefficient. 
Independent sample Student T-test and Mann Whitney U test were used to determine 
metabolic and clinical differences between placebo and probiotic groups at baseline. 
Statistical analysis for within group comparisons were performed twice: using 
intention-to-treat (ITT) analysis, where missing data were dealt by using the last 
observation carried forward (LOCF) method. Per-protocol analysis (PPA) was also 
performed on participants who successfully completed 80% of the trial. Mixed method 
analysis of covariance (ANCOVA) was used to determine between group differences 
after adjusting for baseline observations. All non-normal variables were transformed 
prior to parametric testing. Intervention effects were presented at 95% confidence 
interval (CI). A p-value <0.05 was considered statistically significant. All analysis 
figures were plotted using MS Excel. 
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Chapter 3.  
Effects of a 3-Month Daily Intake of a Multi-Strain 
Probiotic Supplement in Circulating Endotoxin 
Levels and Cardiometabolic Profiles of Naïve Saudi 
T2DM Patients 
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3.1. Introduction 
In the last few years, the gut microbiome has gained considerable interest due to 
its ability to coexist with its human host and complement several key physiologic 
processes peacefully maintaining homeostasis and over-all human health (Backhed et 
al., 2005). One theory that may explain the contribution of gut microbes to metabolic 
disease progression is sub-chronic inflammation secondary to endotoxemia. This state 
occurs when fragments of gut-derived gram negative bacteria (lipopolysaccharides or 
endotoxin) traverse the intestinal mucosa to enter the circulation, and may represent 
an important mediator of low-grade systemic inflammation influenced by the host's 
own gut microbiota and metabolic state (Harte et al., 2010). Previous studies have also 
shown that endotoxin can stimulate an innate immune response from adipose, liver 
and skeletal muscle tissues, leading to increased production of pro-inflammatory 
cytokines (Creely et al., 2007; Miller et al., 2009; Piya et al., 2013; Al-Disi et al, 
2015).  
There has been accumulating evidence pointing to the manipulation of the gut 
microbiome in the prevention and reversal of several chronic non-communicable 
diseases such as obesity, type 2 diabetes mellitus (T2DM) and the metabolic syndrome 
(MetS) (Brunkwall et al., 2017). It is now established that dietary intake and nutrition 
management are significant and clinically effective external factors in modifying the 
gut ecosystem (Singh et al., 2017). Specifically, probiotics, or live bacteria that 
naturally occur in the human body can confer health benefits, these have shown great 
potential as adjuvant therapies for a number of insulin-resistant diseases. Currently, 
randomized clinical trials in this area are limited and more research is required to 
strengthen the case. 
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In this chapter, studies were undertaken to establish whether a 12/13 week 
supplementation of a multi-strain probiotic could induce favourable changes in 
circulating endotoxin levels (primary outcome) and cardiometabolic profile 
(secondary outcome) of naïve T2DM subjects. 
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3.2. Materials and Methods  
The present study was a 12-week single-centre, double-blind, randomised, 
placebo-controlled study. Ethics approval has been mentioned previously (Chapter 
2.2.  
3.2.1 Participants 
A detailed description of participants has been described previsouly (Chapter 2.4). 
A flowchart is shown in figure 3.2.1. 
3.2.2 Probiotic Supplements and Allocation Treatment 
A detailed description of allocation to treatment has been described previously 
(Chapter 2.5). 
3.2.3 Monitoring and Blood Sample Collection 
A detailed description has been provided previously in Chapter 2.8-2.10 
3.2.4 Biochemical Analyses 
Fasting serum samples were analysed for glucose and lipid profile (Total 
cholesterol, HDL and triglycerides) using routine analyser (Konelab, Espoo, Finland). 
LDL-cholesterol was calculated using the Friedewald equation (Whelton et al., 2017). 
Serum insulin and c-peptide were measured using electrochemiluminescence assay 
(Roche Diagnostics, Germany). Coefficients of variation have been provided 
previously in Chapter 2.10. 
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Figure 3.2.1 CONSORT Flowchart showing participants' screening, randomization 
and allocation throughout the 12/13 week intervention study. ITT - intention-to-treat; 
PPA - per protocol analysis 
 
3.2.5 Data Analysis 
In addition to the information previously provided in Chapter 2.11, mixed method 
analysis of covariance (ANCOVA) was used to determine within and between group 
differences after adjusting for baseline observations and covariates including WHR, 
MAP, Glucose (mmol/l), TC/HDL and endotoxin (IU/ml). Intervention effects were 
presented at 95% confidence interval (CI). P-value <0.05 was considered statistically 
significant. 
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3.3 Results 
3.3.1 General Characteristics of Participants 
The demographic characteristics of participants assigned to placebo [N=39, 21 
males, 18 females] and probiotics [N=39, 20 males, 19 females] are shown in table 
3.3.3.1. No statistically significant differences were noted in age (p=0.40), weight 
(p=0.22) and BMI (p=0.59). The placebo group had significantly higher mean waist-
hip ratio than the probiotics group (placebo 1.0±0.1 vs probiotics 0.9±0.1; p=0.02). 
The placebo group also had a significantly lower diastolic (mmHg) (78.6±8.6 vs 
83.6±11.8; p=0.04) and mean arterial blood pressure (95.5±7.7 vs 100.7±11.1; 
p=0.02) than the probiotics group. With regards to glycaemic and lipid parameters, the 
placebo group had significantly lower median glucose (mmol/l) levels [7.0 (5.7-11.2) 
vs 11.7 (8.4-16.4); p<0.001], as well as significantly lower mean circulating levels of 
total cholesterol (mmol/l) (5.2±1.0 vs 5.8±1.3; p=0.04), LDL-cholesterol (3.1±0.9 vs 
3.7±1.3; p=0.05) and total/HDL-cholesterol ratio (5.0±1.3 vs 6.4±2.2; p=0.001) than 
the probiotics group. Lastly, median endotoxin (IU/ml) levels were significantly lower 
in the placebo than the probiotics group [2.1 (1.2 -4.4) vs 4.6 (2.4 -9.9); p=0.002]. The 
rest of the parameters were not significantly different from one another. 
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Table 3.3.1.1 Baseline Parameters According to Placebo and Probiotics. 
 
Parameters Placebo  Probiotics  P-value 
N 39 39  
Males (%) 21 (56.8) 19 (51.4)  
Age (years) 46.6 ± 5.9 48.0 ± 8.3 0.40 
Weight (kg) 79.5 ± 15.7 75.6 ± 11.0 0.22 
BMI (kg/m2) 30.1 ± 5.0 29.4 ± 5.2 0.59 
Waist-Hip Ratio 1.0 ± 0.1 0.9 ± 0.1 0.02 
Systolic BP (mmHg) 129.5 ± 10.3 134.8 ± 14.6 0.07 
Diastolic BP (mmHg) 78.6 ± 8.6 83.6 ± 11.8 0.04 
Mean Arterial Pressure (MAP) 95.5 ± 7.7 100.7 ± 11.1 0.02  
Glucose (mmol/l) 7.0 (5.7 -11.2) 11.7 (8.4 -16.4) <0.001 
Insulin (uU/mL) 13.1 (7.7 -18.7) 9.9 (7.7 -16.4) 0.48 
C-peptide (ng/ml) 0.1 (0.1 -0.5) 0.4 (0.0 -1.8) 0.22 
HOMA-IR 4.1 (2.3 -7.3) 5.3 (3.5 - 10.2) 0.10 
Triglycerides (mmol/l) 2.2 ± 1.4 2.5 ± 1.4 0.36 
Total Cholesterol (mmol/l) 5.2 ± 1.0 5.8 ± 1.3 0.04 
HDL-Cholesterol (mmol/l) 1.1 ± 0.3 1.0 ± 0.3 0.08 
LDL-Cholesterol (mmol/l) 3.1 ± 0.9 3.7 ± 1.3 0.05 
Total-Cholesterol/HDL Ratio 5.0 ± 1.3 6.4 ± 2.2 0.001  
Endotoxin (IU/ml) 2.1 (1.2 -4.4) 4.6 (2.4 -9.9) 0.002 
Note: Data presented as Mean ± SD for normal variables while non-normal variables are 
presented as Median (inter-quartile range).  
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3.3.2 Characteristics of Participants at Baseline and after Three Months 
3.3.2.1 Endotoxin 
 Mean differences between placebo and probiotics group were presented in 
figure 3.3.2.1 and showed a significant difference in the probiotics group from 
baseline and after 3 months in both ITT (p<0.001) and PPA (p<0.001). This difference 
was not observed in the placebo group. 
 Within and between group effects of participants’ characteristics using ITT 
and PPA as well as percentage changes were shown in tables 3.3.2.1.1 and 3.3.2.1.2. 
No difference was noted in endotoxin levels between groups [placebo mean change -
0.20 (percentage change -9.5%) vs probiotics -2.40 (-52.2%); (95% Confidence 
Interval (CI): -0.05-0.36; p=0.15)]. Within group comparisons however showed a 
significant decrease in endotoxin levels in the probiotics group [baseline median = 4.6 
(interquartile range 2.4-7.9) vs 3 months = 2.2 (1.2-3.6); p<0.01)]. This was not 
observed in the placebo group [2.2 (1.2-4.4) vs 1.9 (1.0-2.9); p=0.31)]. Within group 
comparisons using PPA showed the same significant difference in the probiotics group 
[5.1 (3.2-8.4) vs 2.3 (1.2-3.6); p<0.01)] and not in placebo [2.3 (1.2-4.6) 2.0 (1.1-4.7); 
p=0.14)] (Table 3.3.2.1.1).  
 
Figure 3.3.2.1 Mean differences in endotoxin levels in placebo versus probiotics 
using A) Intention-to-treat and B) Per Protocol Analysis 
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Table 3.3.2.1.1 Endotoxin Before and After Supplementation with Placebo or Probiotics Using ITT and PPA 
 
 
 
 
Placebo (N=39, 21 males, 18 females) Probiotics (N=39, 20 males, 19 females) Intervention Effect 
Baseline 3-Months Mean Change P
a Baseline 3-Months Mean Change P
a Effect (95% CI) Pb 
ITT 2.1 (1.2 – 4.4) 1.9 (1.0 – 2.9) -0.20 0.31 4.6 (2.4 – 7.9) 2.2 (1.2 – 3.6) -2.40 <0.01 0.15 (-0.05 - 0.36) 0.15 
 
(N=24, 15 males, 9 females) (N=26, 14 males, 12 females) 
 
PPA 2.3 (1.2 - 4.6) 2.0 (1.1 – 4.7) -0.30 0.14 5.1 (3.2 - 8.4) 2.3 (1.2 - 3.6) -2.80 <0.01 0.20 (-0.05 - 0.45) 0.12 
Note: Endotoxin values presented as median (inter-quartile range); pa and pb denotes p-values for within group differences and between group 
differences respectively obtained from mixed model ANCOVA after adjusting for baseline covariates including WHR, MAP, Glu, (mmol/l), 
TC/HDL and Endo (IU/ml). Significant at p<0.05. 
 
Table 3.3.2.1.2 Percentage Change (%) in Placebo and Probiotics 
 
Parameters 
Intention-to-Treat Per Protocol 
Placebo Probiotics Placebo Probiotics 
Endotoxin (IU/ml) -9.52 -52.17 -13.04 -54.90 
Note: Data presented as percentages (%). 
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3.3.2.2 Anthropometric and Clinical Measures 
Using ITT and compared with the placebo group, participants in the probiotics 
groups had a significant improvement in WHR [placebo 0.0 (0.0%) vs probiotics -0.01 
(-1.11%); (CI: -0.12- -0.01; p=0.02)] (Tables 3.3.2.2.1 and 3.3.2.2.3). No differences 
were noted in weight [0.42 (0.5%) vs -0.28 (-1.4%); (CI: -17.1-1.1; p=0.08)], BMI 
[0.15 (0.5%) vs -0.11 (-0.4%); (CI: -4.92-2.39; p=0.49)], systolic blood pressure [0.43 
(0.3%) vs -5.84 (-0.4%0; (CI: -5.18-10.06; p=0.52)], diastolic blood pressure [1.22 
(1.5%) vs -3.78 (-4.5%); (CI: -5.82-6.58; p=0.90)] and MAP [0.96 (1.0%) vs -4.47 (-
4.4%); (CI: -4.58-6.72; p=0.71)].  
Within group comparisons using ITT showed a significant decrease in systolic 
(baseline mean ± standard deviation = 135.0±15.0 vs 3 months 129.0±11.0; p<0.01), 
diastolic (84.0±12.0 vs 80.0±11.0; p=0.03) as well as mean arterial blood pressure 
(100.7±11.1 vs 96.2±9.7; p<0.01) in the probiotics group post intervention. These 
differences were not observed in the placebo group (p-values for SBP, DBP and MAP; 
0.80, 0.44 and 0.60, respectively). Furthermore, p-values indicated no significant 
changes in either group with regards to weight (placebo = 0.71; probiotics = 0.08), 
BMI (placebo = 0.76; probiotics 0.86) and WHR (placebo = 0.32; probiotics = 0.75) 
after 3 months (Table 3.3.2.2.1).  
 
 
 
 
 
  
70 
 
Table 3.3.2.2.1 Anthropometric Characteristics Before and After Supplementation with Placebo or Probiotics Using Intention-
to-Treat Analysis 
Parameters 
Placebo (N= 39, 21 males, 18 females) Probiotics (N=39, 20 males, 19 females) Intervention Effect 
Baseline 3-Months Mean Change Pa Baseline 3-Months Mean Change Pa Effect (95% CI) Pb 
Weight (kg) 79.5 ± 15.7 79.9 ± 15.9 0.42 0.71 75.6 ± 11.0 75.3 ± 11.3 -0.28 0.77 -8.00 (-17.1 – 1.1)  0.08 
BMI (kg/m2) 30.1 ± 5.0 30.2 ± 5.0 0.15 0.76 29.4 ± 5.2 29.3 ± 5.3 -0.11 0.86 -1.27 (-4.92 - 2.39) 0.49 
WHR 1.0 ± 0.1 1.0 ± 0.1 0.00 0.32 0.9 ± 0.1 0.9 ± 0.1 -0.01 0.75 -0.07 (-0.12 - -0.01) 0.02 
SBP (mmHg) 129.0 ± 10.0 130.0 ± 11.0 0.43 0.80 135.0 ± 15.0 129.0 ± 11.0 -5.84 <0.01 2.44 (-5.18 - 10.06) 0.52 
DBP (mmHg) 79.0 ± 9.0 80.0 ± 8.0 1.22 0.44 84.0 ± 12.0 80.0 ± 11.0 -3.78 0.03 0.38 (-5.82 - 6.58) 0.90 
MAP 95.5 ± 7.7 96.5 ± 7.8 0.96 0.60 100.7 ± 11.1 96.2 ± 9.7 -4.47 <0.01 1.07 (-4.58 - 6.72) 0.71 
Note: Data presented as mean ± SD; pa and pb denotes p-values for within group differences and between group differences respectively obtained 
from mixed model ANCOVA after adjusting for baseline covariates including WHR, MAP, Glu, (mmol/l), TC/HDL and Endo (IU/ml). BMI, body 
mass index; WHR, waist-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; CI – confidence 
interval. Significant at p<0.05. 
 
This significant reduction in WHR was also observed using PPA [0.0 (0.0%) vs -0.01 (-1.11%); (CI: -0.14- -0.03; p=0.01)] (Tables 
3.3.2.2.2 and 3.3.2.2.3). Within group comparisons using the PPA showed no significant changes in all anthropometric measures post 
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intervention in both placebo (p-values for weight, BMI, WHR, SBP, DBP and MAP: 0.43, 0.96, 0.18, 0.65, 0.38, 0.59, respectively) and 
probiotics group (p-values for weight, BMI, WHR, SBP, DBP and MAP: 0.66, 0.98, 0.65, 0.25, 0.15, 0.11, respectively) (Table 3.3.2.2.2).  
 
Table 3.3.2.2.2. Anthropometric Characteristics Before and After Supplementation with Placebo or Probiotics Using Per 
Protocol Analysis 
Parameters 
Placebo (N=24, 15 males, 9 females) Probiotics (N=26, 14 males, 12 females) Intervention Effect 
Baseline 3-Months Mean Change Pa Baseline 3-Months Mean Change Pa Effect (95% CI) Pb 
Weight (kg) 79.5 ± 15.7 79.9 ± 15.9 0.42 0.43 75.5 ± 10.9 75.4 ± 11.4 -0.07 0.66 -2.05 (-11.92 – 0) 0.72 
BMI (kg/m2) 30.1 ± 5.0 30.2 ± 5.0 0.15 0.96 29.4 ± 5.2 29.3 ± 5.4 -0.03 0.98 -0.77 (-4.67 - 3.14) 0.69 
WHR 0.9 ± 0.1 0.9 ± 0.1 0.00 0.18 0.9 ± 0.1 0.9 ± 0.1 -0.01 0.65 -0.08 (-0.14 - -0.03) 0.01 
SBP (mmHg) 129.5 ± 10.8 130.1 ± 11.7 0.57 0.65 132.7 ± 13.7 129.8 ± 12.7 -2.82 0.25 -2.44 (-11.93 - 7.05) 0.61 
DBP (mmHg) 78.4 ± 9.1 80.0 ± 8.5 1.63 0.38 83.2 ± 12.4 80.0 ± 11.7 -3.24 0.15 2.51 (-5.97 - 10.98) 0.55 
MAP 95.4 ± 8.5 96.7 ± 8.6 1.28 0.59 99.7 ± 11.2  96.6 ± 10.7 -3.10 0.11 0.86 (-6.77 - 8.49) 0.82 
Note: Data presented as mean ± SD; pa and pb denotes p-values for within group differences and between group differences respectively obtained 
from mixed model ANCOVA after adjusting for baseline covariates including WHR, MAP, Glu, (mmol/l), TC/HDL and Endo (IU/ml). BMI, body 
mass index; WHR, waist-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; CI – confidence 
interval. Significant at p<0.05. 
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Table 3.3.2.2.3. Percentage Changes (%) in Anthropometric Characteristics in Treatment Groups by Analysis Type 
Parameters 
Intention-to-Treat Per Protocol 
Placebo Probiotics Placebo Probiotics 
BMI (kg/m2) 0.50 -0.37 0.50 -0.10 
Waist-Hip Ratio 0.00 1.11 0.00 1.11 
Systolic BP (mmHg) 0.33 -4.33 0.44 -2.13 
Diastolic BP (mmHg) 1.54 -4.50 2.08 -3.89 
Mean Arterial Pressure (MAP) 1.01 -4.44 1.34 -3.11 
Note: Data presented as percentages (%). 
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3.3.2.3 Glycaemic Profile 
Between group comparisons using the ITT showed a clinically significant 
improvement in HOMA-IR observed in the probiotics group and not in placebo 
[placebo -0.50 (-12.2%) vs probiotics -3.20 (-60.4%); (CI: -0.34- -0.01; p=0.04)]. No 
differences were observed in glucose [placebo 1.0 (14.3%) vs probiotics -3.20 (-
27.4%); (CI: -0.06-0.16; p=0.36)], insulin [placebo -2.40 (-18.3%) vs probiotics -3.0 
(-30.3%); (CI: -0.24-0.07; p=0.29)] and C-peptide [placebo 0.0 (0.0%) vs probiotics -
0.40 (80.0%); (CI: -0.38-0.53; p=0.74)] (Tables 3.3.2.3.1 and 3.3.2.3.3). 
Within group comparisons using the ITT revealed significantly higher glucose 
levels in the placebo group after 3 months intervention [baseline median = 7.0 
(interquartile range 5.7-11.2) vs 3 months = 8.0 (5.9-11.4); p=0.02)] (Table 3.3.2.3.1). 
Furthermore in the placebo group, no significant changes were observed post-
intervention in circulating levels of insulin (p=0.72), C-peptide (p=0.12) and HOMA-
IR (p=0.37). In contrast, post-intervention levels of glucose [11.7 (8.4-16.4) vs 8.5 
(6.2-11.0); p<0.01)], insulin [9.9 (7.7-16.4) vs 6.9 (4.5-9.8); p<0.01)], C-peptide [0.5 
(0.0-1.8) vs 0.1 (0.0-0.3); p=0.01)] and HOMA-IR [5.3 (3.5-10.2) vs 2.1 (1.5-5.2); 
p<0.01)] were significantly lower than baseline in the probiotics group using the ITT 
analysis (Table 3.3.2.3.1).  
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Table 3.3.2.3.1. Glycaemic Characteristics Before and After Supplementation with Placebo or Probiotics Using Intention-to-
Treat Analysis 
Parameters 
Placebo (N= 39, 21 males, 18 females) Probiotics (N=39, 20 males, 19 females) Intervention Effect 
Baseline 3-Months 
Mean 
Change 
Pa Baseline 3-Months 
Mean 
Change 
Pa Effect (95% CI) Pb 
Glu (mmol/l) # 7.0 (5.7-11) 8.0 (5.9-11.4) 1.00 0.02 11.7 (8.4 - 16.4) 8.5 (6.2 – 11.0) -3.20 <0.01 0.05 (-0.06 - 0.16) 0.36 
Ins (IU/mL) # 13.1 (7.7-19) 10.7 (7.7–14.5) -2.40 0.72 9.9 (7.7 - 16.4) 6.9 (4.5 - 9.8) -3.00 <0.01 -0.08 (-0.2 - 0.07) 0.29 
C-Pep(ng/ml) # 0.2 (0.1-0.5) 0.2 (0.1 - 0.9) 0.00 0.12 0.5 (0.0 - 1.8) 0.1 (0.0 - 0.3) -0.40 0.01 0.08 (-0.38 - 0.53) 0.74 
HOMA-IR # 4.1 (2.3–7) 3.6 (3.1 – 5.5) -0.50 0.37 5.3 (3.5 - 10.2) 2.1 (1.5 - 5.2) -3.20 <0.01 -0.17(-0.3- -0.01) 0.04 
Note: Data presented as median (inter-quartile range); #median change presented instead of mean; all non-normal variables were transformed prior 
to parametric testing; pa and pb denotes p-values for within group differences and between group differences respectively obtained from mixed 
model ANCOVA after adjusting for baseline covariates including WHR, MAP, Glu, (mmol/l), TC/HDL and Endo (IU/ml). Glu, glucose; Ins, 
insulin; C-Pep, C-Peptide; HOMA-IR, homeostasis model for insulin resistance; CI – confidence interval. Significant at p<0.05. 
  
A significant difference in glucose levels was observed using PPA in the placebo group [7.1 (5.7-11.2) vs 8.0 (5.9-11.4); p=0.01)] (Table 
3.3.2.3.2).  Between group comparisons using the PPA showed no significant differences in both groups (p-values for glucose, insulin, C-
peptide and HOMA-IR: 0.30, 0.41, 0.79 and 0.11, respectively) (Tables 3.3.2.3.2 and 3.3.2.3.3). Furthermore in the placebo group, no 
significant changes were observed post-intervention in circulating levels of insulin (p=0.49), C-peptide (p=0.16) and HOMA-IR (p=0.29). 
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The same significant improvement in the glycaemic profile persisted even after using the PPA (p-values for glucose, insulin, C-peptide 
and HOMA-IR: <0.01, 0.04, 0.01 and <0.01, respectively) (Table 3.3.2.3.2). 
Table 3.3.2.3.2. Glycaemic Characteristics Before and After Supplementation with Placebo or Probiotics Using Per Protocol 
Analysis 
Parameters 
Placebo (N=24, 15 males, 9 females) Probiotics (N=26, 14 males, 12 females) Intervention Effect 
Baseline 3-Months 
Mean 
Change 
Pa Baseline 3-Months 
Mean 
Change 
Pa Effect (95% CI) Pb 
Glu (mmol/l) # 7.1 (5.7 - 11.2) 8.0 (5.9 - 11.4) 0.90 0.01 11.7 (8.4 - 16.4) 8.5 (6.2-10.9) -3.20 <0.01 0.06 (-0.06 - 0.19) 0.30 
Ins (uU/mL) # 13 (7.5 - 18.7) 10.9 (7.7 - 15.5) -2.10 0.49 9.8 (7.7 - 15.2) 6.8 (4.5 - 9.6) -3.00 0.04 -0.08 (- 0.28 - 0.12) 0.41 
C-Pep(ng/ml)# 0.2 (0.1 - 0.4) 0.3 (0.1 - 0.9) 0.10 0.16 0.7 (0.0 - 2.0) 0.1 (0.0 - 0.3) -0.60 0.01 0.07 (-0.43 - 0.56) 0.79 
HOMA-IR # 4.1 (2.3 - 7.5) 3.6 (3.1 - 6.0) -0.50 0.29 5.2 (3.5 - 10.2) 2.1 (1.5 - 4.4) -3.10 <0.01 -0.18 (-0.39 - 0.04) 0.11 
Note: Data presented as median (inter-quartile range); #median change presented instead of mean; all non-normal variables were transformed prior 
to parametric testing; pa and pb denotes p-values for within group differences and between group differences respectively obtained from mixed 
model ANCOVA after adjusting for baseline covariates including WHR, MAP, Glu, (mmol/l), TC/HDL and Endo (IU/ml). Glu, glucose; Ins, 
insulin; C-Pep, C-Peptide; HOMA-IR, homeostasis model for insulin resistance; CI – confidence interval. Significant at p<0.05. 
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Table 3.3.2.3.3. Percentage Changes (%) in Glycaemic Characteristics in Treatment Groups by Analysis Type 
 
Parameters 
Intention-to-Treat Per Protocol 
Placebo Probiotics Placebo Probiotics 
Glucose (mmol/l) 14.29 -27.35 12.68 -27.35 
Insulin (uU/ml) -18.32 -30.30 -16.15 -30.61 
C-peptide (ng/ml) 0.00 -80.00 50.00 -85.71 
HOMA-IR -12.20 -60.38 -12.20 -59.62 
Note: Data presented as percentages (%). 
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3.3.2.4 Lipid Profile  
Using the ITT analysis, between group comparisons showed no differences in all 
lipid indices: triglycerides [placebo -0.20 (-9.1%) vs probiotics -0.78 (-31.2%); (CI: -
0.96-0.28; p=0.27)], total cholesterol [-0.53 (-10.2%) vs -0.63 (-10.9%); (CI: -0.52-
0.75; p=0.72)], HDL-cholesterol [0.46 (-6.4%) vs 0.14 (-14.0%); (CI: -0.22-0.14; 
p=0.65)], LDL-cholesterol [-0.37 (-11.9%) vs -0.41 (-11.4%); (CI: -0.43-0.79; 
p=0.55)] and total/HDL cholesterol ratio [-0.11 (-2.2%) vs -1.07 (-16.7%); (CI: -0.72-
2.38; p=0.29)] (Tables 3.3.2.4.1 and 3.3.2.4.3).  
Within group comparisons using ITT showed significantly lower levels of total 
cholesterol after intervention in both placebo (baseline mean ± standard deviation 
5.2±1.0 vs 3 months 4.7±0.9; p<0.01) and probiotics group (5.8±1.3 vs 5.1±0.9; 
p<0.01). Only the probiotics group, however, showed significantly lower circulating 
triglycerides (2.5±1.4 vs 1.7±0.7; p=0.04) and LDL-cholesterol (3.6±1.3 vs 3.2±0.9; 
p=0.02) after intervention. Both groups had no significant changes in HDL-cholesterol 
(placebo = 0.46; probiotics = 0.10) and total/HDL cholesterol (placebo = 0.67; 
probiotics = 0.35) ratios post-intervention (Table 3.3.2.4.1).  
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Table 3.3.2.4.1. Lipid Profile Characteristics Before and After Supplementation with Placebo or Probiotics Using Intention-to-
Treat Analysis 
Parameters 
Placebo (N= 39, 21 males, 18 females) Probiotics (N=39, 20 males, 19 females) Intervention Effect 
Baseline 3-Months 
Mean 
Change 
Pa Baseline 3-Months 
Mean 
Change 
Pa Effect (95% CI) Pb 
TG (mmol/l) 2.2 ± 1.4 2.0 ± 0.8 -0.20 0.05 2.5 ± 1.4 1.7 ± 0.7 -0.78 0.04 -0.34 (- 0.96 - 0.28) 0.27 
TC (mmol/l) 5.2 ± 1.0 4.7 ± 0.9 -0.53 <0.01 5.8 ± 1.3 5.1 ± 0.9 -0.63 <0.01 0.11 (-0.52 - 0.75) 0.72 
HDL (mmol/l) 1.1 ± 0.3 1.0 ± 0.3 -0.07 0.46 1.0 ± 0.3 1.1 ± 0.3 0.14 0.10 -0.04 (-0.22 - 0.14) 0.65 
LDL (mmol/l) 3.1 ± 0.9 2.8 ± 0.9 -0.37 0.12 3.6 ± 1.3 3.2 ± 0.9 -0.41 0.02 0.18 (- 0.43 - 0.79) 0.55 
TC/HDL  5.0 ± 1.3 4.9 ± 1.4 -0.11 0.67 6.4 ± 2.2 5.3 ± 4.3 -1.07 0.35 0.83 (-0.72 - 2.38) 0.29 
Note: Data presented as mean ± SD; pa and pb denotes p-values for within group differences and between group differences respectively obtained 
from mixed model ANCOVA after adjusting for baseline covariates including WHR, MAP, Glu, (mmol/l), TC/HDL and Endo (IU/ml). TG, 
triglycerides; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; Endo, endotoxin; CI – confidence interval. 
Significant at p<0.05. 
 
 The same non-significant changes in between group comparisons were observed using the PPA (p-values for triglycerides, total 
cholesterol, HDL- and LDL-cholesterol, total/HDL-cholesterol ratio: 0.26, 0.39, 0.31, 0.21, 0.13, respectively) (Table 3.3.2.4.2 and 
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3.3.2.4.3). Lastly, within group comparisons using PPA in the placebo group showed significantly lower levels of triglycerides (2.1±1.4 
vs 2.0±0.8; p=0.05) and total cholesterol (5.2±1.0 vs 4.7±0.9; p<0.01) post-intervention. Significant improvement in total cholesterol 
levels was observed in the probiotics group (5.8±1.3 vs 5.1±0.9; p<0.01) as well as LDL-cholesterol (3.7±1.2 vs 3.3±0.9; p=0.03) after 3 
months of intervention. The rest of the lipids not previously mentioned do not significantly differ from one another in both placebo and 
probiotics (Table 3.3.2.4.2). 
Table 3.3.2.4.2. Lipid Profile Characteristics Before and After Supplementation with Placebo or Probiotics Using Per Protocol Analysis 
Parameters 
Placebo (N=24, 15 males, 9 females) Probiotics (N=26, 14 males, 12 females) Intervention Effect 
Baseline 3-Months Mean Change Pa Baseline 3-Months Mean Change Pa Effect (95% CI) Pb 
TG (mmol/l) 2.1 ± 1.4 2.0 ± 0.8 -0.20 0.05 2.5 ± 1.4 1.7 ± 0.7 -0.78 0.15 -0.41 (-1.13 - 0.31) 0.26 
TC (mmol/l) 5.2 ± 1.0 4.7 ± 0.9 -0.53 <0.01 5.8 ± 1.3 5.1 ± 0.9 -0.63 <0.01 0.30 (-0.39 - 0.98) 0.39 
HDL (mmol/l) 1.1 ± 0.3 1.0 ± 0.3 -0.07 0.15 1.0 ± 0.3 1.1 ± 0.3 0.15 0.20 -0.10 (-0.30 - 0.10) 0.31 
LDL (mmol/l) 3.2 ± 0.9 2.8 ± 0.9 -0.41 0.11 3.7 ± 1.2 3.3 ± 0.9 -0.44 0.03 0.43 (-0.24 - 1.10) 0.21 
TC/HDL  5.0 ± 1.3 4.9 ± 1.4 -0.13 0.88 6.5 ± 2.2 5.4 ± 4.4 -1.08 0.41 1.33 (-0.39 - 3.05) 0.13 
Note: Data presented as mean ± SD; pa and pb denotes p-values for within group differences and between group differences respectively obtained 
from mixed model ANCOVA after adjusting for baseline covariates including WHR, MAP, Glu, (mmol/l), TC/HDL and Endo (IU/ml). TG, 
triglycerides; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; Endo, endotoxin; CI – confidence interval. 
Significant at p<0.05. 
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Table 3.3.2.4.3 Percentage Changes (%) in Lipid Characteristics in Treatment Groups by Analysis Type 
 
Parameters 
Intention-to-Treat Per Protocol 
Placebo Probiotics Placebo Probiotics 
Triglycerides (mmol/l) -9.09 -31.20 -9.52 -31.20 
Total Cholesterol (mmol/l) -10.19 -10.86 -10.19 -10.86 
HDL-Cholesterol (mmol/l) -6.36 14.00 -6.36 15.00 
LDL-cholesterol (mmol/l) -11.94 -11.39 -12.81 -11.89 
Total/HDL-Cholesterol Ratio -2.20 -16.72 -2.60 -16.62 
Note: Data presented as percentages (%). 
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3.3.5 Associations of Endotoxin to Anthropometrics, Glycaemic and Lipid Profiles 
Measured 
Table 3.3.5.1 shows the bivariate associations between endotoxin and parameters 
measured. In all participants, endotoxin was significantly associated with diastolic BP 
(R=0.27; p=0.03) (Figure 3.3.5.1) and MAP (r=0.26; p=0.04) (Figure 3.3.5.2). HDL- 
cholesterol was inversely and significantly associated with endotoxin levels in all 
participants (R=-0.25; p=0.04) (Figure 3.3.5.3) and in the probiotics group (R=-0.35; 
p=0.05) (Figure 3.3.5.4). In the probiotics group, there were also significant associations 
between endotoxin and triglycerides (R=0.37; p=0.04) (Figure 3.3.5.5) and total/HDL 
cholesterol ratio (R=0.42; p=0.02) (Figure 3.3.5.6). The latter was also significant in all 
participants (R=0.32; p<0.01) (Figure 3.3.5.7). No significant associations were seen 
between endotoxin and any of the glycaemic parameters in all participants as well as after 
stratification to treatment groups. 
Lastly, none of the participants complained of any serious side effects from the 
clinical trial. The most common complaint were minor gastrointestinal discomfort 
(feeling bloated and increased flatulence during the first week of treatment) (N=5, 1 in 
the placebo group and 4 in the probiotics group) which is common for first time probiotics 
users. This symptom gradually faded during the first weeks of treatment. 
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Table 3.3.5.1 Bivariate Correlations between Endotoxin, Anthropometrics, 
Glycaemic and Lipid Profiles of Participants at Baseline. 
Parameters 
ALL (N=78) Placebo (N=39) Probiotics (N=39) 
R P-value R P-value R P-value 
Age (years) -0.06 0.64 -0.13 0.48 -0.16 0.40 
Weight (kg) -0.11 0.38 0.00 0.99 -0.03 0.86 
BMI (kg/m2) -0.09 0.48 -0.02 0.91 -0.06 0.78 
Waist-Hip Ratio -0.15 0.27 0.01 0.98 0.03 0.89 
Systolic BP (mmHg) 0.25 0.05 0.16 0.40 0.21 0.28 
Diastolic BP (mmHg) 0.27 0.03 0.25 0.19 0.10 0.59 
Mean Arterial Pressure (MAP) 0.26 0.04 0.22 0.23 0.09 0.63 
Glycaemic Profile 
Glucose (mmol/l) 0.22 0.08 0.15 0.44 -0.01 0.96 
Insulin (uU/ml) -0.12 0.35 -0.18 0.35 -0.10 0.59 
C-peptide (ng/ml) 0.05 0.67 -0.21 0.27 -0.04 0.84 
HOMA-IR 0.01 0.92 -0.11 0.56 -0.11 0.57 
Lipid Profile 
Triglycerides (mmol/l) 0.21 0.09 -0.02 0.92 0.37 0.04 
Total Cholesterol (mmol/l) 0.19 0.14 0.09 0.64 0.28 0.13 
HDL-Cholesterol (mmol/l) -0.25 0.04 0.09 0.63 -0.35 0.05 
LDL-Cholesterol (mmol/l) 0.14 0.27 -0.03 0.88 0.23 0.22 
Total/HDL Cholesterol Ratio 0.32 <0.01 0.07 0.73 0.41 0.02 
Note: Data presented as Spearman Correlation coefficients; Numbers in bold indicate 
significance; significant at p<0.05. 
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Figure 3.3.5.1. Significant positive association (R=0.27; p=0.03) between log 
endotoxin and diastolic blood pressure (mmHg) in all participants at baseline. 
 
 
 
Figure 3.3.5.2. Significant positive association (R=0.26; p=0.04) between log 
endotoxin and mean arterial blood pressure in all participants at baseline. 
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Figure 3.3.5.3. Significant inverse association (R=-0.25; p=0.04) between log 
endotoxin and HDL-cholesterol (mmol/L) in all participants at baseline. 
 
Figure 3.3.5.4. Significant inverse association (R= -35; p=0.05) between log 
endotoxin and HDL-cholesterol (mmol/L) in the probiotics group at baseline. 
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Figure 3.3.5.5. Significant positive association (R=0.37; p=0.04) between log 
endotoxin and triglycerides (mmol/L) in the probiotics group at baseline. 
 
 
Figure 3.3.5.6. Significant positive association (R=0.42; p=0.02) between log 
endotoxin and total/HDL-cholesterol in all participants at baseline. 
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Figure 3.3.5.7. Significant positive association (R=0.32; p<0.01) between log 
endotoxin and total/HDL-cholesterol in the probiotics group at baseline. 
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3.4. Discussion 
The present protocol is a 3-month randomized, double-blind, placebo-controlled 
clinical trial on the potential endotoxin-lowering effects of an 8-strain probiotics 
supplement among participants with T2DM. In this study, within-subject effects indicate 
significant and favourable changes in the probiotics group post-supplementation in terms 
of endotoxin, glycaemic and lipid reduction. However, it was observed that between-
subjects effects, circulating endotoxin levels in the probiotics group were no different than 
placebo, yet clinically significant improvement in HOMA-IR and modest reduction in 
WHR (% change 1.1% versus 0 in placebo; p<0.01) in the probiotics group were noted. 
The significant associations of endotoxin with lipid components as observed in the 
present study has been hypothesised to be due to endotoxin's high affinity with 
chylomicrons as it passes through the gastrointestinal mucosa (Ghoshal et al., 2009). 
Several other interventional studies demonstrated the immediate effect in lipid patterns as 
endotoxin levels are altered either through intravenous dose (Hudgins et al., 2003) or 
through high fat dietary intake (Harte et al., 2012). In the present study, the reduction of 
circulating endotoxin levels secondary to probiotics supplementation had a parallel 
improvement in the lipid profile of the probiotics group. Whilst this improvement between 
groups showed non-significance, it should be noted that even after randomisation, the 
probiotics group were metabolically worse at baseline, having higher endotoxin levels 
and worse lipid profile as opposed to the placebo group. 
People with T2DM and those with persistent insulin-resistance commonly exhibit 
higher metabolic endotoxemia than their non-diabetic and non-insulin-resistant 
counterparts (Gomes et al., 2017). Animal studies demonstrated that increased levels of 
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circulating insulin may alter intestinal permeability, and this may partially explain higher 
circulating endotoxin levels among individuals with higher insulin levels. This increased 
permeability allows gut endotoxins to leak in the circulation, which, in turn, initiates a 
cascade of inflammatory reactions via the innate immune pathway, thus explaining the 
subclinical inflammation in obesity and insulin-resistant states (Brun et al., 2007). Some 
evidence also suggested that the use of probiotics as a supplement may strengthen a 
weakened intestinal barrier, preventing endotoxin influx in the circulation and ultimately 
reducing subclinical inflammation (Le Barz et al., 2015). As such by manipulating 
endotoxin levels through the introduction of probiotics in the digestive tract, it is believed 
that many endotoxin-induced metabolic disorders can be reversed, if not controlled.  
A recent meta-analysis of RCTs among T2DM participants on probiotic 
supplementation revealed that multiple species of probiotics and interventions longer than 
8 weeks had stronger metabolic benefits in terms of improved glucose control and lipid 
profiles (Hu et al., 2017). The use of the 8-strain probiotics supplement affirmed some of 
these beneficial effects in reducing abdominal adiposity (measured as WHR) and insulin 
resistance (HOMA-IR as noted in meta-analysis studies). The lack of significant changes 
in lipid profile and other indices assessed between groups do not supersede previous 
findings, as non-significant results may still be clinically meaningful but other factors in 
play such as the time effects and baseline differences between both groups may have 
affected the results. The current findings in this study were nevertheless in agreement with 
a recent double-blind, randomized trial, involving 43 participants (Placebo N=22 and 
Probiotic mix N=21) who were given 8 weeks supplementation of probiotic mix 
(Lactobacillus acidophilus and casei; Lactococcus lactis; Bifidobacterium bifidum and 
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lactis; 2×1010 colony-forming units/day) and noted a significant reduction in abdominal 
adiposity with no concomitant decrease in endotoxin levels (Gomes et al., 2017).  The 
mentioned study in comparison to the present one had a shorter duration of intervention, 
lesser probiotic strains used and had a different primary endpoint as well as cohort used. 
Nevertheless, three probiotic species used in the former and the present study, namely, 
Bifidobacterium bifidum, Lactobacillus acidophilus and Lactobacillus casei, have been 
demonstrated to significantly improve glycaemic, inflammatory and lipid profiles of 
patients with gestational diabetes mellitus after 6 weeks of supplementation as well 
(Karamali et al., 2016; Badehnoosh et al., 2017). Whilst Lactococcus lactis, another 
potent probiotic species used in this study, has also recently reported to reverse type 2 
diabetes in non-obese diabetic mice, in combination with low-dose anti-CD3, through a 
series of actions including decline in insulin autoantibody positivity and stable reversal of 
hyperglycemia (Takiishi et al., 2017). Addtionally another bacterial strain, Lactobacillus 
salivarius was also shown to reverse diabetes-induced intestinal defense impairment 
through reversal of enteric dysbiosis and decreased endotoxin levels in streptozotocin-
induced diabetic mice (Chung et al., 2016). Studies using Lactobacillus salivarius as a 
stand-alone probiotic supplement for 4-6 weeks in women with gestational diabetes, 
however, was not associated with any improvement in metabolic health and pregnancy 
outcome (Lindsay et al., 2015). These highlight that the effects of probiotics are often 
species or strain/strains-specific. In this study, most likely, the cumulative potency of the 
8 species employed may have contributed to the significant improvements in the HOMA-
IR and WHR of the probiotics group. A recent randomized clinical trial involving 136 
Malaysians with T2DM supplemented with either placebo or probiotics (Bifidobacterium 
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and Lactobacillus) for 12 weeks also showed improvement in terms of glycaemic control 
(Firouzi et al., 2017), similar to the findings of this study. Despite several trials conducted 
in the T2DM population, there is still lack in uniformity of findings and this in part may 
arise due to discrepancies in sample size, duration of treatment, different inclusion criteria 
and type of analyses performed during each research study.  
The subjects in this current study given the probiotic did not elicit significant changes 
in BMI or body weight over time. This confirms several studies, including the recent 
meta-analysis by Park and Bae, who concluded limited efficacy of probiotics in weight 
management (Park and Bae, 2015). However, clinical trials overall are still very limited 
and therefore current evidence on probiotics, as weight loss agents are at most, suggestive. 
The significant reduction in abdominal adiposity in the probiotics group shown in the 
present study however is promising, but the actual changes may not be clinically 
meaningful, given the short duration of intervention and the small percent change. 
Furthermore, there was no significant improvements in blood pressure, although a recent 
study in animal models showed remarkable improvements in blood pressure after 8 week 
administration of Lactobacillus casei (Yap et al., 2014). A recent meta-analysis by 
Khalesi et al., from 9 clinical trials also concluded that probiotic administration may 
modestly improve blood pressure, and the potency maybe enhanced if multiple species 
and strains are taken for more than 8 weeks (Khalesi et al., 2014). Majority of the 
participants in the present study were normotensive and endothelial function may not have 
been that compromised. This may partially explain why no significant decrease in blood 
pressure was observed after probiotics supplementation. Nevertheless, the significant 
positive association between endotoxin and blood pressure confirms previous findings 
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(Andrade et al., 2017) and that the beneficial effects of probiotics in improving blood 
pressure maybe be tested using a duration of supplementation longer than the present 
study.   
The present chapter has several limitations. Gut microbiome analysis was not 
measured, therefore, successful colonization of these strains in the intestinal tract cannot 
be confirmed. Dietary intake and physical activity of all participants were also not 
monitored and this could explain beneficial changes in the placebo group. Despite 
randomisation and blinding, there were still significant differences between placebo and 
probiotics group at baseline, with the probiotics group being metabolically worse than 
placebo, and these covariates were factored during data analyses. Corrections for p-value 
(Bonferoni) to reduce type 1 error were not done as this would be at the expense of 
increasing type 2 error, and the sample size is already at the minimal level where sound 
conclusions can still be derived, although positive results, whether elicited by chance, 
cannot be ruled out as well. The study's strengths include it's randomized, double-blind, 
placebo-controlled design and well defined cohort from a unique ethnic group. Despite 
the large dropout rate from participants, the study remained sufficiently powered and 
adequately blinded.  
 
 
 
 
95 
 
3.5. Conclusions 
Despite the lack of difference in endotoxin levels between placebo and probiotics 
group, this study has demonstrated the beneficial effects of a 12-week, multi-strain 
probiotic supplementation in medication naïve T2DM individuals in terms of improved 
HOMA-IR and modest reduction in abdominal adiposity. A larger cohort and a longer 
duration of treatment may be necessary to confirm its effects in abdominal obesity as the 
present results, though significant, appears very small. 
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Chapter 4 
Effects of a 6-Month Daily Intake of a Multi-Strain 
Probiotic Supplementation in Circulating Endotoxin 
Levels, Inflammation, Adipocytokines and 
Cardiometabolic Profiles of Naïve Saudi T2DM 
Patients 
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4.1 Introduction 
Disequilibrium in the gut, also known as gut dysbiosis, significantly contributes 
in the pathogenesis of obesity-related diseases due to a weakened intestinal barrier which 
leads to chronic low-grade inflammation (Sato et al., 2017). One acceptable theory is that 
probiotics strengthen the intestinal barrier function, thus preventing leakage of pro-
inflammatory stimulants in the circulation (Ling et al., 2016). This theory supports a role 
for the gut microbiota in the pathogenesis of diet-induced obesity and related metabolic 
disorders, which, theoretically, might be reversible with dietary and/or gut microbiota 
manipulation (Ly et al., 2011). In a recent review of 14 clinical trials ascertaining the 
effects of probiotics on weight loss and body fat, the beneficial effects of probiotics were 
noted to be strain-specific (Crovesy et al., 2017). In animal studies, treatment with 
probiotics may be beneficial in insulin-resistant states (Memmarast et al., 2017; Husebye 
et al., 2001). A few human intervention trials also support this concept, with a recent meta-
analysis of 12 studies implicating a clinically improved HbA1c and circulating fasting 
insulin among patients with T2DM (Yao et al., 2017). Nevertheless, majority of the 
interventional studies in probiotics amongst patients with T2DM are either short term 
studies not longer than 3 months and/or that mono-strains were used as supplementation.  
The previously known exclusive role of the human adipose tissue as a fat depot 
has been completely debunked with the discovery of adipocytokines, proteins which are 
known to mediate metabolism, inflammation and immunity (Tilg and Moschen, 2006). 
Expansion of adipose tissue during weight gain produces pro-inflammatory   
adipocytokines which can trigger systemic inflammation responsible for chronic low-
grade inflammation observed in obesity-related diseases (e.g., insulin resistance and the 
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metabolic syndrome) (Pereira and Alvarez-Leite, 2014). Furthermore, obesity-induced 
inflammation by itself is complex, as it also involves other factors such as the gut 
microbiota (Frazier et al., 2011). It is now well known that one of the hallmarks of insulin 
resistance and obesity-related complications is "metabolic endotoxemia", a by-product of 
a weak or "leaky" gut barrier (Shen et al, 2013). It makes sense that by improving gut 
health in general, or strengthening the permeability of intestinal barriers in particular, may 
hold the key in preventing and moderating some of the chronic metabolic disorders 
prevalent in developed and newly industrialized countries (Bischoff et al., 2014). 
Gut microbiota manipulation in the reversal of diet-induced obesity and related 
metabolic disorders can be achieved most effectively through bariatric surgery as surgery-
induced weight loss significantly reduces the amount of body fat, consequently decreasing 
food intake and altering gut microbiota composition, including levels of adipocytokines 
(Li and Richard, 2017; Adami et al., 2016). As with all invasive procedures however, 
bariatric surgery has its own list of risks and complications. Dietary interventions 
therefore, such as consumption of probiotics/prebiotics, may be the second best option, as 
these supplements can potentially strengthen the intestinal barrier leading to reduction of 
systemic endotoxin (lipopolysaccharides of commensal bacteria residing in the 
gastrointestinal tract). Endotoxins are known to promote sub-chronic inflammation 
(Noble et al., 2017). As the gut flora is the main source of endotoxin, treatment with 
probiotics may influence the circulating levels of endotoxin by altering the microbiota 
composition. To date, however, few studies have examined the effects of probiotics on 
the circulating levels of endotoxin in metabolic diseases over a 6 month period. Although 
a small study in patients with cirrhosis given probiotics did lead to a 25% reduction in 
99 
 
endotoxin (Backhed et al., 2005) whilst a further study showed no effects on endotoxin 
load (Horvath et al., 2016). In a short term study however by Simon and colleagues, they 
observed that a 4-week intake of Lactobacillus reuteri led to an improvement in insulin 
sensitivity among glucose tolerant individuals, yet no changes in endotoxin levels were 
observed with increased insulin levels were probably secondary to augmented incretin 
release (Simon et al., 2015). This lack of change in endotoxin maybe due to the short 
intervention period. Nevertheless, the ability of probiotics and Lactobacilli in particular, 
in strengthening intestinal integrity and potentially reducing endotoxin levels, have been 
demonstrated consistently, with the most recent study examining the permeability change 
in the gut through trans-epithelial resistance (TER) tests in rat models with necrotizing 
enterocolitis (NEC) injected with the probiotic strain (Blackwood et al., 2017). Other 
probiotic strains that were observed to reduce endotoxemia include the Bacillus species 
(McFarlin et al., 2017) and Bifidobacteria through enhancement of intestinal barrier 
function (Yang et al., 2017). 
To the best of our knowledge, there is still limited evidence on the effects of a 
long duration, multi-strain probiotics supplementation on circulating endotoxin levels and 
their concomitant effects in adipocytokines and inflammatory markers among naïve 
T2DM patients. Furthermore, data is scarce with regards to the effects of these 
supplements in the Arabian population, an ethnic group highly predisposed to obesity and 
insulin-resistant-related diseases (Rahim et al., 2014). The present study therefore 
explored the potential beneficial effects of a 6-month multi-strain probiotics 
supplementation on these biomarkers and cardiometabolic parameters in adult Saudi 
participants with naïve T2DM. 
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4.2 Methods 
This is a 6-month, single-centre, double-blind, randomised, placebo-controlled 
study. Ethical approval and trial registrations have been mentioned previously (Chapter 
2.1, 2.2). 
4.2.1 Participants 
Detailed recruitment of participants has been mentioned in Chapter 2.5. A 
flowchart has been provided previously (Figure 2.4.1). 
 
4.2.2 Probiotic Supplements and Allocation 
Detailed trial protocol has been mentioned previously in Chapter 2.5 
4.2.3 Monitoring and Blood Sample Collection 
Measurements of all carediometabolic parameters, endotoxin, inflammation and 
adipocytokines have been described in detail in Chapter 2.9 and 2.10. 
4.2.4 Data Analysis 
Detailed data analysis has been previously mentioned in Chapter 2.11. In addition and 
specific to this chapter, mixed method analysis of covariance (ANCOVA) was used to 
determine within and between group changes adjusted for baseline covariates which 
included leptin, TNF-α, endotoxin, WHR, glucose and total cholesterol/HDL ratio. For 
the purpose of this chapter, the first 3 covariates were excluded from the presentation as 
they are discussed separately in the succeeding chapter. P-value <0.05 was considered 
statistically significant. 
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4.3 Results 
4.3.1 Baseline Characteristics of Placebo and Probiotics Group 
Baseline comparison of placebo and probiotics groups has been previously 
presented in table 3.3.1.1.  
4.3.2 Changes in Anthropometrics and Clinical Measures in both Placebo and 
Probiotics Group Before and after 6-month Intervention  
Table 4.3.2 shows within and between group comparisons in the anthropometric 
and clinical measures of both placebo and probiotics group using ITT analysis. In this 
approach, there was a significant over-all difference between placebo and probiotics in 
WHR (p=0.004) as well as both in 3 months (p=0.005) and 6 months of intervention 
(p=0.01) despite having no discernible difference in both groups in terms of percentage 
change (figure 4.3.2.1). There were no significant differences in BMI between placebo 
and probiotics over-all (p=0.35) as well as at 3 months [% change 0.10 vs -0.10; (CI: -
6.35 – 2.14); p=0.32] and 6 months post-intervention [-0.40 vs 0.0; (CI: -6.09 - 2.34; 
p=0.38] (figure 4.3.2.2). Over-all at 6 months post-intervention, between group 
comparisons also showed no differences in systolic blood pressure (p=0.65) (Figure 
4.3.2.3), diastolic blood pressure (p=0.83) (Figure 4.3.2.4) and mean arterial blood 
pressure (p=0.97) (Figure 4.3.2.5). Within group comparisons showed that both the 
placebo and probiotics groups also had no significant changes in all anthropometric and 
clinical measures after 3 and 6 months of intervention (Table 4.3.2).  
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Table 4.3.2. Anthropometric measures before and after intervention with placebo or probiotics among T2DM patients (ITT Analysis) 
Parameters Group Intervention Effects (95% CI) 
Placebo  
(N = 30) 
Probiotics  
(N = 31) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
BMI (kg/m2) 
     Baseline 30.1 ± 5.0 29.4 ± 5.2 
-2.10 (-6.35 - 2.14) -1.88 (-6.09 - 2.34) -1.96 (-6.20 - 2.24)      3 months 30.2 ± 5.0 29.3 ± 5.3 
     6 months 29.7 ± 5.0  29.4 ± 5.2 
     𝑋ത (% Change) at 3 months 0.10 (0.33) -0.10 (-0.34) 0.32 0.38 0.35      𝑋ത (% Change) at 6 months -0.40 (-1.33) 0.00 (0.00) 
Waist-Hip Ratio 
     Baseline 1.0 ± 0.1 0.91 ± 0.1 
-0.09 (-0.14 - -0.03) -0.08 (-0.13 - -0.02) -0.08 (-0.14 - -0.03)      3 months 1.0 ± 0.1 0.87 ± 0.1 
     6 months 1.0 ± 0.1 0.86 ± 0.1 
     𝑋ത (% Change) at 3 months 0.0 (0.0) 0.03 (0.001) 0.005 0.01 0.004      𝑋ത (% Change) at 6 months 0.0 (0.0) 0.5 (0.002) 
Systolic Blood Pressure (mmHg) 
     Baseline 129.5 ± 10.3 134.8 ± 14.6 
-2.33(-10.89 - 6.23) -1.13 (-9.81 - 7.56) -1.98 (-10.4 - 6.47)      3 months 129.9 ± 11.1 129.0 ± 11.4 
     6 months 129.2 ± 11.3 130.6 ± 12.5 
     𝑋ത (% Change) at 3 months 0.40 (0.31) -5.80 (-4.30) 0.59 0.80 0.64      𝑋ത (% Change) at 6 months -0.30 (-0.23) -4.20 (-3.12) 
Diastolic Blood Pressure (mmHg) 
     Baseline 78.6 ± 8.6 83.6 ± 11.8 
0.45 (-6.99 - 7.88) 2.07 (-6.20 - 10.33) 0.81 (-6.74 - 8.37)      3 months 79.8 ± 8.1 79.8 ± 11.5 
     6 months 77.3 ± 9.1 81.0 ± 11.7 
     𝑋ത (% Change) at 3 months 1.20 (1.53) -3.80 (-4.55) 0.90 0.62 0.83      𝑋ത (% Change) at 6 months -1.30 (-1.65) -2.60 (-3.11) 
Mean Arterial Pressure (mmHg) 
     Baseline 95.5 ± 7.7 100.6 ± 11.1 
-0.48 (-7.16 - 6.21) 1.00 (-6.16 - 8.17) -0.12 (-6.81 - 6.57)      3 months 96.5 ± 7.8 96.2 ± 9.7 
     6 months 100.7 ± 11.1 97.5 ± 9.9 
     𝑋ത (% Change) at 3 months 1.00 (1.05) -4.40 (-4.37) 0.89 0.78 0.97      𝑋ത (% Change) at 6 months 5.20 (5.45) -3.10 (-3.08) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc denotes p-value between groups over-
all; Results are obtained from mixed method ANCOVA after adjustment for baseline covariates including leptin, TNF-α, endotoxin, WHR, glucose and total 
cholesterol/HDL ratio; CI – confidence interval; significance at p<0.05. 
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Table 4.3.3 shows within and between group comparisons in the anthropometric 
and clinical measures of both placebo and probiotics group using PPA. Between group 
comparison showed an over-all significant difference in BMI in both placebo and 
probiotics post-intervention [-0.50 vs 0.20; (CI: -10.7 - -0.14); p = 0.04] as well as WHR 
[0.0 vs 0.0; (CI: -0.16 - -0.01); p = 0.03]. Similar to the ITT analysis, there were no 
difference between groups over-all in systolic (p=0.51); diastolic (p=0.82) and mean 
arterial pressure (p=0.86). Within group comparisons showed no significant changes in 
both groups (Table 4.3.3). Mean values of anthropometric measures were plotted as bar 
charts in both placebo and probiotics group (Figures 4.3.1-4.3.5). 
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Table 4.3.3. Anthropometric measures before and after intervention with placebo or probiotics among T2DM patients (PP Analysis) 
Parameter Group Intervention Effects (95% CI) 
Placebo 
(N = 16) 
Probiotics  
(N = 23) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
BMI (kg/m2) 
     Baseline 29.1 ± 4.9 27.3 ± 4.1 
-1.59 (-6.65 - 3.46) -5.43(-10.64- -0.23) -5.44(-10.7 - -0.14)      3 months 29.4 ± 5.0 27.4 ± 4.2 
     6 months 28.6 ± 4.8 27.5 ± 3.9 
     𝑋ത (% Change) at 3 months 0.30 (1.03) 0.10 (0.37) 0.53 0.04 0.04      𝑋ത (% Change) at 6 months -0.50 (-1.72) 0.20 (0.73) 
Waist-Hip Ratio 
     Baseline 0.92 ± 0.08 0.89 ± 0.06 
-0.09 (-0.16- -0.03) -0.11 (-0.19 - -0.03) -0.09 (-0.16 - -0.01)      3 months 0.91 ± 0.05 0.90 ± 0.08 
     6 months 0.90 ± 0.06 0.90 ± 0.08 
     𝑋ത (% Change) at 3 months 0.0 (0.0) 0.0 (0.0) 0.005 0.01 0.03      𝑋ത (% Change) at 6 months 0.0 (0.0) 0.0 (0.0) 
Systolic Blood Pressure (mmHg) 
     Baseline 129.8 ± 8.1 133.4 ± 13.4 
-4.74 (-15.75- 6.28) -3.1 (-16.89- 10.7) -4.4 (-18.23 - 9.39)      3 months 129.9 ± 8.7 128.3 ± 10.5 
     6 months 128.6 ± 8.9 130.9 ± 11.1 
     𝑋ത (% Change) at 3 months 0.10 (0.08) -5.10 (-3.82) 0.39 0.65 0.51      𝑋ത (% Change) at 6 months -1.20 (-0.92) -2.50 (-1.87) 
Diastolic Blood Pressure (mmHg) 
     Baseline 76.2 ± 9.0 83.9 ± 11.0 
1.71 (-8.37 - 11.80) 3.77 (-7.74 - 15.28) 1.07 (-8.55 - 10.69)      3 months 81.1 ± 5.5 80.1 ± 7.5 
     6 months 75.5 ± 9.3 81.8 ± 8.4 
     𝑋ത (% Change) at 3 months 4.90 (6.43) -3.80 (-4.53) 0.73 0.50 0.82      𝑋ത (% Change) at 6 months -0.70 (-0.92) -2.10 (-2.50) 
Mean Arterial Pressure (mmHg) 
     Baseline 94.1 ± 7.1 100.4 ± 10.6 
-0.44 (-9.46 - 8.58) 1.48 (-8.42 - 11.38) -0.76 (-9.99 - 8.47)      3 months 97.4 ± 5.0 96.1 ± 7.6 
     6 months 93.2 ± 7.5 98.1 ± 8.1 
     𝑋ത (% Change) at 3 months 3.30 (3.51) -4.30 (-4.28) 0.92 0.76 0.86      𝑋ത (% Change) at 6 months -0.90 (-0.96) -2.30 (-2.29) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc denotes p-value between groups 
over-all; Results are obtained from mixed method ANCOVA after adjustment for baseline covariates including leptin, TNF-α, endotoxin, WHR, glucose and total 
cholesterol/HDL ratio;; CI – confidence interval; significance at p<0.05. 
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Figure 4.3.2.1 Mean waist-hip ratio before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) Per 
Protocol Analysis; P-value denotes between group difference over-all; significant at p<0.05. 
 
 
106 
 
 
Figure 4.3.2.2 Mean BMI (kg/m2) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) Per 
Protocol Analysis; P-value denotes between group difference over-all; significant at p<0.05. 
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Figure 4.3.2.3 Mean systolic blood pressure (mmHg) before and after intervention in placebo and probiotics group using A) Intention-to-
Treat and B) Per Protocol Analysis; P-value denotes between group difference over-all; significant at p<0.05. 
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Figure 4.3.2.4 Mean diastolic blood pressure (mmHg) before and after intervention in placebo and probiotics group using A) Intention-
to-Treat and B) Per Protocol Analysis; P-value denotes between group difference over-all; significant at p<0.05. 
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Figure 4.3.2.5 Mean arterial pressure (mmHg) before and after intervention in placebo and probiotics group using A) Intention-to-Treat 
and B) Per Protocol Analysis; P-value denotes between group difference over-all; significant at p<0.05. 
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4.3.3 Changes in Glycaemic Indices in both Placebo and Probiotics Group Before 
and after 6-month Intervention  
Table 4.3.4 shows the between and within group comparisons between placebo 
and probiotics groups over time in terms of glycaemic indices. No difference was 
observed over-all in glucose levels between placebo and probiotics groups [1.1 vs -4.5 
(CI: -0.07 – 0.14); p = 0.54] (figure 4.3.3.1). A borderline significance was observed in 
insulin levels [-0.30 vs – 3.80 (CI: -0.40 – 0.01); p = 0.07] (figure 4.3.3.2). No difference 
was observed in C-peptide levels [0.80 vs -0.30 (CI:-0.22 – 0.61); p = 0.34] (Figure 
4.3.3.3) and an over-all significant difference was noted in HOMA-IR [0.80 vs -3.40 (CI: 
-0.59 - -0.17); p = 0.001] (Figure 4.3.3.4). Within group comparisons showed that in the 
placebo group, there was a significant increase in c-peptide levels at 6 months as 
compared to both baseline and 3 months (p<0.05). The rest of the glycaemic parameters 
in the placebo group did not significantly change over time. In the probiotics group, a 
significant decrease was observed in median levels of glucose and insulin after 3 months 
and a further significant decrease after 6 months. Median levels of c-peptide significantly 
decreased after 6 months in the probiotics group. A significant decrease was also noted in 
the HOMA-IR over time in both 3 months (p<0.05) and 6 months (p<0.05) post-
intervention (Table 4.3.4).  
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Table 4.3.4. Glycaemic parameters before and after intervention with placebo or probiotics among T2DM patients (ITT Analysis)  
Parameters Group Intervention Effects (95% CI) 
Placebo  
(N = 30) 
Probiotics  
(N = 31) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
Glucose (mmol/L) 
     Baseline 7.0 (5.7 - 11.2) 11.7 (8.4 - 16.4) 
0.10 (-0.01 - 0.21) 0.07 (-0.04 - 0.18) 0.03 (-0.07 - 0.14)      3 months 8.0 (5.9 - 11.4) 8.5 (6.2 - 10.9)A 
     6 months 8.1 (6.9 - 11.4) 7.2 (5.3 - 9.1)AB 
     𝑋ത (% Change) at 3 months 1.00 (14.29) -3.20 (-27.35) 0.08 0.19 0.54      𝑋ത (% Change) at 6 months 1.10 (15.71) -4.50 (-38.46) 
Insulin (IU/ml) 
     Baseline 12.4 (8.0 - 18.7) 9.9 (7.7 - 16.4) 
-0.12(-0.31 - 0.07) -0.19(-0.41 - 0.03) -0.20(-0.40 - 0.01)      3 months 10.8 (8.3 - 15.5) 6.9 (4.5 - 9.8)A 
     6 months 12.1 (8.0 - 17.4) 6.1 (3.6 - 9.6)A 
     𝑋ത (% Change) at 3 months -1.60 (-12.90) -3.00 (-30.30) 0.20 0.09 0.07      𝑋ത (% Change) at 6 months -0.30 (-2.42) -3.80 (-38.38) 
C-peptide (ng/ml) 
     Baseline 0.1 (0.1 - 0.5) 0.4 (0.0 - 1.8) 
0.44 (-0.02 - 0.90) 0.24 (-0.16 - 0.65) 0.20 (-0.22 - 0.61)      3 months 0.2 (0.1 - 0.9) 0.1 (0.0 - 0.3)A 
     6 months 0.9 (0.1 - 1.9)A 0.1 (0.0 - 0.4) 
     𝑋ത (% Change) at 3 months 0.10 (100.00) -0.30 (-75.00) 0.06 0.23 0.34      𝑋ത (% Change) at 6 months 0.80 (800.00) -0.30 (-75.00) 
HOMA-IR 
     Baseline 3.9 (2.3 - 6.5) 5.3 (3.5 - 10.2) 
-0.21(-0.41- -0.02) -0.34(-0.55- -0.12) -0.38(-0.59- -0.17)      3 months 3.9 (3.3 - 6.0) 2.1 (1.5 - 5.2)A 
     6 months 4.7 (3.6 - 6.7) 1.9 (1.2 - 3.1)A 
     𝑋ത (% Change) at 3 months 0.00 (0.00) -3.20 (-60.38) 0.03 0.004 0.001      𝑋ത (% Change) at 6 months 0.80 (20.51) -3.40 (-64.15) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc 
denotes p-value between groups over-all; A denotes significance within groups compared to baseline; B denotes significance within 
groups compared to 3 monthsResults are obtained from mixed method ANCOVA after adjustment for baseline covariates including 
leptin, TNF-α, endotoxin, WHR, glucose and total cholesterol/HDL ratio; CI – confidence interval; significance at p<0.05. 
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Table 4.3.5 shows the same glycaemic comparisons between groups using the 
PPA. No difference was noted in levels of glucose [0.6 vs -5.30; (CI: -0.05 – 0.230; p = 
0.19], insulin [2.6 vs -6.7; (CI:-0.56 – 0.11); p = 0.18] and C-peptide [1.2 vs -1.0; (CI: -
0.52 – 0.53); p = 0.99]. A borderline significant difference was observed in HOMA-IR 
[1.44 vs -5.30; (CI: -0.76 – 0.01); p = 0.05]. Within group comparisons showed a 
significant decrease in glucose levels after 3 months (p<0.05) and 6 months (p<0.05) in 
the probiotics group as well as insulin (both p-values <0.05 at 3 and 6 months, 
respectively), c-peptide (both p-values <0.05 at 3 and 6 months, respectively) and 
HOMA-IR (both p-values <0.05 at 3 and 6 months, respectively). In the placebo group, 
c-peptide levels were significantly higher after 6 months of intervention compared to 
baseline (p<0.05) (see Table 4.3.5). Changes in all glycaemic indices over time are also 
presented in Figures 4.3.3.1-4.3.3.4. 
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Table 4.3.5. Glycaemic measures before and after intervention with placebo or probiotics among T2DM patients (PP Analysis) 
Parameter Group Intervention Effects (95% CI) 
Placebo 
(N = 16) 
Probiotics  
(N = 23) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
Glucose (mmol/L) 
     Baseline 6.9 (5.3 - 8.0) 12.3 (8.7 - 16.9) 
0.09 (-0.04 - 0.23) 0.12 (-0.02 - 0.27) 0.09 (-0.05 - 0.23)      3 months 7.2 (5.9 - 13.1) 8.5 (6.5 - 10.2)A 
     6 months 7.5 (6.7 - 11.4) 7.0 (5.3 - 8.4)A 
     𝑋ത (% Change) at 3 months 0.30 (4.35) -3.80 (-30.89) 0.18 0.09 0.19      𝑋ത (% Change) at 6 months 0.60 (8.70) -5.30 (-43.09) 
Insulin (IU/ml) 
     Baseline 14.6 (8.8 - 24.9) 12.1 (8.8 - 14.7) 
-0.14(-0.37 - 0.08) -0.18(-0.56 - 0.20) -0.22(-0.56 - 0.11)      3 months 13.6 (9.6 - 19.3) 6.9 (4.5 - 9.5)A 
     6 months 17.2(12.1 - 21.3) 5.4 (3.6 - 9.1)A 
     𝑋ത (% Change) at 3 months -1.00 (-6.85) -5.20 (-42.98) 0.21 0.34 0.18      𝑋ത (% Change) at 6 months 2.60 (17.81) -6.70 (-55.37) 
C-peptide (ng/ml) 
     Baseline 0.2 (0.1 - 0.5) 1.1 (0.2 - 2.0) 
0.55 (0.03 - 1.07) -0.14(-0.63 - 0.34) 0.00 (-0.52 - 0.53)      3 months 0.1 (0.1 - 0.6) 0.2 (0.1 - 0.3)A 
     6 months 1.4 (0.5 - 2.0)AB 0.1 (0.1 - 0.2)A 
     𝑋ത (% Change) at 3 months -0.10 (-50.00) -0.90 (-81.82) 0.04 0.54 0.99      𝑋ത (% Change) at 6 months 1.20 (600.00) -1.00 (-90.91) 
HOMA-IR 
     Baseline 4.06 (2.5-12.3) 7.2 (4.7-11.0) 
-0.24(-0.49 - 0.01) -0.24(-0.66 - 0.18) -0.38(-0.76 - 0.01)      3 months 4.5 (3.1-6.5) 2.6 (1.7-4.5)A 
     6 months 5.5 (4.1-6.7) 1.9 (1.2-2.5)A 
     𝑋ത (% Change) at 3 months 0.44 (10.84) -4.60 (-63.89) 0.06 0.24 0.05      𝑋ത (% Change) at 6 months 1.44 (35.47) -5.30 (-73.61) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc 
denotes p-value between groups over-all; A denotes significance within groups compared to baseline; B denotes significance within 
groups compared to 3 months; Results are obtained from mixed method ANCOVA after adjustment for baseline covariates including 
leptin, TNF-α, endotoxin, WHR, glucose and total cholesterol/HDL ratio; CI – confidence interval; significance at p<0.05. 
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Figure 4.3.3.1 Median glucose (mmol/L) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and 
B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within 
group comparison; significant at p<0.05. 
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Figure 4.3.3.2 Median insulin (IU/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) 
Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within group 
comparison; significant at p<0.05. 
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Figure 4.3.3.3 Median C-peptide (ng/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and 
B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within 
group comparison; significant at p<0.05. 
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Figure 4.3.3.4 Median HOMA-IR before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) Per 
Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within group 
comparison; significant at p<0.05. 
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4.3.4 Changes in Lipid Profile in both Placebo and Probiotics Group Before and 
after 6-month Intervention  
Changes in lipid profile in both groups using the ITT analysis were shown in Table 
4.3.6. Between group comparisons showed no differences in placebo and probiotics 
groups over-all in levels of triglycerides [-0.10 vs -1.20; (CI: -1.19-0.17; p = 0.14] (Figure 
4.3.4.1), total cholesterol [-0.30 vs -1.10; (CI: -1.17 – 0.220; p = 0.18] (Figure 4.3.4.2), 
HDL-cholesterol [-0.10 vs -0.30; (CI: -0.82 – 0.39); p = 0.66] (Figure 4.3.4.3), LDL-
cholesterol [-0.10 vs – 0.80; (CI: -0.82 – 0.39); p = 0.48] (Figure 4.3.4.4) and total/HDL-
cholesterol ratio [-0.30 vs -1.10; (CI: -0.81 – 1.80); p = 0.45) (Figure 4.3.4.5). Within 
group analysis showed no significant changes in the placebo group over time. In the 
probiotics group however and as compared to baseline, significant improvements were 
observed in terms of decreased triglycerides after 3 months (p<0.05) and 6 months 
(p<0.05), total cholesterol (p-values <0.05) and total/HDL cholesterol ratio after 6 months 
of intervention (p<0.05).  
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Table 4.3.6 Lipid profile before and after intervention with placebo or probiotics among T2DM patients (ITT Analysis) 
Parameters Group Intervention Effects (95% CI) 
Placebo  
(N = 30) 
Probiotics  
(N = 31) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
Triglycerides (mmol/L) 
     Baseline  2.2 ± 1.4 2.5 ± 1.4 
-0.04 (-0.71 - 0.63) -0.65 (-1.48 - 0.19) -0.51 (-1.19 - 0.17)      3 months 2.0 ± 0.8 1.7 ± 0.7A 
     6 months 2.1 ± 1.6 1.3 ± 0.6A 
     𝑋ത (% Change) at 3 months -0.20 (-9.09) -0.80 (-32.00) 0.92 0.13 0.14      𝑋ത (% Change) at 6 months -0.10 (-4.55) -1.20 (-48.00) 
Total Cholesterol (mmol/L) 
     Baseline 5.2 ± 1.0 5.8 ± 1.3 
-0.35 (-1.07 - 0.36) -0.63 (-1.41 - 0.14) -0.47 (-1.17 - 0.22)      3 months 4.7 ± 0.9 5.1 ± 0.9 
     6 months 4.9 ± 1.0 4.7 ± 1.1A 
     𝑋ത (% Change) at 3 months -0.50 (-9.62) -0.70 (-12.07) 0.32 0.10 0.18      𝑋ത (% Change) at 6 months -0.30 (-5.77) -1.10 (-18.97) 
HDL-Cholesterol (mmol/L) 
     Baseline 1.1 ± 0.3 1.0 ± 0.3 
-0.05 (-0.21 - 0.12) -0.06 (-0.25 - 0.13) -0.04 (-0.21 - 0.14)      3 months 1.0 ± 0.3 1.1 ± 0.3 
     6 months 1.0 ± 0.4 1.3 ± 0.4 
     𝑋ത (% Change) at 3 months -0.10 (-9.09) 0.10 (10.00) 0.56 0.54 0.66      𝑋ത (% Change) at 6 months -0.10 (-9.09) 0.30 (30.00) 
LDL-Cholesterol (mmol/L) 
     Baseline 3.1 ± 0.9 3.6 ± 1.3 
-0.30 (-0.94 - 0.34) -0.28 (-0.95 - 0.39) -0.22 (-0.82 - 0.39)      3 months 2.8 ± 0.9 3.2 ± 0.9 
     6 months 2.8 ± 1.0A 2.7 ± 1.0 
     𝑋ത (% Change) at 3 months -0.30 (-9.68) -0.40 (-11.11) 0.35 0.40 0.48      𝑋ത (% Change) at 6 months -0.10 (-9.68) -0.80 (-22.22) 
Total Cholesterol/HDL-Cholesterol Ratio 
     Baseline 5.2 ± 1.0 5.8 ± 1.3 
1.12 (-0.65 - 2.89) 0.19 (-0.72 - 1.10) 0.49 (-0.81 - 1.80)      3 months 4.7 ± 0.9 5.1 ± 0.9 
     6 months 4.9 ± 1.0 4.7 ± 1.1A 
     𝑋ത (% Change) at 3 months -0.50 (-9.62) -0.70 (-12.07) 0.21 0.67 0.45      𝑋ത (% Change) at 6 months -0.30 (-5.77) -1.10 (-18.97) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc denotes p-value between groups 
over-all; A denotes significance within groups compared to baseline; Results are obtained from mixed method ANCOVA after adjustment for baseline covariates 
including leptin, TNF-α, endotoxin, WHR, glucose and total cholesterol/HDL ratio; CI – confidence interval; significance at p<0.05. 
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Table 4.3.7 shows the changes in lipid profile in both groups using the PP analysis. 
Between group comparisons showed borderline significant differences in placebo and 
probiotics groups over-all in levels of triglycerides [-0.30 vs -1.30; (CI: -2.12  -0.12; p = 
0.08] and total cholesterol [-0.10 vs -1.20; (CI: -2.03 – 0.06; p = 0.06]. No differences 
were observed in HDL-cholesterol [-0.10 vs -0.40; (CI: -0.24 – 0.29); p = 0.84], LDL-
cholesterol [0.10 vs – 1.0; (CI: -1.25 – 0.59); p = 0.46] and total/HDL-cholesterol ratio 
[1.0 vs -3.4; (CI: -2.15 – 2.41); p = 0.91). Similar to the ITT comparisons, within group 
analysis in PP showed no significant changes in the placebo group over time. In the 
probiotics group, significant improvements were observed in terms of decreased 
triglycerides after 3 months (p<0.05) and 6 months (p<0.05) and total cholesterol (p-
values <0.05) after 6 months of intervention. The rest of the lipid profile in the probiotics 
group had no significant change over time. Changes in lipid profile in both groups are 
also presented in figures 4.3.4.1-4.3.4.5. 
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Table 4.3.7. Lipid profile before and after intervention with placebo or probiotics among T2DM patients (PPA) 
Parameter Group Intervention Effects (95% CI) 
Placebo 
(N = 16) 
Probiotics  
(N = 23) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
Triglycerides (mmol/L) 
     Baseline 2.0 ± 1.0 2.5 ± 1.4 
0.14 (-0.66 - 0.93) -1.20 (-2.58 - 0.17) -1.00 (-2.12 - 0.12)      3 months 2.2 ± 0.8 1.7 ± 0.7A 
     6 months 2.3 ± 2.0 1.2 ± 0.5A 
     𝑋ത (% Change) at 3 months 0.20 (10.00) -0.80 (-32.00) 0.73 0.08 0.08      𝑋ത (% Change) at 6 months 0.30 (15.00) -1.30 (-52.00) 
Total Cholesterol (mmol/L) 
     Baseline 5.2 ± 1.0 5.8 ± 1.3 
-0.18 (-1.05 - 0.68) -1.18 (-2.38 - 0.02) -0.99 (-2.03 - 0.06)      3 months 4.8 ± 0.9 5.1 ± 0.9 
     6 months 5.1 ± 1.0 4.6 ± 1.0AB 
     𝑋ത (% Change) at 3 months -0.40 (-7.69) -0.70 (-12.07) 0.67 0.05 0.06      𝑋ത (% Change) at 6 months -0.10 (-1.92) -1.20 (-20.69) 
HDL-Cholesterol (mmol/L) 
     Baseline 1.1 ± 0.3 0.9 ± 0.3 
-0.07 (-0.27 - 0.12) 0.01 (-0.29 - 0.31) 0.03 (-0.24 - 0.29)      3 months 1.0 ± 0.3 1.1 ± 0.3 
     6 months 1.0 ± 0.5 1.3 ± 0.4 
     𝑋ത (% Change) at 3 months -0.10 (-9.09) 0.20 (22.22) 0.46 0.96 0.84      𝑋ത (% Change) at 6 months -0.10 (-9.09) 0.40 (44.44) 
LDL-Cholesterol (mmol/L) 
     Baseline 3.1 ± 0.8 3.6 ± 1.2 
-0.18 (-0.99 - 0.63) -0.34 (-1.36 - 0.68) -0.33 (-1.25 - 0.59)      3 months 2.8 ± 1.0 3.2 ± 0.8 
     6 months 3.2 ± 0.8 2.6 ± 0.8 
     𝑋ത (% Change) at 3 months -0.30 (-9.68) -0.40 (-11.11) 0.66 0.50 0.46      𝑋ത (% Change) at 6 months 0.10 (3.23) -1.00 (-27.78) 
Total Cholesterol/HDL-Cholesterol Ratio 
     Baseline 4.9 ± 1.3 6.9 ± 2.3 
1.76 (-0.30 - 3.82) -0.24 (-1.55 - 1.07) 0.13 (-2.15 - 2.41)      3 months 5.0 ± 1.2 5.8 ± 5.0 
     6 months 5.9 ± 2.7 3.5 ± 0.8 
     𝑋ത (% Change) at 3 months 0.10 (2.04) -1.10 (-15.94) 0.09 0.71 0.91 
     𝑋ത (% Change) at 6 months 1.00 (20.41) -3.40 (-49.28) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc denotes p-value between groups 
over-all; A denotes significance within groups compared to baseline; B denotes significance within groups compared to 3 months; Results are obtained from mixed 
method ANCOVA after adjustment for baseline covariates including leptin, TNF-α, endotoxin, WHR, glucose and total cholesterol/HDL ratio; CI – confidence 
interval; significance at p<0.05. 
122 
 
 
Figure 4.3.4.1 Mean triglycerides (mmol/L) before and after intervention in placebo and probiotics group using A) Intention-to-Treat 
and B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within 
group comparison; significant at p<0.05. 
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Figure 4.3.4.2 Mean total cholesterol (mmol/L) before and after intervention in placebo and probiotics group using A) Intention-to-Treat 
and B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within 
group comparison; significant at p<0.05. 
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Figure 4.3.4.3 Mean HDL-cholesterol (mmol/L) before and after intervention in placebo and probiotics group using A) Intention-to-
Treat and B) Per Protocol Analysis; P-value denotes between group difference over-all; significant at p<0.05. 
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Figure 4.3.4.4 Mean LDL-cholesterol (mmol/L) before and after intervention in placebo and probiotics group using A) Intention-to-
Treat and B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in 
within group comparison; significant at p<0.05. 
 
 
126 
 
 
 
 
 
Figure 4.3.4.5 Mean total/HDL-cholesterol (mmol/L) before and after intervention in placebo and probiotics group using A) Intention-
to-Treat and B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in 
within group comparison; significant at p<0.05. 
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4.3.8 Baseline Characteristics of Placebo and Probiotics Group in Endotoxin, 
Inflammation and Adipocytokine Profiles 
Baseline comparison of placebo and probiotics groups are presented in Table 
4.3.8. Both groups are comparable in terms of age and BMI (not shown in table). At 
baseline, the probiotics group had a significantly higher median levels of TNFα and IL-6 
(p-values 0.01 and 0.04, respectively). With regards to adipocytokine profile, the 
probiotics group had a significantly higher median levels of leptin than the placebo group 
(p=0.04). Endotoxin, which is the primary endpoint of the study, was significantly higher 
in the probiotics group than placebo at baseline (p=0.002) (table 4.3.8).  
Table 4.3.8. Baseline Characteristics according to Intervention Groups  
 Parameters Placebo  Probiotics  P-value 
N 39 39  
M/F 21/18 19/20  
Inflammatory Markers Profile  
TNF α (pg/ml) 0.5 (0.2 - 0.9) 0.9 (0.3 - 1.3) 0.01 
IL-6 (pg/ml) 3.7 (1.9 - 11.4) 5.6 (3.0 - 19.1) 0.04 
CRP (ug/ml) 2.7 (1.9 - 6.2) 5.6 (2.8 - 6.4) 0.29 
Adipocytokine Profile 
Leptin (pg/ml) 3.6 (1.4 - 7.6) 5.8 (2.5 - 17.2) 0.04 
Adiponectin (ug/ml) 11.4 (8.7 - 16.4) 8.3 (6.5 - 18.0) 0.09 
Resistin (ng/ml) 6.3 (4.2 - 11.4) 10.8 (5.3 - 16.9) 0.12 
Endotoxin (IU/ml) 2.2 (1.2 – 4.5) 4.8 (2.6 - 8.4) 0.002 
Note: Data presented as Mean ± SD for normally distributed data while non-normally normally 
distributed data are presented as Median (inter-quartile range). P-value significant at p<0.05.  
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4.3.9 Changes in Inflammatory Markers in both Placebo and Probiotics Group 
Before and after 6-month Intervention  
Changes in inflammatory markers in both the placebo and probiotic group is 
shown in Table 4.3.9 using the ITT analysis. After 6 month intervention, no significant 
difference in placebo and probiotics were observed in TNFα [-0.40 vs -0.60; (CI:-0.12 – 
0.21); p = 0.57] (Figure 4.3.9.1), IL-6 [-2.8 vs -3.9; (CI:-0.61 – 0.18); p = 0.28] (Figure 
4.3.9.2) and C-reactive protein [0.40 vs -2.9; (CI:-0.54 – 0.07); p = 0.13] (Figure 4.3.9.3). 
Within group comparisons however showed that all these inflammatory markers 
improved over time in the probiotics group, with levels of TNFα decreasing significantly 
after 6 months (p<0.05), as well as IL-6 in both 3 months (p<0.05) and 6 months (p<0.05) 
and CRP (p<0.05). These within group changes were not observed in the placebo group 
(Table 4.3.9). 
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Table 4.3.9 Inflammatory Markers before and after intervention with placebo or probiotics among T2DM patients (ITT Analysis) 
Parameters Group Intervention Effects (95% CI) 
Placebo  
(N = 30) 
Probiotics  
(N = 31) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
TNFα (pg/ml) 
     Baseline 0.5 (0.2 - 0.8) 0.9 (0.4 - 1.2) 
0.16 (-0.03 - 0.34) 0.07 (-0.12 - 0.26) 0.05 (-0.12 - 0.21)      3 months 0.5 (0.2 - 0.8) 0.6 (0.3 - 0.9) 
     6 months 0.3 (0.2 - 0.8) 0.3 (0.2 - 0.7)AB 
     𝑋ത (% Change) at 3 months 0.00 (0.00) -0.30 (-33.33) 0.10 0.46 0.57      𝑋ത (% Change) at 6 months -0.20 (-40.00) -0.60 (-66.67) 
IL-6 (pg/ml) 
     Baseline 3.6 (1.4- 11.4) 5.1 (2.7 - 18.8) 
-0.20 (-0.59 - 0.19) -0.14 (-0.51 - 0.22) -0.21 (-0.61 - 0.18)      3 months 0.8 (0.6 - 4.4) 1.4 (0.7 - 18.0)A 
     6 months 0.8 (0.7 - 3.8) 1.2 (0.8 - 3.6)A 
     𝑋ത (% Change) at 3 months -2.80 (-77.78) -3.70 (-72.55) 0.31 0.43 0.28      𝑋ത (% Change) at 6 months -2.80 (-77.78) -3.90 (-76.47) 
C-Reactive Protein (ug/ml) 
     Baseline 3.0 (1.9 - 6.2) 5.5 (2.7 - 6.1) 
-0.11 (-0.40 - 0.18) -0.20 (-0.47 - 0.07) -0.23 (-0.54 - 0.07)      3 months 2.9 (1.5 - 4.7) 3.1 (1.4 - 5.7)A 
     6 months 3.4 (2.6 - 5.6) 2.6 (1.2 - 4.9)A 
     𝑋ത (% Change) at 3 months -0.10 (-3.33) -2.40 (-43.64) 
0.44 0.14 0.13      𝑋ത (% Change)  at 6 months 0.40 (13.33) -2.90 (-52.73) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc 
denotes p-value between groups over-all; A denotes significance within groups compared to baseline; B denotes significance within 
groups compared to 3 months; Results were obtained from mixed method ANCOVA with baseline covariates including leptin, TNF-α, 
endotoxin, WHR, glucose and total cholesterol/HDL ratio; CI- confidence interval; significance at p<0.05. 
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Changes in the circulating inflammatory markers in both groups using PPA is 
shown in table 4.3.10. Similar to the ITT, no significant difference in placebo and 
probiotics were observed in levels of TNFα [-0.30 vs -0.90; (CI:-0.30 – 0.37); p = 0.81], 
IL-6 [-5.0 vs -16.0; (CI:-0.99 – 0.63); p = 0.63] and C-reactive protein [1.8 vs -2.3; (CI:-
0.46 – 0.58); p = 0.78]. Within group comparisons however showed significant 
improvements over time in the probiotics group in levels of TNFα (p<0.05) and IL-6 in 
both 3 months (p<0.05) and 6 months (p<0.05). No significant improvement in CRP 
levels were seen in the probiotics group. No improvement were seen in all inflammatory 
markers in the placebo group (Table 4.3.10). Changes in inflammatory profile in both 
groups using PPA are also presented in figures 4.3.9.1-4.9.3.3. 
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Table 4.3.10. Inflammatory markers before and after intervention with placebo or probiotics among T2DM patients (PP Analysis) 
Parameter Group Intervention Effects (95% CI) 
Placebo 
(N = 16) 
Probiotics  
(N = 23) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
TNFα (pg/ml) 
     Baseline 0.5 (0.3 - 0.6) 1.1 (0.7 - 1.4) 
0.27 (0.04 - 0.51) 0.00 (-0.41 - 0.40) 0.04 (-0.30 - 0.37)      3 months 0.6 (0.3 - 0.9) 0.8 (0.6 - 0.9) 
     6 months 0.2 (0.1 - 0.2) 0.2 (0.1 - 0.3)AB 
     𝑋ത (% Change) at 3 months 0.10 (20.0) -0.30 (-27.3) 0.03 0.99 0.81      𝑋ത (% Change) at 6 months -0.30 (-60.0) -0.90 (-81.8) 
IL-6 (pg/ml) 
     Baseline 5.8 (4.3 - 9.2) 18.0 (5.1 - 20.8) 
-0.23 (-0.78 - 0.32) -0.07 (-0.47 - 0.33) -0.18 (-0.99 - 0.63)      3 months 0.5 (0.2 - 1.5) 10.7 (0.3 - 18.9)A 
     6 months 0.8 (0.7 - 1.6) 2.0 (0.8 - 2.8)A 
     𝑋ത (% Change) at 3 months -5.30 (-91.4) -7.30 (-40.6) 0.40 0.70 0.63      𝑋ത (% Change) at 6 months -5.00 (-86.2) -16.00 (-88.9) 
C-Reactive Protein (ug/ml) 
     Baseline 3.8 (2.2 - 6.6) 6.4 (5.8 - 6.6) 
-0.16 (-0.58 - 0.26) -0.09 (-0.51 - 0.32) 0.06 (-0.46 - 0.58)      3 months 2.1 (1.2 - 6.2) 4.9 (3.8 - 6.0) 
     6 months 5.6 (3.8 - 5.7) 4.1 (2.6 - 4.9) 
     𝑋ത (% Change) at 3 months -1.70 (-44.74) -1.50 (-23.44) 0.43 0.61 0.78      𝑋ത (% Change) at 6 months 1.80 (47.37) -2.30 (-35.94) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc 
denotes p-value between groups over-all; A denotes significance within groups compared to baseline; B denotes significance within 
groups compared to 3 months; Results were obtained from mixed method ANCOVA with baseline covariates including leptin, TNF-α, 
endotoxin, WHR, glucose and total cholesterol/HDL ratio; CI - confidence interval; significance at p<0.05. 
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Figure 4.3.9.1 Median TNF-α (pg/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) 
Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within group 
comparison; significant at p<0.05. 
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Figure 4.3.9.2 Median IL-6 (pg/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) Per 
Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within group 
comparison; significant at p<0.05. 
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Figure 4.3.9.3 Median C-Reactive protein (μg/ml) before and after intervention in placebo and probiotics group using A) Intention-to-
Treat and B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in 
within group comparison; significant at p<0.05.  
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4.3.10. Changes in Adipocytokine Profile and Endotoxin levels in both Placebo and 
Probiotics Group Before and after 6-month Intervention  
Changes in circulating adipocytokines and endotoxin in both groups using the ITT 
analysis are shown in Table 4.3.11. No differences were observed in placebo and 
probiotics with regards to levels of leptin [-1.1 vs -2.7; (CI:-0.18 – 0.61); p=0.27] (Figure 
4.3.10.1), adiponectin [0.0 vs 6.1; (CI:-0.22-0.18); p = 0.84] (Figure 4.3.10.2), resistin 
[5.0 vs -6.8; (CI: -0.30-0.13); p = 0.44] (Figure 4.3.10.3) and endotoxin [0.80 vs -3.20; 
(CI:-0.33-0.13); p = 0.38] (Figure 4.3.10.4). Within group comparisons showed that in the 
placebo group, there was a significant increase in resistin levels after 6 months compared 
to baseline (p<0.05) as well as a significant increase in the endotoxin group after 6 months 
as compared to 3 months (p<0.05). Within group comparison in the probiotics group 
showed a significant increase in circulating adiponectin levels after 6 months (p<0.05), a 
significant decrease in resistin levels after 6 months (p<0.05) and a significant 
improvement in endotoxin levels after 6 months of intervention (p<0.05). No significant 
changes in both groups were noted in leptin.  
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Table 4.3.11 Adipocytokines and Endotoxin Before and After Intervention with Placebo or Probiotics among T2DM Participants (ITT 
Analysis) 
Parameters Group Intervention Effects (95% CI) 
Placebo  
(N = 30) 
Probiotics  
(N = 31) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
Leptin (pg/ml) 
     Baseline 3.9 (1.6 - 7.6) 5.8 (2.5 - 17.2) 
0.24 (-0.13 - 0.62) 0.20 (-0.22 - 0.62) 0.22 (-0.18 - 0.61)      3 months 4.0 (1.6 - 7.0) 3.5 (2.2 - 10.0) 
     6 months 2.8 (0.9 - 6.9) 3.1 (2.1 - 9.7) 
     𝑋ത (% Change) at 3 months 0.10 (2.56) -2.30 (-39.66) 0.20 0.35 0.27      𝑋ത (% Change) at 6 months -1.10 (-28.21) -2.70 (-46.55) 
Adiponectin (pg/ml) 
     Baseline 11.1 (8.7 - 16.6) 8.5 (6.4 - 14.6) 
-0.08 (-0.29- 0.13) -0.04 (-0.23- 0.15) -0.02(-0.22 - 0.18)      3 months 9.7 (5.1 - 16.8) 10.4 (7.2 - 18.7) 
     6 months 11.1 (5.7 - 16.0) 14.6 (7.8 - 24.4)A 
     𝑋ത (% Change) at 3 months -1.40 (-12.61) 1.90 (22.35) 0.44 0.64 0.84      𝑋ത (% Change) at 6 months 0.00 (0.00) 6.10 (71.76) 
Resistin (ng/ml) 
     Baseline 6.3 (4.2 - 11.4) 11.7 (6.4 - 18.8) 
0.05 (-0.18 - 0.27) -0.02(-0.25 - 0.21) -0.08(-0.30 - 0.13)      3 months 11.8 (6.2 - 19.1) 6.2 (3.7 - 14.5) 
     6 months 11.3 (5.3 - 15.2)A 4.9 (3.1 - 8.3)A 
     𝑋ത (% Change) at 3 months 5.50 (87.30) -5.50 (-47.01) 0.67 0.86 0.44      𝑋ത (% Change) at 6 months 5.00 (79.37) -6.80 (-58.12) 
Endotoxin (IU/ml) 
     Baseline 2.1 (1.2 – 4.4) 4.6 (2.4 – 7.9) 
0.13 (-0.12 - 0.38) -0.10(-0.35 - 0.14) -0.10(-0.33 - 0.13)      3 months 1.9 (1.0 – 2.9) 2.2 (1.2 – 3.6)A 
     6 months 2.9 (1.9 - 7.0)B 1.4 (1.0 - 2.1)A 
     𝑋ത (% Change) at 3 months -0.20 (-9.52) -2.40 (-52.17) 0.30 0.40 0.38      𝑋ത (% Change) at 6 months 0.80 (38.10) -3.20 (-69.57) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc 
denotes p-value between groups over-all; A denotes significance within groups compared to baseline; Results were obtained from mixed 
method ANCOVA with baseline covariates including leptin, TNF-α, endotoxin, WHR, glucose and total cholesterol/HDL ratio; CI - 
confidence interval; significance at p<0.05. 
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Changes in circulating adipocytokines and endotoxin in both groups using the PP 
analysis are shown in Table 4.3.12. No differences over-all were observed in placebo and 
probiotics with regards to levels of leptin [-1.6 vs -2.8; (CI:-1.15 – 0.73); p=0.62], 
adiponectin [-1.8 vs 1.3; (CI:-0.23-0.25); p = 0.96], resistin [5.0 vs -7.2; (CI: -0.45-0.23); 
p = 0.44] and endotoxin [0.90 vs -3.60; (CI:-0.21-0.42); p = 0.50]. Within group 
comparisons showed no changes in all adipocytokine markers in the placebo group. 
Endotoxin levels in the placebo group however showed a significant increase over time 
as compared to baseline (p<0.05). In the probiotics group, a significant decrease in leptin 
levels were observed after intervention (p<0.05) as well as a significant decrease in 
resistin levels (p<0.05). Endotoxin levels also significantly decreased overtime and this 
was apparent in both 3 months (p<0.05) and 6 months intervention (p<0.05). Changes in 
adipocytokine profile and endotoxin levels in both groups using PPA are also presented 
in figures 4.3.10.1-4.3.10.4. 
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Table 4.3.12 Adipocytokines and Endotoxin Before & After Intervention with Placebo or Probiotics among T2DM Participants (PP 
Analysis) 
Parameter Group Intervention Effects (95% CI) 
Placebo 
(N = 16) 
Probiotics  
(N = 23) 
Pa 
(0 vs 3 M) 
Pb 
(0 vs 6 M) 
Pc 
Leptin (pg/ml) 
     Baseline 2.1 (1.4 - 9.3) 5.8 (3.3 - 20.0) 
0.43 (-0.07 - 0.93) -0.22 (-1.33- 0.90) -0.21 (-1.15- 0.73)      3 months 4.4 (3.2 - 15.2) 5.7 (3.1 - 9.8) 
     6 months 0.5 (0.3 - 3.5) 3.0 (0.8 - 9.6)AB 
     𝑋ത (% Change) at 3 months 2.30 (109.52) -0.10 (-1.72) 0.09 0.67 0.62      𝑋ത (% Change) at 6 months -1.60 (-76.19) -2.80 (-48.28) 
Adiponectin (ug/ml) 
     Baseline 10.8 (8.7 - 14.3) 9.4 (5.6 - 18.0) 
0.16 (-0.10 - 0.42) -0.03(-0.30 - 0.23) 0.01 (-0.23 - 0.25)      3 months 9.5 (5.0 - 17.2) 9.4 (6.8 - 14.8) 
     6 months 9.0 (5.4 - 12.9) 10.7 (7.2 - 19.8) 
     𝑋ത (% Change) at 3 months -1.30 (-12.04) 0.00 (0.00) 0.22 0.80 0.96      𝑋ത (% Change) at 6 months -1.80 (-16.67) 1.30 (13.83) 
Resistin (ng/ml) 
     Baseline 6.3 (4.2 - 11.4) 11.7 (4.6 - 19.6) 
0.07 (-0.24 - 0.38) -0.11 (-0.53- 0.30) -0.11 (-0.45- 0.23)      3 months 15.4 (6.2 - 22.5) 7.7 (4.6 - 14.1) 
     6 months 11.3 (4.8 - 15.8) 4.5 (3.1 - 7.6)A 
     𝑋ത (% Change) at 3 months 9.10 (144.44) -4.00 (-34.19) 0.64 0.58 0.50      𝑋ത (% Change) at 6 months 5.00 (79.37) -7.20 (-61.54) 
Endotoxin (IU/ml) 
     Baseline 1.7 (0.9 – 2.6) 5.0 (3.2 - 8.5) 
0.29 (-0.01 - 0.58) 0.13 (-0.24 - 0.50) 0.11 (-0.21 - 0.42)      3 months 1.7 (0.9 – 2.7) 2.4 (1.3 - 4.3)A 
     6 months 2.6 (1.6 - 12.7)A 1.4 (0.9 - 3.4)A 
     𝑋ത (% Change) at 3 months 0.00 (0.00) -2.60 (-52.00) 0.06 0.47 0.50      𝑋ത (% Change) at 6 months 0.90 (52.94) -3.60 (-72.00) 
Note: Pa denotes p-value between groups at baseline and 3 months; Pb denotes p-value between groups at baseline and 6 months; Pc 
denotes p-value between groups over-all; A denotes significance within groups compared to baseline; B denotes significance within 
groups compared to 3 months; Results were obtained from mixed method ANCOVA with baseline covariates including leptin, TNF-α, 
endotoxin, WHR, glucose and total cholesterol/HDL ratio; significance at p<0.05. 
143 
 
 
 
Figure 4.3.10.1 Median leptin (ng/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) 
Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within group 
comparison; significant at p<0.05. 
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Figure 4.3.10.2 Median adiponectin (μg/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat 
and B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within 
group comparison; significant at p<0.05. 
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Figure 4.3.10.3 Median resistin (ng/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and B) 
Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within group 
comparison; significant at p<0.05. 
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Figure 4.3.10.4 Median endotoxin (IU/ml) before and after intervention in placebo and probiotics group using A) Intention-to-Treat and 
B) Per Protocol Analysis; P-value denotes between group difference over-all; * denotes significance compared to baseline in within 
group comparison; significant at p<0.05. 
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4.4 Discussion 
In this randomised controlled study, the aim was to determine the beneficial 
effects of 6-month probiotic supplementation in endotoxemia, inflammation, and 
cardiometabolic parameters among naïve T2DM patients. Comparison between groups 
noted significant clinical difference in HOMA-IR, in favour of the probiotics group. No 
significant between group differences were observed in terms of endotoxin (primary 
endpoint), lipid profile, other glycaemic indices and anthropometrics, with the exception 
of WHR, in favour of placebo.  
In this study, whilst it was identified that circulating endotoxin levels were 
significantly reduced post-intervention within the probiotics group, this wasn’t significant 
over-all compared to placebo. Depending on the type of analysis used, significant 
improvements were also noted in the inflammatory and anti-inflammatory adipocytokines 
markers in the probiotics group over time. However when compared to placebo, no 
significant differences were observed in all these markers. Several intervention studies 
confirm the endotoxin-lowering effects of certain probiotic strains including 
Bifidobacteria and Lactobacillus on peritoneal dialysis patients (Wang et al., 2015), 
among novice long distance triathletes in combination with antioxidants and prebiotics 
(Roberts et al., 2016) and in patients with cirrhosis (Bajaj et al., 2014); although findings 
from cirrhotic patients are inconsistent as some studies show no effect in endotoxin levels 
(Horvath et al., 2016). It is worthy to note that variations in the endotoxin lowering effects 
of probiotics are highly related to probiotic strain used, duration of intervention and 
baseline metabolic status of patients. The study of Horvath for instance (Horvath et al., 
2016), used the same probiotic formulation used in this study and while they also noted 
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no significant difference between endotoxin levels after intervention in both arms, it is 
difficult to compare patient populations as liver functions significantly influences markers 
of intestinal permeability and possibly endotoxin levels (Arab et al., 2017). 
Our study is to our knowledge, one of the very few to demonstrate the effects of a 
medium term multi-strain probiotics supplementation in several adipocytokines, such as 
leptin, adiponectin and resistin amongst T2DM patients. Certain probiotics, specifically, 
lactic acid bacteria strains have demonstrated in vitro that they can differentially modulate 
adipokine expression and the inflammatory response (Fabersani et al., 2017). Worthy to 
note is that 6 of the 8 probiotics strains used in the present study belong to the lactic acid 
bacteria class. In alignment with previous findings therefore, this study demonstrated 
improved levels of an anti-inflammatory adipocytokine, adiponectin as well as decreased 
levels of inflammatory markers in the probiotics group although no dramatic change was 
not in the placebo, which appears masked when group interaction effects over-all point to 
no clinically significant difference.  
Previous observations have shown that endotoxins from non-commensal bacteria 
may affect adipocytokine levels secondary to translocation induction of several intestinal 
microbial antigens into the circulation, creating altered adipokine profile and intestinal 
dysbiosis (Cani et al., 2009). The endotoxin-reducing ability of probiotics by creating a 
stronger intestinal barrier function may partially explain improved adipocytokine levels 
among those taking probiotic supplements. In animal studies, induced conditions such as 
non-alcoholic fatty liver disease (NAFLD) where intestinal barrier was compromised, 
inclusion of probiotic mixture in the diet demonstrated improved lipids, better 
149 
 
adipocytokines (leptin and resistin) and healthier levels of inflammatory markers (TNF-α 
and IL-6) than those fed without the probiotics mixture (Al-Muzafar and Amin, 2017).  
While this is not the first interventional study to examine the effects of probiotics 
on patients with T2DM, the present study addressed a previous meta-analysis of 
randomised trials which suggested that probiotics consumption for a longer duration and 
use of multiple strains may potentially increase the modest benefits of probiotics 
supplementation in glucose metabolism (Zhang et al., 2016). Furthermore, the recent 
meta-analysis of Hu and colleagues observed that trials with longer durations of 
intervention using multiple probiotic strains had more beneficial cardiometabolic effects 
on patients with T2DM (Hu et al., 2017). The use of 8 strains in the present study most 
likely provided a cumulative potency in the probiotics intervention aside from the longer 
duration of 6 months. A separate clinical trial that used a different set of probiotics strains 
also showed modest changes, with an improved metabolic status in T2DM patients, this 
discrepancy could be due to sample size difference, duration of intervention and patient 
selection, amongst others (Firouzi et al., 2017). Over-all, most meta-analyses of 
interventional studies reaffirm that probiotics intake among patients with T2DM can 
modestly decrease insulin resistance and improve glycaemic indices when taken as a 
standalone supplement (Li et al, 2016; Yao et al., 2017; Sun and Buys 2016; Zhang et al., 
2016). Effects on blood pressure were also not observed despite the longer duration of 
treatment even though it was observed in animal studies in combination with other agents 
such as prebiotics and synbiotics (Tunanpong et al., 2017). 
The authors acknowledge several limitations. Successful colonization of 
probiotics in the intestinal tract cannot be confirmed since stool samples were not 
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obtained. The study also has a lower uptake and completion rate than desired and therefore 
potentially affecting the study outcomes. Worthy to note however (as also mentioned in 
the previous chapters) is that the probiotics group was metabolically worse than placebo; 
had a poorer glucose control, higher lipids, endotoxin and adiponectin at baseline and so 
whilst no changes between placebo and probiotics group were observed, it should be taken 
into consideration that they didn't start at the same level even after randomisation. Despite 
limitations, this is the first and longest randomised controlled trial to ascertain the effects 
of a multi-strain probiotic supplementation in reducing endotoxin, inflammatory and 
adipocytokine profiles in Saudis with T2DM. 
4.5 Conclusions 
In summary, the present study is the first and the longest clinical trial done to 
ascertain the effects of probiotics in endotoxemia, inflammation and cardiometabolic 
parameters in naive Saudi T2DM patients. This randomised clinical trial demonstrated 
that a daily multi-strain probiotic supplementation for 6 months significantly reduced 
endotoxin levels and improved inflammatory and anti-inflammatory adipocytokine 
profiles among Saudi T2DM participants in the probiotics group, but comparison with the 
placebo group revealed no apparent significant changes. Furthermore, probiotic 
supplementation for 6 months can significantly reduce HOMA-IR and modestly improve 
lipids in this population. The present findings also suggest that probiotics supplementation 
as a monotherapy may not be clinically effective for weight loss. As participants in the 
present study were treatment naïve, further studies on the effects of probiotics compared 
with standard therapies for T2DM are needed. 
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Chapter 5 
Final Discussion 
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5.1 Discussion 
 The concept of gut microbiota manipulation to reverse several known diseases, 
T2DM included, through probiotic supplementation, has only recently gained 
considerable interest among nutritionists and biomedical scientists. The abundance of 
successful preliminary animal model studies where metabolomics and metagenomics 
approaches have been performed has reignited interest in probiotic intervention studies to 
shift to human subjects (Panwar et al., 2013). Furthermore, currently probiotics as a 
functional food (Stanton et al., 2001) is a multi-billion dollar industry, gaining momentum 
only in recent years despite largely unverified claims. As such interest has developed as 
researchers seek to evaluate such functional food and assess probiotic supplements 
leading to increased publications in the field (Zheng et al., 2017). 
 Within this context studies were undertaken in this thesis to initiate a randomised, 
double-blind, placebo-controlled clinical trial approach, to determine the different 
beneficial effects of an 8-strain probiotic supplementation amongst Saudi adults with 
T2DM over a 6 month duration. These effects were observed at different points over time 
in several indices including circulating endotoxin, anthropometrics, glycaemic, lipid, 
inflammatory and adipocytokine profiles. The studies revealed that while substantial 
improvements in the indices of interest were more apparent in the probiotics group over 
time, these effects and with the exception of HOMA-IR, were not clinically significant 
when compared with placebo. Furthermore after randomisation, it was clear that the 
probiotics group were more insulin-resistant and metabolically worse compared to the 
placebo group and this has somehow compromised effects that can be otherwise deemed 
clinically significant. While the present finding is not new since many recent meta-
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analyses conducted on the effects of probiotics in patients with T2DM universally 
conclude the clinical benefits of probiotic supplementation in improving glycaemic 
parameters (Wang et al., 2017; Sun and Buys, 2016; Hu et al., 2017), the present studies 
conducted still contributed new insights. First is the probiotic supplements themselves 
and the study design. The use of an 8-strain probiotic supplement to be given over a 6-
month in the present study has never been tested in the T2DM population. The same 
probiotics supplement however has been tested in other populations over shorter duration 
with mostly beneficial outcomes. One such study by Steenbergen and colleagues provided 
first evidence that intake of probiotics reduce negative thoughts associated with sad mood 
(Steenbergen et al., 2015). Other benefits of the probiotics supplements used in the 
previous study included the reduction of migraines (de Roos et al., 2015) and improved 
immune function via increased neopterin levels and reactive oxygen species production 
by neutrophils amongst cirrhotic patients (Horvath et al., 2016). The last study also 
showed minimal influence of probiotics in gut endothelial function, as observed by no 
discernible changes in endotoxin levels, similar to the present study. The formulation and 
choice of the 8-strain probiotics supplement is also worthy of mention. This probiotic 
combination has been investigated for its ability to not only improve endothelial barrier 
but also for its potency to inhibit mast cell activation, inhibit pro-inflammatory cytokines 
and more importantly, to decrease endotoxin load (van Hemert S and Ormel G, 2014), 
which is the main endpoint of the present studies conducted. 
 The second novelty in the present studies conducted is the choice of cohort. 
Clinical trials on probiotic supplementation in the Arabic T2DM population, has also 
never been performed previously. This is important since the gut microbiome, although 
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mostly populated by Firmicutes and Bacteroidetes is highly affected not only by the 
health status of the individual, but more so by geography and ethnicity (Gupta et al, 2017). 
These diversity in gut microbiome has been observed as early as the first year of life 
(Stearns et al., 2017). The effects therefore of probiotics are not only strain-specific but 
also highly varied depending on the individual's gut microbiome make up and health 
status. Findings of the present study therefore adds value to the current literature in terms 
of ethnic-specific effects of probiotics supplementation among patients with T2DM. 
 Exactly how probiotic supplementation reverses abnormal metabolism has been 
studied extensively. Some of the well-known mechanisms of actions of probiotics include 
beneficial alteration of the gut microbiome, competitive inhibition with other bacterial 
components via adherence to the mucosa and epithelium, strengthening of the intestinal 
epithelial barrier function and modification of the immune response in favour of the host 
(Bermudez-Brito et al., 2012; Thomas and Versalovic, 2010). It is worth mentioning that 
significant improvements in the probiotics group were demonstrated over time in terms 
of reduction of endotoxin, glycaemic, lipid, adipocytokine and inflammatory profiles. 
Whilst these effects were not demonstrated in the placebo group, both arms (placebo and 
probiotics) were not equal in insulin resistance, inflammatory and CVD risk status at 
baseline. Therefore these positive effects observed in the probiotics group may largely be 
due to an over-all improved epithelial barrier secondary to probiotics supplementation. 
The significant reduction of circulating endotoxin levels, in the probiotics group in 
particular, may have directly caused these effects, since previous studies from the same 
population have consistently demonstrated the significant associations of endotoxin with 
several cardiometabolic factors in the same ethnic group and having the same disease 
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(T2DM), including the metabolic syndrome (Al-Disi et al., 2015; Harte et al., 2012; Al-
Attas et al., 2009). Since endotoxin is largely stored within the gut, it makes sense that 
prevention of endotoxin from leaking out of the gut through a strengthened intestinal 
barrier would translate to a better and healthier cardiometabolic profile. 
 Lastly, the clinically significant difference in WHR in favour of the probiotics 
group at 3 months intervention and in placebo at 6 months is in contradiction to one 
another yet also confirms the conflicting results from various meta-analyses on the anti-
obesity effects of probiotics consumption in humans (Nova et al., 2016; Crovesy et al., 
2017; Sayon-Orea et al., 2017). Currently, the beneficial effects of probiotics appear to 
be more successful in animal models (Karimi et al., 2017; Kobyliak et al., 2017). Worthy 
to mention is that the probiotics supplementation in the present studies of the thesis was 
used as a standalone treatment given in the absence of exercise and diet-related 
modifications in the intervention as well as a lesser controlled environment. A recent 
randomised clinical trial by Gomes and colleagues (2017) however parallels the present 
thesis' finding on abdominal obesity reduction, but this was in combination with a 
prescribed dietary regimen, hence the higher percentage change (>5%) reduction in waist 
circumference as compared to the WHR assessed in the present thesis (<0.01%). Whether 
anti-obesity efficacy of probiotics will be enhanced in combination with the mentioned 
strategies remain to be proven. Nevertheless, the over-all evidence for weight loss 
secondary to probiotics is still scarce. Furthermore, the efficacy of probiotics are strain 
specific and highly dependent on various intrinsic components within the individual and 
this could probably explain the inconsistencies of findings in the literature. 
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5.2 Limitations of the Present Studies 
 Two major limitations in the present studies were noted. First is the sample size. 
A priori sample size determination is mandatory for all successful clinical trials. In this 
case, it was calculated that at N=60 per arm group (total of 120 participants), the effect 
size will have 80% power to detect a statistically significant difference. The actual number 
of participants who completed the 6-month trial was 39 (N=16 for placebo and N=23 for 
probiotics). This explains why strong and significant changes in the probiotics group over 
time did not translate into clinically meaningful changes when compared with placebo. 
 The second limitation is the persistent discrepancy between baseline values of the 
probiotics and the placebo group despite randomisation, as is the nature of clinical trials. 
Baseline characteristics show that whilst age and BMI were matched for both placebo and 
probiotics group, the probiotics group were actually cardiometabolically worse than 
placebo. Whilst this was addressed by adjusting analyses for baseline differences, the 
additional adjustments of covariates made it more difficult to elicit the desired treatment 
effect because of the added statistical stringency to the small cohort. This is worth 
highlighting because the probiotics group made a more substantial improvement and 
hence the disparity with the control. Nevertheless despite the limitations and the rigorous 
analyses done, a significant improvement was observed in terms of decreased insulin 
resistance over time, in favour of the probiotics group. As insulin resistance is intricately 
linked to most of the cardiometabolic indices measured, the clinically significant 
improvement suggests that probiotics supplementation do confer beneficial effects when 
consumed by the T2DM population.  
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 Other limitations as mentioned previously, albeit minor, include the lack of 
evidence to prove successful gut colonization of probiotic bacteria since RT-PCR was not 
performed at this stage. Indeed, whilst the need for the probiotic bacteria to be alive after 
ingestion is mandatory, the practical aspect of determining whether successful 
colonization occurred would support the concept, although absence of gut microbiome 
data does not necessarily mean absence of efficacy (Rowland et al., 2010).  
 
 
5.3 Future Directions 
 In light of the present findings, additional clinical trials are clearly warranted, 
especially in the Middle Eastern region. Before addressing this however, the general 
population should be given to determine the importance of public health awareness of the 
benefits of consuming probiotics supplements. The concept of probiotics is largely 
unheard of and people generally were unaware that probiotics have been a steady part of 
the Arabian diet in the form of fermented products such as yoghurt and laban (fermented 
milk). As awareness is heightened it is expected that this may reduce dropout rates as 
subsequent probiotics trials are conducted. Clinical trials in Saudi Arabia in particular is 
still at its infancy. A recent observation from Jamjoom and colleagues (2015) revealed 
that there were only 39 clinical trials conducted in Saudi Arabia and where a Saudi 
Arabian institution was principally responsible over a span of 13 years and this was 
severely dwarfed in comparison to 807 clinical trials registered over a span of three years 
in one German university alone. Other recommendations include conducting several 
probiotics clinical trials to other populations such as pregnant women and children using 
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different doses, probiotics strains, intervention duration and in combination with other 
agents such as diet, exercise, prebiotics and other supplements, to name a few. 
 
 
5.4 Conclusions 
 The present thesis performed a randomised, double-blind, placebo-controlled 
clinical trial of 6-month duration to determine the effects of a multi-strain probiotic 
supplementation in reducing endotoxin levels and altering the statuses of anthropometry, 
glycaemia, lipids, inflammatory and adipocytokines in the Saudi adult population with 
newly diagnosed T2DM. Findings from the thesis as conducted in the several studies 
presented offer important information that will expand our current understanding on how 
multi-strain probiotic supplements work in the diabetic population coming from a 
relatively homogenous ethnic background. The findings also shed light on the challenges 
of conducting randomised clinical trials in this area of the world where such studies that 
offer high level of evidence are still evolving and would require greater input and 
participation from the general population. It is clear that whilst further interventional trials 
that meet the required statistical power are necessary to reaffirm the present findings, the 
significant improvement in insulin resistance in favour of the probiotics group despite the 
low sample size turn post intervention and the rigorous analysis performed merit clinical 
attention. Whether the same effects will be elicited in the presence of other medications 
and diabetes-related complications remains to be investigated. Nevertheless and in light 
of this positive result in the present thesis, probiotics supplementation appears useful as 
an adjuvant therapy in medication naïve patients with known insulin resistance and early 
phase T2DM.  
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Appendix V Study Questionnaire 
 ةيبرعلا ةكلمملاةيدوعسلا  
يلاعلا ميلعتلا ةرازو 
دوعس كلملا ةعماج 
ةيويحلا تارشؤملا ثاحبأ زكرم  
Kingdom Of Saudi Arabia 
Ministry Of Higher Education 
King Saud University 
Biomarkers Research Program 
Serial No. : _______                  Date:       /       / 2013              
 
National ID:  _ - _ _ _ _ - _ _ _ _-   ةيوهلا مقر  
Sex   سنجلا :    Male   ركذ        Female  ىثنأ 
Name: __________________   مسلاا   
Age: ___________________   رمعلا   
Birth Date     /     /        ةدلاولا خيرات         Place  __________________   ناكملا        Phone  
______________   نوفلتلا  
ةيعامتجلاا ةلاحلا  
Marital status 
بزعأ 
 
Single 
جوزتم 
 
Married 
قلطم 
 
Divorced 
لمرأ 
 
Widowed 
لفط 
 
Child 
 
 يلئاعلا خيراتلا   Family history 
ىلولأا ةجردلا نم براقأ يركس 
  
Diabetes 1st degree 
 ةجردلا نم براقأ يركس
ةيناثلا 
 
Diabetes 2nd degree 
مدلا طغض عافترا 
 
Hypertension 
نوهدلا عافترا 
 
Hyperlipidemia 
 
Chronic 
Gastrointestinal 
Disease 
ةنمس 
  
Obesity 
 ناطرس 
 
Cancer 
 ددح 
ـــــــــــــــــــــــــــــــــــــــــــــــ 
 Others ىرخأ : _____________________-
_________________________________________________________ 
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Smoking      نيخدتلا 
 Smokerنخدم     Sheshah  
 هشيش 
 Ex-Smoker قباس نخدم 
 Never smoked      ً اقلاطأ نخدي مل 
- # of packs/day _____________   يف رئاجسلا بلع ددع
   مويلا 
- Duration (years) ____________  تاونسلاب ةدملا 
- Years quitted ______________  علاقلإا تاونس 
 
 
طــــقف تادــــــــيسلل ةــــــلئسأ    For Female Subjects Only 
Are you pregnant  [   ] Yes   معن   [    ] No  لا       ؟ لماح تنأ له 
 
 
Medications: Please list all medications you are currently taking in the space provided 
 
 
Please Answer the Following Questions: Check if appropriate: 
 
        YES   NO 
 
1. Do you have any gastrointestinal disorder?   ___   ___ 
2. Have you used antibiotics for the past 6 months?  ___   ___ 
3. Have you used probiotics regularly for the past 3 months? ___   ___ 
- Almarai Vetal Laban 
- Protexin Capsule 
- Other Dairy products (yoghurt, low-fat, high-fat, skimmed) 
With probiotics label 
4. Clinical trial participation in the past 6 months?  ___   ___ 
5. Are you taking any of the following regularly? 
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- Insulin/insulin analogs     ___   ___ 
- Corticosteroids      ___   ___ 
- Antacids (For hyperacidity)     ___   ___ 
- H2-receptor blockers (For hyperacidity, ulcer)   ___   ___ 
- Proton Pump Inhibitors (For hyperacidity, ulcer)   ___   ___ 
- Loperamide (For diarrhea)     ___   ___ 
- Cholestryramine (For high cholesterol)    ___   ___ 
- Omega-3 supplements (cod liver oil)    ___   ___ 
- Sex steroids       ___   ___ 
 
For DMT2 Patients 
 
1. Did your anti-DM medication change in the past 6 mos? ___   ___ 
2. Will your medications change within 1 year?  ___   ___ 
 
Anthropometrics 
 
 Values 
 
Date Taken 
Baseline 
 
Week 8 Week 26 
Height (cm)    
Weight (kg)    
Waist (cm)    
Hip (cm)    
Systolic BP (mmHg)    
Diastolic BP (mmHg)    
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Blood Tests 
 
 Values 
 
Date Taken 
Baseline Week 8 Week 26 
Fasting glucose    
HBA1c    
Insulin     
C-Peptide    
Triglycerides    
Total Cholesterol    
LDL-Cholesterol     
HDL-Cholesterol    
Endotoxin    
IL-6    
CRP    
TNF-α    
Leptin    
Adiponectin    
Resistin    
 
 
 
 
 
210 
 
CONSENT 
 
I fully agree to participate in this study as a subject [A 26-week, Randomized, Double-blind, 
Placebo-controlled Study to Explore the Effects of Probiotics on Endotoxin Levels in Patients 
with Type 2 Diabetes Mellitus].  
 
I am aware that I will be receiving intervention and that blood will be collected from me at 
different time points. 
 
The doctors and investigators in-charge have oriented me about the study in a language that I can 
understand, as well as the risk factors and problems that I may encounter. They were able to 
answer all my questions and doubts about the study and my level of participation. 
 
The doctors and investigators in-charge can go through my medical records in relation to the study 
providing full confidentiality of my information. 
 
I am aware that there will be no problem if in case I decide to stop the intervention. 
 
I have the right to withdraw from this study at any time without mentioning reasons. 
 
 
 
 
Patient’s Full Name, Signature and Date 
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